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As part of the broad strategy in Edinburgh and beyond to discover new treatments for 
progressive Multiple Sclerosis (MS), the aims for my PhD project were: (1) to address the lack 
of an in vitro phenotypic drug screening platform that is able to fully recapitulate myelin 
sheath formation, with the long-term goal being to enhance the discovery of pro-
remyelination therapies in progressive MS, and target the poor drug discovery rates in brain 
disorders which is partially due to poor disease modelling, and (2) the exploration of non-




In multiple sclerosis, an inflammatory autoimmune process destroys the oligodendrocytes 
that provide neuronal support by forming multi-layered compact myelin sheaths around 
axons, leading to neurodegeneration. Although there are drugs available to suppress the 
inflammatory attack to limit the formation of demyelinated lesions, no treatments currently 
exist to promote the regeneration of these myelin sheaths once the damage has occurred. 
Cell based screens have formed an important part of the strategy used to discover such 
regenerative drugs. The majority of published cell-based phenotypic drug screens to target 
repair have focused on the differentiation of oligodendrocyte precursor cells into 
oligodendrocytes rather than their ability to form mature protective myelin sheaths. 
However, in many MS lesions, pre-myelinating oligodendrocytes are present, and studies on 
oligodendrocyte biology show that differentiation and myelination are regulated by distinct 
mechanisms. There is therefore a need for novel drug screens that target the later 
myelinating stages of oligodendrocyte development. 
 
Results 
Using a 3D microfibre system for in vitro myelin sheath formation (described by Bechler, 
Byrne and ffrench-Constant (2015)), I first asked whether compounds that had been 
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identified as increasing differentiation in conventional 2D culture systems enhanced 
myelination in the 3D cultures. While Benztropine and Clemastine showed an increase in the 
number of MBP+ (differentiated) oligodendrocytes in the 2D system, consistent with 
previous publications, no increase in myelin sheath formation was seen with any of the drugs 
in the 3D system, highlighting the potentially important differences between differentiation 
and myelin sheath formation for drug discovery. 
Next I developed a multiwell plate based assay to allow 3D myelination assays to be used for 
drug screening. Using electrospinning to produce PLA microfibres, I was able to develop and 
optimise a technique to insert and suspend the fibres across the bottom of a 96-well plate 
that can be incorporated into an automated pipeline for high-throughput drug screening. The 
3D myelin sheaths could be imaged using the Leica SP8 confocal system with the 
MatrixScreener extension and the Opera Phenix high-content screening system. 
Finally, I addressed the problem of imaging myelin in such screens. CARS was shown to be 
able to preferentially detect myelin sheaths in fixed and live slices in regions and time-points 
of varying myelin densities. As the development of new myelin sheaths requires the 
formation of lipid and therefore the incorporation of hydrogen, the consumption of D2O 
(heavy water) with a 2H atom allowed the non-invasive labelling and detection of myelin 
sheaths using SRS. Future experiments will allow us to confirm whether this deuterium 
detection is preferential and/or specific to new myelin sheaths. 
 
Significance 
With only about 10% of drugs that enter Phase I trials successfully launching into clinics, there 
is an important need for more effective drug screens that better model disease-relevant 
processes and so reduce late-stage failures. The high-throughput-compatible 96-well plate 
with suspended PLA microfibres that combines the recent progresses in 3D cellular model 
systems with bioengineering and the recent advances in high content imaging systems may 
give us the opportunity to more accurately model these disease-relevant structures in vitro, 
and therefore improve drug discovery for regenerative therapies in multiple sclerosis and 
other myelin diseases. 
The research on Raman-based label-free imaging of myelin sheaths is not only applicable for 
imaging myelin sheaths in the context of drug validation, but could be important for live 
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imaging of brain slices and detection of newly-formed myelin sheaths without the need for 





Multiple Sclerosis is a disease that results from our own immune system attacking the 
protective myelin sheets surrounding the long nerve fibres (axons) of our neurons. The cells 
that make myelin sheets are oligodendrocytes, and they develop in our nervous system from 
a stem cell-like state and undergo a process called differentiation (in which cells become 
more specialised) to produce myelin sheets that wrap around axons in 3D tube-like structures 
called myelin sheaths. Myelin sheaths act like the plastic covering around electrical wires, 
and therefore the damage to these structures results in the malfunctioning and death of the 
neurons that transmit signals around our body. However, evidence suggests that there is a 
failure of the oligodendrocytes to recover the myelin sheaths in Multiple Sclerosis. Current 
treatments only dampen the immune system attack to prevent damage to the myelin sheaths, 
but no treatments are available to improve their replacement once the damage has already 
occurred. 
One way to discover new treatments is by testing a wide range of potential drugs 
simultaneously in multi-well plates (plates to grow cells in with 96 individual wells or more) 
to identify ones that improve certain characteristics (phenotypes) of the cells affected in 
disease. Current drug discovery efforts to target the replacement of the lost myelin sheaths 
has been conducted by looking for drugs that increase the number of oligodendrocytes 
developing from the stem cell-like state to a 2D myelin sheet-producing differentiated 
oligodendrocytes by looking for proteins that detect this process has occurred. However, as 
the oligodendrocytes are not given axons to wrap around, it is not possible to detect whether 
these drugs will actually increase the formation of the 3D tube-like myelin sheaths. 
In my thesis, I have therefore created a new multi-well plate that allows us to test multiple 
drugs simultaneously and identify oligodendrocytes that are forming myelin sheaths. To do 
this, I used a technique called electrospinning, which is akin to making candy floss out of 
sugar or Spider-Man making webs from his web shooters. Electrospinning allows us to make 
micrometre-thin fibres that are the same diameter as axons by applying a high voltage to a 
polymer and collecting the fibres that are produced in this process. I was able to produce and 
insert these electrospun fibres into a multi-well plate, so that when oligodendrocytes 
differentiate from their stem cell-like state to their differentiated state, they can also produce 
the 3D myelin sheaths around these artificial axons. In this way, we can detect drugs that 
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increase the formation of myelin sheaths to improve their replacement and decrease the 
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CHAPTER I. LITERATURE REVIEW 
 
As part of the broad strategy in Edinburgh and beyond to discover new treatments for 
progressive Multiple Sclerosis (MS), the aims for my PhD project were: (1) to address the lack 
of an in vitro phenotypic drug screening platform that is able to fully recapitulate myelin 
sheath formation, with the long-term goal being to enhance the discovery of pro-
remyelination therapies in progressive MS, and target the poor drug discovery rates in brain 
disorders which is partially due to poor disease modelling, and (2) the exploration of non-
linear optical imaging microscopy techniques that targets both the resolution and speed to 
study myelination. 
To place this into context, in this introduction I will therefore review: (1.1) Multiple Sclerosis, 
and the evidence towards why remyelination is an important therapeutic target in the 
treatment of this disease, (1.2) the current immunomodulatory treatments available for the 
prevention of lesion formation but not regeneration once damage has already occurred, (1.3) 
oligodendrocyte functions and the role of myelin sheaths in the CNS, particularly their role in 
providing metabolic support to axons, (1.4) the distinct stages of oligodendrocyte 
development, starting from the birth of the precursor cells to the formation of myelin sheaths, 
(1.5) the causes of the remyelination failure that contributes to progressive MS, including the 
evidence towards a significant block in later stage myelin sheath formation in MS lesions and 
why this might be, (1.6) the reasons why drug discovery for remyelination has been so 
difficult, reviewing both the problems with CNS disease in general and specific issues around 
MS research, (1.7) the current phenotypic cell-based methods for assessing myelination, 
including their caveats in being able to model myelin sheath formation in vitro when used for 
drug discovery, and (1.8) how we can image these cells in vitro. Finally (1.9) I will bring these 
parts together and discuss current evidence suggesting that existing screening strategies are 
poor at addressing an important property of oligodendrocyte biology; that differentiation 





1.1 Multiple Sclerosis  
 
1.1.1 Cause and classification 
 
Multiple Sclerosis (MS) is a neurological disorder characterised by chronic 
inflammation of the CNS, and affects more than two million people globally (GBD 
2015 Neurological Disorders Collaborator Group, 2017). In the ‘outside-in’ theory 
of the pathogenesis of MS, the disease can be characterised into two main 
phases (Figure 1.1): (1) an inflammatory phase where focal areas of 
demyelination occur, leaving underlying axons denuded, and (2) subsequent 
neurodegeneration (Bruck, 2005; Lublin et al., 2014; Stefano et al., 1998). An 
alternative ‘inside-out’ hypothesis suggests that autoreactivity against myelin 
precedes inflammation and demyelination (Traka et al., 2015). In both theories, 
following the demyelination, the loss of myelin results in conduction velocity 
block or reduction, refractory period of transmission being extended, and 
impairment of high frequency axonal signal transmission (McDonald and Sears, 
1970). With prolonged myelin loss, i.e. when remyelination fails, the vulnerability 
of the denuded axons to continued inflammatory attack along with loss of 
metabolic support result in axonal death, leading to progressive and permanent 






Figure 1.1 Summary of the main phases of Multiple Sclerosis 
In MS, myelin sheaths and oligodendrocytes undergo an inflammatory attack (‘outside-in’ theory) 
or autoreactivity (‘inside-out’ theory), resulting in demyelination. In some cases, new 
oligodendrocytes are able to come into the lesion and remyelinate. However, when remyelination 
fails, the axons that have been left exposed undergo axonal degeneration. 
(Figure by ScideLight) 
 
Based on the progression of symptoms, MS can be categorised into ‘relapsing-
remitting’ MS (RRMS), ‘secondary progressive’ MS (SPMS), or ‘primary 
progressive’ MS (PPMS). 80% of patients are first diagnosed with RRMS, where 
there are phases of MS-related symptoms (‘relapse’, where focal demyelinated 
lesions occur in different areas of the CNS) and phases of no symptoms 
(‘remission’, or resolution of the inflammatory attack, remyelination, and 
compensation by the brain), with this form of MS being characterised by acute 
inflammatory immune activity and therefore having the best response to 
immunomodulatory treatment (Figure 1.2). Two-thirds of RRMS patients 
progress onto SPMS, where the disease becomes a continuous progressive 
worsening of symptoms and increasing disability, after about 25 years 
(Weinshenker et al., 1989), with more than 80% of RRMS patients eventually 
developing SPMS, which is due to neurodegeneration and more resistant to 
treatment. The remaining 20% of patients are diagnosed with PPMS, where there 
is progressive accumulation of disability from the disease onset, mostly due to 
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neuronal damage, with no major relapses and remissions (Bitsch and Brück, 2002; 




Figure 1.2 Schematic of major cell types and current treatments for MS 
The diagram summarises some of the major cell types targeted for current non-inflammatory 
treatments for MS. 
For example, Dimethyl fumarate, although the mechanism is not fully understood, works to 
decrease inflammation caused by the immune system in the peripheral lymph nodes. Fingolimod 
prevents T and B cells from leaving the lymph nodes, and interferon beta and glucocorticoids are 
interferons and hormones, respectively, which dampen inflammation. 
In the CNS, Natalizumab is an antibody-based treatment that sticks to T cells to stop them 
reaching the CNS, and Ocrelizumab targets the CD20 on B cells to have its anti-inflammatory 
effect. 




Based on epidemiological studies, the prevalence of MS is higher in females and 
with increasing latitude, with Scotland having the highest rate of MS diagnosis in 
the world (Pugliatti, Sotgiu and Rosati, 2002; Handel et al., 2011; Mcdonald et al., 
2019). Compared to England with an estimated prevalence of 164 per 100,000, 
Scotland has a prevalence of 209 per 100,000, with the highest rate being 402 
per 100,000 in Orkney (Multiple Sclerosis Trust, 2018). The increased risk of MS 
diagnosis in certain populations have been linked to risk factors such as certain 
genetic variations like HLA-DRB1 risk alleles (IMSGC and WTCCC, 2011), levels of 
vitamin D intake (Mokry et al., 2015; Munger et al., 2004; Laursen et al., 2016), 
and exposure to Epstein-Barr virus (Belbasis et al., 2014; Guan et al., 2019). Due 
to the disability associated with MS, resulting in patients not being able to work, 
there is also a high economic burden associated with the disease, with an 
estimated €27,000 per patient and €15 billion total in Europe in 2010 
(Gustavsson et al., 2011; Olesen et al., 2012). 
MS lesions can be classified into 4 distinct types: active demyelinating, chronic 
active, chronic inactive, and remyelination lesions. Active demyelinating lesions 
are the initial forms of MS lesions, and are therefore most often found in patients 
in the remitting phase of RRMS or early on in SPMS. These lesions are 
hypercellular, containing macrophages and microglia digesting myelin sheaths 
and astrocytes (Kutzelnigg et al., 2005; Kuhlmann et al., 2017). Chronic active 
lesions are characterised by a chronic demyelinated lesion surrounded by 
activated phagocytotic cells (Prineas et al., 2001; Zrzavy et al., 2017) containing 
breakdown products of myelin proteins (Kuhlmann et al., 2017), representing an 
expanding lesion which sometimes show active or expanding premyelinating or 
early myelinating OLs (Fard et al., 2017). Chronic inactive lesions represent an 
end-stage of lesion formation, with no active inflammation or remyelination, and 
are hallmarked by a significant reduction in OPCs, OLs, and inflammatory cells 
such as microglia (Wolswijk, 2000; Zrzavy et al., 2017). Shadow plaques are 
lesions in which the active inflammation has subsided, and are characterised by 
thinner myelin sheaths. They also do not have the significant increase in 
macrophage infiltration as would be seen in an active demyelinating lesion that 
have not completely been demyelinated (Patrikios et al., 2006). The appearance 
of these thin myelin sheaths have previously been thought to be due to 
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remyelination, but a more recent theory suggests that they may also be 
attributed to compromised myelin sheaths that survived demyelination (Yeung 
et al., 2019).   
 
1.1.2 Remyelination in MS 
 
Remyelination is one of the major therapeutic interventions in treatment 
development for MS, particularly in progressive forms where remyelination and 
clinical remission fails. Remyelination can be detected extensively in the lesions 
of MS patients, and are characterised by thinner myelin sheaths (Blakemore, 
1974). Prineas et al. (1993) observed ~20% of plaques in patients who died 18 
months or longer after clinical onset showing remyelination in at least 10% of the 
plaque area (Prineas et al., 1993), Patrikios et al. (2006) detected 60 to 96% of 
the global lesion area showing remyelination in a subset of 20% of the patients 
(Patrikios et al., 2006), and Patani et al. (2007) identified that 22% of WM lesions 
were fully myelinated and 73% showed at least partial remyelination (Patani et 
al., 2007). These quantifications show that remyelination does occur in a subset 
of lesions in a subset of MS patients as an endogenous regeneration process. 
 
Remyelination is important because of the evidence that is neuroprotective and 
promotes functional recovery, In 1979, Smith et al. (1979) showed that once 
remyelination begins following an injection of lysophosphatidyl choline (LPC) 
into the spinal cord of a cat to form an acute lesion, impulse conduction, 
measured by pairs of platinum or stainless steel electrodes implanted into the 
spinal cord, begins to progressively return to normal, with efficient impulse 
conduction being restored in the demyelinated axons even though the myelin 
sheaths have the characteristic thinner and shorter properties of remyelination 
(Smith, Blakemore and McDonald, 1979). Although computational studies 
predict that that conduction will not completely return to normal due to the 
thinner myelin sheaths in remyelination (Smith and Koles, 1970), this suggests 
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that functional recovery of the saltatory conduction can be restored with 
remyelination. 
Cuprizone to induce global demyelination followed by irradiation to prevent 
endogenous remyelination showed that with transplantation of embryo-derived 
neural progenitors to promptly restore remyelination capacities increased axon 
survival when compared to cuprizone and irradiation-treated mice without cell 
transplantation (Irvine and Blakemore, 2008). However, transplanted neural 
stem cells have been shown to have a neuroprotective and immunomodulatory 
effect that is distinct from the effects of remyelination (Pluchino et al., 2005), 
and this effect therefore cannot be excluded when considering the decreased 
axonal damage seen in this study. Muscarinic acetylcholine receptor M1 is a 
potent negative regulator of OL differentiation and myelination. When M1 
muscarinic receptor (Chrm1) was genetically ablated in OPCs in an EAE mouse 
model, the acceleration and enhancement of the remyelination process resulted 
in increased preservation of axons and functional recovery (Mei et al., 2016), 
supporting that the remyelination by the transplanted cells did contribute to 
axonal protection, at least to a certain extent. In addition, endogenous 
remyelination in a dietary manipulated model of demyelination in cats showed 
restoration of function (Duncan et al., 2009), and thin myelin sheaths, which are 
the hallmarks of remyelination, in canines with hypomyelinating genetic 
mutations persisted and preserved axonal function (Duncan et al., 2017). These 
studies highlight the axon-protective benefits of remyelination as a potential 
therapeutic advantage of remyelination treatments. 
 
1.2 Current Treatments for MS – Immunomodulatory, not regenerative 
 
In acute relapses of MS, corticosteroids have been used as a potent anti-inflammatory and 
immunosuppressive treatment to shorten its duration and improve recovery rate. Its mode 
of action is through binding to cytosolic glucocorticoid receptors to mediate genomic effects 
in inducing anti-inflammatory cytokines and inhibiting pro-inflammatory ones, as well as non-
genomic effects in activation of signal cascades that suppress the immune response (Sloka 
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and Stefanelli, 2005; Stahn et al., 2007). Although corticosteroids reduced worsening or non-
improvement of the relapse 5 weeks from symptom exacerbation (Citterio et al., 2013; Deun 
and Pesch, 2017), they do not modify the disease, and are therefore do not have long-term 
benefits in its usage. 
Several disease-modifying treatments for MS exist, mainly being immunosuppressants, 
immunomodulators, and monoclonal antibodies, and include azathioprine, 
cyclophosphamide, interferon β (IFNβ, glatiramer acetate, methotrexate, mitoxantrone, 
natalizumab, and most recently ocrelizumab (Filippini et al., 2013; Mulero, Midaglia and 
Montalban, 2018). These drugs inhibit various immune cells and cytokines to suppress and 
prevent new inflammatory attacks, and therefore decrease the formation of new lesions and 
the occurrence of relapses, and are therefore most efficient in RRMS. A 2013 meta-analysis 
suggests that natalizumab, followed by IFNβ-1a and mitoxantrone, is the most effective at 
improving the disease course (Filippini et al., 2013). Ocrelizumab, which was first approved 
for use in the UK in 2018, is the first and only current drug approved for treatment of PPMS 
(Mulero, Midaglia and Montalban, 2018).  
Currently, no disease-modifying treatments are available that is able to target the non-
inflammatory neurodegenerative phase of the disease, highlighting a significant clinical 
challenge. One intervention technique for targeting the neurodegenerative phase of the 
disease would be remyelination therapies. However, no therapies that effectively enhance 
remyelination is available, although several are in clinical trials including Opicinumab against 
LINGO-1, and clemastine, discussed in the next section.  
 
1.3 Oligodendrocytes and the Role of their Myelin Sheaths in the CNS 
 
Oligodendrocytes (OLs) were first identified by Scottish pathologist William Ford Robertson 
in 1899 when he noticed a unique subset of small branched cells that could be labelled with 
platinum, which he referred to as ‘mesoglia’. It was re-discovered and first described as the 
myelin-producing cells of the central nervous system (CNS) in 1922 by Spanish 
neurohistologist and pathologist Pío del Río-Hortega following his development of the silver 
carbonate method to distinguish OLs and microglia from Spanish neuroscientist and 
pathologist Santiago Ramón y Cajal’s “third element” of the CNS, the “first and second 
9 
 
elements” being neurons and astrocytes. The term myelin was first coined by the German 
pathologist Rudolf Ludwig in 1854, derived from the Greek word myelos after the colour and 
texture of bone marrow, and first described by Dutch scientist Antoni van Leeuwenhoek in 
1717. (reviewed by Boullerne 2016; Pérez-Cerdá et al. 2015) 
Myelination is a predominantly postnatal process, with oligodendrocyte precursor cells 
(OPCs) continuing to be maintained, proliferate, and produce myelinating OLs into adulthood 
(Hughes et al., 2013; Young et al., 2013a; Yeung et al., 2014), with the ability to reinitiate the 
growth of mature myelin sheaths (Snaidero et al., 2014). Changes in the white matter (WM) 
of related brain regions in learning sensory-motor (Bengtsson et al., 2005), novel visuo-motor 
(Scholz et al., 2009), and cognitive (Lee et al., 2010) tasks have been identified by diffusion 
tensor imaging highlighting the relevance of white matter plasticity and myelination 
remodelling throughout life. The high degree of cellular and molecular conservation of 
myelination across various species, such as with an early OL progenitor stage transcription 
factor olig2 in zebrafish (Park et al., 2002), to mammals, such as chick (Zhou, Choi and 
Anderson, 2001) and mice (Zhou and Anderson, 2002), also highlights the evolutionary 
importance of the function of these structures in the CNS. Our current understanding on the 
role of OLs and their myelin sheaths support the idea that they have two key functions in 
supporting neuronal function: (i) speeding up axonal signalling via saltatory conduction, and 
(ii) providing metabolic support to neurons and their axons. 
 
1.3.1 Saltatory Conduction 
 
Myelination restricts the clustering of ion channels required for nerve 
conduction to unmyelinated segments, called nodes of Ranvier, which are 
flanked by myelin sheaths, to propagate axonal signalling via these nodes, in a 
process called saltatory conduction (Figure 1.3) (Rushton, 1951; Hodgkin and 
Huxley, 1952; Waxman, 1977). The presence of myelin sheaths dictates the 
pattern and localisation of ion channels, such as distinct sodium channel subunits 
in nodes of myelinated (Nav1.6) versus unmyelinated (Nav1.2) axons (Boiko et al., 
2001). Mechanisms of nodes of Ranvier construction involve OL-derived 
extracellular matrix components, axonal-myelin sheath adhesion molecules as 
barriers, and cytoskeletal scaffolds to stabilise the positioning of sodium 
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channels (Susuki et al., 2013). Other non-myelin sheath-related mechanisms 
include clustering of sodium channels and other nodal proteins to node-forming 
regions (Kaplan et al., 1997, 2001; Freeman et al., 2015). 
 
 
Figure 1.3 Node of Ranvier and Saltatory Conduction 
Schematic diagram of a myelinating oligodendrocyte wrapping myelin sheaths around the axon 
of a neuron. 
This clusters the voltage-gated sodium channels, restricting the active depolarising regions to 
these nodes, allowing signals to be transmitted along the axon quickly along the nodes of 
Ranvier. 
Figure drawn on BioRender. 
 
Changes to the internodal, the distance between nodes, structure and 
parameters contribute to variations in the conduction velocity of the axon 
(Moore et al., 1978). Increasing the distance between internodes increases 
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conduction velocity, although only to a certain point, where it reaches a “flat 
maximum” (Huxley and Stampfli, 1949; Wu et al., 2012). Even minor changes to 
the ratio between the thickness of the myelin sheath and axon unit compared to 
the axon calibre (g ratio), with a maximum value when the ratio is between 0.6 
and 0.7 based on computer simulation (Smith and Koles, 1970), and diameter 
changes in myelinated axons, as shown along the optic nerve of the ferret (Baker 
and Stryker, 1990), can significantly affect conduction velocity. This allows not 
only for the speeding up of conduction velocity through the presence of myelin 
sheaths, but for the control of conduction times by internodal parameters 
variation, as exampled in the auditory brainstem of the chicken for precise 
temporal integration of the auditory information in order to achieve sound 
localisation (Seidl, Rubel and Harris, 2010; Seidl, Rubel and Barria, 2014). 
 
1.3.2 Metabolic Support 
 
In addition to its role in saltatory conduction, myelin sheaths are also thought to 
provide metabolic support to the underlying axon that it ensheaths. Proteolipid 
protein (PLP)-deficient mice and 2’,3’-cyclic nucleotide phosphodiesterase 
(Cnp1)-inactivated mice, which are both major components of myelin sheaths, 
were able to form structurally normal myelin sheaths, but showed severe axonal 
pathology as a primary phenotype ahead of subsequent myelin abnormalities 
(Griffiths et al., 1998; Lappe-Siefke et al., 2003). This emphasises the role of 
myelin sheaths beyond physical ensheathment and demonstrates the 
requirement of specific myelin proteins in promoting neuronal health and 
survival, with importance in demyelinating conditions like MS, where the loss of 
these myelin sheaths results in several axonal damage (Trapp et al., 1998), and 
leads to progressive neurodegeneration.  
One mechanism by which OLs could be metabolically supporting axons is through 
the transfer of glucose and lactate. Cytochrome c oxidase (COX) is a component 
of the electron transport chain required for mitochondrial respiration. 
Fünfschilling et al. (2012) produced conditional Cox10 mutant mice by crossing 
the Cox10flox/flox animals with Cnp1Cre/+ or Plp1-CreERT2 lines to knockout Cox10 
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expression in myelinating cells, with Cox10 mutants being unable to form stable 
COX, and therefore its loss biasing ATP generation towards aerobic glycolysis and 
lactate production versus glucose metabolism. In these mutant animals, there 
were no detectable signs of OL pathology, changes in g-ratio, nor increases in 
apoptotic cells or inflammatory cells in the WM of adult animals despite 
confirmed absence of COX activity by histochemical measurements and the 
presence of severe peripheral neuropathy. This suggested that the survival and 
maintenance of OLs, their myelin sheaths, and associated axons are not affected 
by mitochondrial dysfunction once myelination had already occurred. In 
experiments exploring this, they noted that when brain lactate concentration 
was measured by localised proton magnetic resonance spectroscopy, there was 
a large increase in accumulated lactate levels in the cortex and white matter of 
mutant animals in the presence of volatile isoflurane anaesthesia, with levels 
decreasing rapidly following the withdrawal of the anaesthetic, suggesting its 
rapid use by local metabolisation (Fünfschilling et al., 2012). This led to the 
discovery that lactate is transported exclusively by monocarboxylate 
transporters, with monocarboxylate transporter 1 (MCT1) being highly enriched 
in OLs, predominantly in myelin sheaths. Oligodendrocyte-specific loss of MCT1 
was shown to lead to axonal dysfunction, and ultimately neuronal cell death (Lee 
et al., 2012). Studying the mechanism of metabolic support in an exogenous 
glucose deprivation (aglycemic) paradigm, Meyer et al. (2018) showed that in the 
corpus callosum, the dialysis of lactate could only partially rescue action 
potential activity in mouse brain slices during aglycemic conditions compared to 
70% by glucose addition, suggesting that glucose is the most efficient at 
providing axonal support in the corpus callosum. The simultaneous blocking of 
OL MCT1/2 and OL GLUT1 during aglycemic conditions in slices with OLs dialysed 
with glucose resulted in the complete loss of action potential activity, 
demonstrating that both glucose and lactate transporter activity may be 
required from OLs during aglycemic conditions to sustain axonal activity. 
Collectively, these provide evidence towards an important role of glucose and 
myelin-derived lactate, for axonal ATP production via the citric acid cycle, in 
axonal health, survival, and function (Figure 1.4).  
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Another mechanism through which OLs may provide metabolic support is 
through the activity-dependent release of exosomes, which carry various 
proteins and RNA, to axons (Figure 1.4). In culture, glutamate signalling from 
axons was able to evoke exosome release through OL N-methyl-D-aspartate 
receptor (NMDAR) and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
receptor (AMPAR) stimulation and subsequent Ca2+ signalling, with the 
exosomes then being taken up by the neurons. These exosomes were shown to 
improve neuronal viability in conditions simulating oxidative stress and nutrient 
deprivation (Frühbeis et al., 2013). Although further research is required to test 
the in vivo role of OL-derived exosomes in axonal metabolic support, along with 
whether other biologically and disease-relevant mechanisms exist, it provides 




Figure 1.4 Schematic of the two proposed models of metabolic support between 
oligodendrocytes and axons 
The two proposed models of metabolic support by which oligodendrocytes transfer glucose and 
lactate to the underlying axons are illustrated: (1) the transportation of glucose and myelin-
derived lactate for axonal ATP production via the citric acid cycle, and (2) the activity-dependent 
release of exosomes carrying various proteins and RNA to the underlying axons. 
Adapted from Fünfschilling et al., 2012; Frühbeis et al., 2013. 





1.4 Oligodendrocyte development 
 
In order for myelin sheath formation to be achieved, an OL needs to go through various 
stages of development (Figure 1.5 A). The oligodendrocyte precursor cells (OPCs) from which 
they form were first characterised by Raff and colleagues in 1983 (Raff, Miller and Noble, 
1983), and shown to proliferate within the CNS in the rat optic nerve in adults in 1986 
(ffrench-Constant and Raff, 1986) and in newborn animals in 1987 (Dubois-Dalcq, 1987), and 
in the rat telencephalon in 1989 (Gard and Pfeiffer, 1989). Further experiments provided 
evidence for the presence of OPCs in the adult human CNS including a 1992 study in which 
Armstrong et al. (1992) were able to isolate O4+ (early oligodendrocyte lineage marker), 
galactocerebroside-negative (GalC-, oligodendrocyte marker), and glial fibrillary acidic 
protein-negative (GFAP-, astrocyte marker) OPCs from the adult human CNS of patients 
undergoing partial temporal lobe removal for epilepsy that differentiate into 
oligodendrocytes in vitro. They were also able to identify these O4+ GalC- GFAP- OPCs in 
“tissue prints”, where they mildly digested the brain tissue enzymatically to adhere a thin 
layer of the cells onto a coverslip, to check for their presence in vivo.  
OPCs follow a specific transcriptional and morphological trajectory, as originally described by 
del Río-Hortega, and characterised by Dubois-Dalcq et al. (1986) in the distinct expression 
pattern of myelin-associated glycoprotein (MAG), proteolipid protein (PLP), and myelin basic 
protein (MBP) in rodent-derived OLs independent of neuronal signals. More recent single-
cell sequencing data in mouse (Figure 1.5 B) (Marques et al., 2016) and post-mortem human 
tissue (Figure 1.5 C) (Jäkel et al., 2019) confirm this trajectory from OPCs to 
immature/intermediate differentiated OLs, and finally into fully mature myelin sheath-





Figure 1.5 Morphological and Transcriptional Developmental Stages of Oligodendrocytes 
A. Morphological developmental stages of an oligodendrocyte. 
(Figure designed by ScideLight) 
B. t-Distributed stochastic neighbour embedding projecting from single-cell RNA sequencing of 
juvenile and adult mouse CNS showing the transcriptional trajectory from OPCs to mature 
OLs. 
VLMC = vascular and leptomeningeal cells; OPC = oligodendrocyte precursor cell; COP = 
differentiation-committed oligodendrocyte precursor cell; NFOL = newly formed 
oligodendrocyte; MFOL = myelin-forming oligodendrocyte; MOL = mature oligodendrocyte 
(Figure from Marques et al. 2016) 
C. SCN3E pseudotime analysis of single-nucleus RNA sequencing of human oligodendrocyte 
lineage cells from the WM of post-mortem human brains.  
(Figure from Jäkel et al. 2019) 
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1.4.1 Oligodendrocyte Precursor Cells 
 
OPCs have been shown to have various developmental origins and time-points, 
followed by migration throughout the CNS in response to intrinsic and extrinsic 
cues to diversify and become heterogeneous based on brain region and age 
(Kessaris et al., 2006; Pringle and Richardson, 1993; Spitzer et al., 2019; Sun et 
al., 1998). Adult OPCs, which were first shown to exist in the adult CNS in 1986 
(ffrench-Constant and Raff 1986), are abundant throughout and continue to 
increase and proliferate in the adult CNS (Clarke et al., 2012; Young et al., 2013b), 
being estimated to make up between 2 to 9% of the total cell population (Pringle 
et al., 1992; Dawson et al., 2003). They can be identified by the presence of NG2 
chondroitin sulphate proteoglycan (Stallcup and Beasley, 1987), platelet derived 
growth factor receptor A (PDGFRA) (Pringle et al., 1992), and ganglioside 
antibody A2B5 (Raff, Miller and Noble, 1983), although these are not exclusively 
expressed by OPCs, and are therefore combined with OL lineage markers Sox10 
(Kuhlbrodt et al., 1998) and Olig2 (Zhou and Anderson, 2002) to verify their 
presence. The transcription factors Sox10 and Olig2, along with Nkx2.2 are also 
essential for terminal differentiation of OPCs into oligodendrocytes (Claus Stolt 
et al., 2002; Lu et al., 2002; Takebayashi et al., 2002; Zhou, Choi and Anderson, 
2001). Adult OPCs may also respond and behave differently, at least to some 
degree, in comparison to neonatal OPCs, that are present during development, 
due to the evidence that they both respond to and modulate neuronal activity, 
with the neuronal network changing with age (Maldonado et al., 2013; Sakry et 
al., 2014). 
 
1.4.1.1 The birth of OPCs in vivo 
 
OPCs, identified by in situ hybridisation and immunohistochemistry, can first be 
detected in the ventral region of the ventricular germinal zones (VZs) near the 
floor plate, a region that also gives rise to motor neurons, at embryonic day 12.5 
(E12.5) in mice (Timsit et al., 1995), at E14 in rats (Pringle and Richardson, 1993), 
and 45 days post-conception in humans (Hajihosseini, Tham and Dubois-Dalcq, 
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1996) in the spinal cord. These OPCs arise under the influence of Sonic Hedgehog 
(SHH) (Alberta et al., 2001) over the same range of concentration as with motor 
neuron induction, suggesting a potential theory in which a common precursor 
population generates both types of cells at different times during development 
(Richardson et al. 1997). They then proliferate rapidly and migrate widely, 
becoming dispersed throughout the grey and white matter of the ventral spinal 
cord by E16 and uniformly distributed in the cord by E18 in rats (Pringle and 
Richardson, 1993), with similar patterns of dispersion being observed in humans 
(Hajihosseini, Tham and Dubois-Dalcq, 1996). A SHH signalling pathway-
independent, late, and transient second wave of OPC generation also occurs in 
the dorsal spinal cord, at E14.5 in mice (Cai et al., 2005), that do not migrate 
widely and are produced through trans-differentiation of a subset of radial glial 
cells (Fogarty, Richardson and Kessaris, 2005). In the forebrain, the 
developmental origin of OPCs appear to occur in three waves in a temporal 
ventral-to-dorsal gradient, likewise with the SHH signalling pathway important 
for ventral OPC generation (Tekki-Kessaris et al., 2001), as shown by Cre-lox fate 
mapping in transgenic mice. The first wave is in the medial ganglionic eminence 
(MGE) and anterior entopeduncular area (AEP) in the ventral forebrain at E11.5 
which go on to populate the embryonic telencephalon, before the second wave 
from the lateral and caudal ganglionic eminences (LGE and CGE) at E15, followed 
by the final third wave within the postnatal cortex. These sequentially and 
spatially distinct populations of OPCs appear to be redundant as targeted 
destruction of any one population results in the remaining cells re-populating the 
region, and the MGE- and AEP-derived OPCs from the first wave being eliminated 
during postnatal life (Kessaris et al., 2006). In postnatal mice, ventrally-derived 
OPCs make up 80% of the oligodendrocyte (OL) lineage cells in the spinal cord 
and 20% in the corpus callosum, and dorsally-derived OPCs outcompete 
ventrally-derived ones in the myelination of dorsal axons despite having similar 
electrical properties (Tripathi et al., 2011). These OPCs start to express markers 
of differentiation into OLs from shortly before birth, and continue to generate 
new myelinating oligodendrocytes into adulthood, with myelinogenesis peaking 
at 2 to 4 weeks in postnatal mice but continuing until at least 8 months of age, 
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and heterogeneous OPC populations of cycling and quiescent or slowly dividing 
cells (Rivers et al., 2008). 
 
1.4.1.2 OPC migration 
 
In order for myelination to occur, a series of developmental events must occur, 
starting with oligodendrocyte precursor cells migrating to the correct locations, 
proliferating to sufficient quantities, and then differentiating into mature 
oligodendrocytes. The patterning and regional specification of oligodendrocyte 
development occur due to an interaction between cell-intrinsic and regionally 
restricted extrinsic factors, with OPCs initially appearing in discrete locations in 
the embryonic CNS but becoming homogeneously distributed throughout in the 
adult with their origin and migration distance being well conserved between 
birds and mammals (Miller, 1996; Olivier et al., 2001), and OPCs being shown to 
be extremely migratory with implants from the olfactory bulb of wild type mice 
into shiverer animals showing extensive dispersion of normal myelination 
beyond the point of the original graft (Lachapelle et al. 1983). Although the exact 
mechanism through which this dispersion occurs is not well understood, this 
process likely involves contact-mediated interactions with pre-formed axonal 
tracts. For example, OPCs were shown to migrate along the optic nerve axon in 
an axophilic manner in chick embryos, unaffected by the removal of neural cell 
adhesion molecule (N-CAM)-associated PSA (Ono et al., 1997), and that axonal 
topography may guide the migration pattern of OPCs isolated from the rat optic 
nerve (Webb et al., 1995), while, conversely, barriers to prevent OPC migration 
may exist such as in the junctional region of the rat optic nerve that prevents 
OPCs from entering the retina where myelination may impair vision by 
decreasing the ability of light to reach the photoreceptors (ffrench-Constant et 
al., 1988). In the mouse embryonic optic nerve, semaphorin receptors, 
neuropilin-1 and -2, and netrin-1 receptors, deleted in colorectal cancer (DCC) 
and unc5H1, were shown to modulate OPC migration through a balance of their 
effects, with Sema 3A being repulsive and netrin-1 being attractive, and Sema 3F 
being both chemoattractive and mitogenic (Spassky et al., 2002). Both 
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polysialylated-neural cell adhesion molecule (PSA-NCAM) and polysialic acid 
(PSA) also influence OPC migration in late embryonic and early postnatal stages. 
PSA-NCAM-positive neural precursors from the subventricular zone were 
detected in lysolecithin-induced demyelination in the corpus callosum, giving 
rise to oligodendrocytes that had a role in the myelin repair (Nait-Oumesmar et 
al., 1999), and PSA was shown to be a requirement for OPC migration from in 
vitro explant cultures (Wang, Rougon and Kiss, 1994). Through the use of the 
Boyden microchemotaxis chamber and the Dunn direct viewing chamber, Zhang 
et al. (2004) showed the role of PSA and PSA-NCAM in establishing the 
directionality of the migratory behaviour of OPC along the PDGF concentration 
gradient. However, their removal does not eliminate the random migration of 
OPCs in a homogeneous PDGF concentration, suggesting that they are not 
required for the motility itself. More recently, Tsai et al. (2016) showed the role 
of the vasculature in the migration of OPCs in the developing nervous system, 
with the architecture of the vasculature being important for the migratory 
behaviour of OPCs in vivo in mice, and the Wnt-chemokine receptor 4 (Wnt-Cxcr4) 
signalling potentially being important for the regulation of this OPC-endothelial 
cell interaction. The migration of OPCs is therefore likely coordinated through 
several, potentially redundant, pathways, along axons and the vasculature to 
result in their dispersion throughout the CNS. 
 
1.4.1.3 OPC proliferation 
 
As discussed below, PDGF and FGF, along with other growth factors such as 
epidermal growth factor (EGF) (Yang et al., 2017) and G protein-coupled receptor 
GPR56 (Giera et al., 2015), are mitogenic for OPCs (Figure 1.6). In defined 
medium containing PDGF and lacking thyroid hormone (TH), OPCs proliferate for 
many passages without differentiating. There appears to be a cell-intrinsic clock 
that counts the number of divisions before undergoing differentiation into OLs 
(Temple and Raff, 1985; Barres, Lazar and Raff, 1994; Tang, Tokumoto and Raff, 
2000), with OPCs isolated from younger tissue allowing for more divisions 
(Temple and Raff, 1986; Durand and Raff, 2000). This timer appears to be 
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composed of two components, with the first part driven by mitogens like PDGF 
activating cell-surface receptors to promote continued proliferation and 
measure elapsed time, and the second part being regulated by the presence of 
hydrophobic intracellular signals like THs, glucocorticoids, and retinoid acids, to 
stop cell division and trigger cell differentiation (Barres, Lazar and Raff, 1994; 
Durand and Raff, 2000). The cell-cycle inhibitor p27/Kip1 accumulation in OPCs 
appearing to be an important component of the timing mechanism, with p27 null 
animals going through one or two additional cycles of division compared to WT 
cells before differentiating (Durand et al., 1998; Durand and Raff, 2000). 
During embryogenesis, the rate of cell division declines from 24 hours in E12.5 
mouse spinal cord to over 100 hours at E17 as the number of OPCs increase. The 
saturation of PDGF signalling accelerating this cell cycle seems to suggest its role 
as the rate limiting step in vivo, with the rate of cell cycle decline appearing to 
correlate with the decrease in PDGF signalling during development and the final 
cell number being proportional to the supply of PDGF available. The limiting 
factor in OPC proliferation in the embryo therefore appears to be due to 
environmental factors, the availability of PDGF, rather than a cell-intrinsic 
mechanism (Van Heyningen, Calver and Richardson, 2001). In the adult CNS, the 
density of OPCs appear to be controlled by a cell-intrinsic homeostatic 
mechanism, in which cortical OPCs constantly survey their local environment 
using motile filopodia and growth cones to continuously migrate at an average 
rate of 2μm per day to areas where they can maintain their unique territory 
through self-avoidance of other OPCs. At this later stage, the proliferation of 
OPCs therefore seem to be maintained through a balance of growth and 
repulsion to ensure that they are available to replace lost and damaged OPCs in 
repair and regeneration rather than populate the CNS as in development (Ethan 





Figure 1.6 Schematic of OPC development with known markers and factors influencing its 
development 
The diagram represents some of the key markers for the stages of oligodendrocyte development 
(below the figures) and the various factors that induce or inhibit their transitions (above). 
Figure was drawn on BioRender. 
 
1.4.1.4 OPC differentiation 
 
Several mechanisms regulate the differentiation of oligodendrocytes and the 
myelination process. One potential mechanism would be the expression of 
extracellular ligands which, to date, have all been inhibitory in nature, including 
Jagged via the Notch pathway with Notch1 receptors being expressed on OPCs 
(Wang et al., 1998), PSA-NCAM, with its expression on all fibres during 
development and its downregulation leading to myelination on PSA-NCAM-
negative axons (P. Charles et al., 2000), and LINGO-1, which is expressed in OLs 
and the attenuation of its function leading to increased differentiation and 
myelination through the activation of RhoA (Mi et al., 2005). The Wnt/β-catenin 
pathway (Figure 1.6) may also play a complex role in OL development, with a 
genome-wide screen of transcription factor-encoding genes in remyelinating 
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rodent lesions and human MS lesions showing active and dynamic expression of 
the Wnt pathway mediator Tcf4/Tcf7l2, which was also identified as playing an 
important role for OPC maturation in an independent in silico screen (Fu et al., 
2009), in lesioned WM, the activation of β-catenin signalling during OL 
development and remyelination, their subsequent downregulation in mature 
OLs, and the disruption of the Wnt/β-catenin signalling delaying both 
developmental myelination and remyelination (Fancy et al., 2009). The targeted 
disruption of Tcf4/Tcf7l2 in mice blocks OL differentiation (Ye et al., 2009), 
suggesting that the role of the Wnt/β-catenin pathway is in the initial stages of 
differentiation, with its subsequent downregulation being required for 
continued differentiation to occur. The inhibition of Rho-A/Rho-associated 
kinase (ROCK) signalling pathway (Figure 1.6) appears to enhance myelinating 
OLs in rodent and human OPCs, in human neuron-OPC co-cultures, and in 
remyelination in rat brain tissue (Pedraza et al., 2014). In addition, he G protein-
coupled receptor GPR17 (Chen et al., 2009) and ɣ-secretase (Watkins et al., 2008) 
appear to have inhibitory effects on myelination through yet unknown ligands. 
As discussed further below, the electrical activity of axons appear to be 
important for OPC development and myelination. Neuronal activity may affect 
OL differentiation through influencing the expression of surface ligands and 
receptors, such as L1 and neural cell adhesion molecule (NCAM) (Itoh et al., 
1995), the activity of adenosine receptors on OPCs, which inhibit OPC 
proliferation and promote differentiation and myelination (Stevens et al., 2002), 
or indirectly through stimulating leukaemia inhibitory factor (LIF) release from 
astrocytes which promote myelination (Ishibashi et al., 2006). More recently, the 
G protein-coupled receptor endothelin receptor B (Figure 1.6) and PKC epsilon 
were shown to increase the number of myelin sheaths produced by individual 
OLs in mice and zebrafish in experience-dependent neuronal activity-associated 
myelination (Swire et al., 2019). 
Intrinsic factors may also play a role in the control of OL behaviour, such as 
transcriptional regulation, with factors such as Olig1, Nkx2.2, Sox10, Ascl1, YY1, 
and Tcf4 being required for the production of mature OLs, and the removal of 
“inhibitory” transcription factors like Id2, Id4, Sox6 and Hes5 that maintain 
undifferentiated OPCs allowing the progression of OPC development (Wegner, 
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2008). The myelin gene regulatory factor (MRF) is a transcriptional regulator that 
is specifically expressed in postmitotic terminally differentiated OLs, with its 
knockdown and overexpression preventing and promoting the expression of 
myelin genes, respectively. The absence of MRF from OL lineage cells results in 
severely neurologically abnormal mice with premyelinating OLs that fail to 
myelinate, highlighting their critical role for OL maturation and myelination 
(Emery et al., 2009). Chromatin remodelling and epigenetics may be another 
intrinsic mechanism through which OL differentiation is regulated, with the 
inhibition of histone deacetylases (HDACs) resulting in hypomyelination, 
prolonged expression of OPC markers, and delayed expression of differentiation 
markers (Shen, Li and Casaccia-Bonnefil, 2005), with HDACs being required at 
multiple stages of OPC development to inhibit the Wnt/β-catenin pathway and 
being recruited by Yin Yang 1 (YY1) to repress inhibitors of myelin gene 
expression like Tcf4 and Id4 (He et al., 2007; Ye et al., 2009). MicroRNAs may also 
regulate OL differentiation and myelination, with targeted deletion of Dicer1 
disrupting miRNA processing and normal CNS myelination, and miR-219 being 
shown to be necessary and sufficient for OL differentiation (Dugas et al., 2010). 
 
1.4.1.5 Death of newly differentiated oligodendrocytes 
 
As first shown by Barres et al. (1992a, 1992b) in the developing rat optic nerve, 
about 50% of newly differentiated oligodendrocytes die in a process 
characteristic of programmed cell death within a few days after being generated. 
In in vitro conditions, this death is preventable through exposing the cells to 
conditioned medium from their in vivo neighbouring cells, or through exposure 
to PDGF and insulin-like growth factors (IGFs). Decrease in normal OL death by 
up to 90% is achievable by increasing exposure to PDGF in the developing optic 
nerve, resulting in the doubling of the number of OLs. In the developing rat brain, 
Trapp et al. (1997) subsequently showed that newly differentiated 
premyelinating OLs either myelinated axons or underwent cell death, with about 
20% of these newly formed OLs degenerating in P7 to P21 cerebral cortex, and 
those that ensheathed and formed compact myelin being exempt from dying. 
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Cumulatively, this suggests that once OPCs have differentiated into OLs, there is 
competition for the limited availability of growth factors, which act via the 
extracellular matrix (ECM) as discussed further below, and the presence of 
axonal influences that promote their survival and maturation into myelinating 
OLs, with in vivo imaging showing most pre-myelinating OLs undergoing 
apoptosis prior to myelination (Hill, Li and Grutzendler, 2018; Hughes et al., 
2018).  One of the key molecular mechanisms through which the regional and 
temporal specificity of myelination may be regulated is the transcription factor 
EB (TFEB), which is highly expressed in differentiating and premyelinating OLs. 
Mice with conditional knock out of this transcription factor exhibit precocious 
and ectopic myelination with thicker myelin sheath formation, suggesting its role 
in myelination specificity and control. Sun et al. (2018) showed that TFEB 
functions in a cell-autonomous manner to promote OL apoptosis and prevent 
their maturation via the pro-apoptotic factor PUMA, and regulates the spatial 
and temporal specificity of CNS myelination by activating the PUMA-Bax-Bak 
pathway, and therefore suggesting a molecular mechanism through which OPC 
proliferation is controlled to not cause hypermyelination. 
 
1.4.1.6 Factors that regulate OPC development 
 
1.4.1.6.1 Growth factors 
OPCs express platelet-derived growth factor alpha-receptors, PDGFRα, with the 
mitogen PDGF-AA released by neighbouring astrocytes promoting DNA synthesis, 
increased proliferation and motility, and regulating their cell cycle and the timing 
of their differentiation into oligodendrocytes, with oligodendrocytes losing 
PDGFRs as they mature (Figure 1.6) (Noble et al., 1988; Richardson et al., 1988; 
Hart et al., 1989; Pringle et al., 1992; Calver et al., 1998). PDGF therefore appears 
to be important for the normal development of the oligodendrocyte lineage, 
with PDGF-A null mice showing severe deficiencies in OPC development, with the 
hindbrain and midbrain showing 42% and 28% PDGFRα+ cells, respectively, 
compared to wild-type control at E15, whereas the subunit PDGF-B null mice 
showed no difference to the wild-type. In postnatal mice, there is also a similar 
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reduction in PDGFRα+ cells in PDGF-A null animals, although the extent is region-
dependent, with almost 100% vs. an 80% reduction in the optic nerve compared 
to the cerebral cortex at birth, with a parallel decrease in the subsequent number 
of oligodendrocytes and the extent of myelin formation (Fruttiger et al., 1999). 
PDGF interacts with other molecules and their receptors to achieve its mitogenic 
activity, such as the membrane protein NG2 chondroitin sulfate proteoglycan 
(NG2) and the ECM glycoprotein tenascin-C (TN-C). NG2 expression is strongly 
co-localised and regulated in parallel with and their co-expression important for 
the proliferative response of PDGF (Nishiyama et al., 1996). The loss of TN-C from 
the matrix results in faster OPC migration in vitro, and shows reduced OPC 
proliferation from the loss of PDGF responsiveness, with TN-C acting via the αvβ3 
integrin receptor, which is expressed during OPC differentiation (Milner et al., 
1997), to increase the mitogenic effects of PDGF on OPCs (Garcion, Faissner and 
ffrench-Constant, 2001). 
Fibroblast growth factors (FGFs) highly influence OLs at various stages of their 
development (Figure 1.6), with the FGF receptors (FGFRs) expressed on OL 
lineage cells changing through the maturation process in vitro and FGF2 effecting 
OL development at all stages (Butt and Dinsdale, 2005; Fortin et al., 2005; 
Furusho et al., 2011, 2012; Murtie et al., 2005). In vitro, the combination of PDGF 
and FGF2 promote continuous division of OPCs without differentiation for a 
prolonged period, with FGF2 maintaining PDGFα receptor expression on OPCs 
(Bögler et al., 1990; McKinnon et al., 1990). Terminal differentiation of OPCs 
seem to be blocked by the FGF8 and FGF17 ligands on FGFR3, process growth on 
differentiated OLs being triggered by FGF9 on the FGFR2 signalling pathway, and 
OPCs and OLs both being targeted by FGF18 acting on the FGFR2 and FGFR3, with 
FGFR expression changing from FGFR3 to FGFR2 as OPCs differentiate into OLs. 
Ligand availability and the changing expression of FGFRs appear to critically 
regulate normal OL development, with FGF2 activation of FGFR1 promoting OPC 
proliferation but having deleterious effects on OLs, leading to the loss and 
preventing new generation of myelin-forming OLs (Butt and Dinsdale, 2005; 
Fortin et al., 2005). However, although Fgfr1 and Fgfr2 appear to be required for 
the initial OPC generation in the mouse ventral forebrain by cooperating with 
Shh signalling, their conditional deletion showed that, unlike what has previously 
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been shown in in vitro experiments, they did not appear to be required for the 
proliferation of OPCs in vivo (Furusho et al., 2011). In Fgf2 null mice, although its 
knockout out in the germline did not affect OPC proliferation in the developing 
spinal cord, there was an increase in the number of differentiated OLs, 
suggesting that in vivo, FGF2 and FGFR1 play an important role in the inhibition 
of differentiation in OL lineage cells (Murtie et al., 2005). Fgfr1 and Fgfr2 deletion 
in differentiated OLs in vivo in mice showed reduced Erk1/2-MAPK signalling 
pathway activity, and showed hypomyelination with thinner myelin sheath 
formation, although OPC proliferation and differentiation, and axonal 
ensheathment and myelination initiation were unaffected (Furusho et al., 2012). 
Cumulatively, these studies show the complexity of Fgf signalling in the normal 
CNS, with different members of the FGF family and their receptors affecting 
different stages of OL lineage cell development. 
Neuregulins are a family of transmembrane and soluble protein isoforms that 
have been implicated in the survival, proliferation, migration, and differentiation 
of oligodendrocyte lineage cells in their normal development, with their absence 
in active MS lesions potentially contributing towards poor remyelination (Canoll 
et al., 1996; Flores et al., 2000; Viehover et al., 2001). Heregulin binds to erbB2, 
erbB3, and erbB4 receptors from a family of tyrosine kinases which are all 
expressed on OL lineage cells, to induce a time- and dose-dependent 
phosphorylation of Akt. Dominant negative overexpression of Akt through 
adenoviral gene transfer activated the caspase cascade to induce apoptosis in 
both OPCs and OLs, and growth factor deprivation-induced apoptosis of OPCs 
could be prevented by heregulin. This suggests a role for the phosphatidylinositol 
(PI)-3 kinase/Akt pathway in the survival of OL lineage cells (Flores et al., 2000), 
which was also shown to be the pathway through which Neuregulin 3 (NRG3) 
elicited its OL survival role in the embryonic CNS through the activation of the 
erbB4, an important receptor for brain development (Carteron, Ferrer-Montiel 
and Cabedo, 2006). Glial growth factor (GGF), specifically GGF2, is a soluble 
recombinant isoform of neuregulin which mediates its effect, likewise, via the 
erbB2, erbB3, and erbB4 receptors. GGF2 has been shown to be a potent 
mitogen of OPCs, promote their survival, and prevent their differentiation, with 
cortical neurons releasing a soluble mitogen whose effects can specifically be 
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blocked by antibodies against GGF (Canoll et al., 1996). In the developing rat 
optic nerve, neuregulin was shown to support the survival of aged OPCs and OLs, 
and increase or decrease death induced by nerve transection by neutralising or 
delivering the growth factor, respectively (Fernandez et al., 2000). Cumulatively, 
these suggest an axon-associated regulatory role in the survival and proliferation 
of OL lineage cells by neuregulins. In the migration of OPCs, neuregulin 1 (NRG1) 
acts on the erbB4 receptor in the developing embryo, with Nrg1 acting as a 
potent chemoattractant during the first wave of OPC migration but not during 
later postnatal stages, and a deficit in erbB4 leading to impaired OPC migration 
during development, highlighting the role of NRG1/erbB4 signalling pathway in 
early development OPC migration (Ortega et al., 2012). The NRG1/erbB pathway 
also has a role in regulating CNS myelination, although it is not essential for 
myelin sheath formation as in the PNS (Vartanian, Fischbach and Miller, 1999). 
Co-cultures of OPCs with NRG1 type III deficient dorsal root ganglions (DRGs) 
result in normal differentiation and myelinate, although to a lesser degree than 
with wild type DRGs. Transgenic NRG1 type I or type III overexpression lead to 
hypermyelination, although the expression of NRG1 type III is not sufficient to 
drive myelination in unmyelinated axons such as the sympathetic neurons. 
Haploinsufficient mice for NRG1 type III are hypomyelinated in the brain, but 
unaffected in the optic nerve and spinal cord. Cumulatively, this suggests a 
region-specific role for NRG1 in the extent of myelination, specifically in the brain 
(Brinkmann et al., 2008; Taveggia et al., 2008). Like the FGFs, the family of 
neuregulins have a pleiotropic effect on the OL lineage cells in a developmental 
stage, region-specific, and isoform-dependent manner. 
Neurotrophins are another class of growth factors that regulate various stages 
of OL development. In particular, neurotrophin-3 (NT3) has been shown to be 
important for promoting the survival of OPCs, and, in conjunction with PDGF, to 
also be able to stimulate OPC proliferation. TrkC, the high-affinity receptor for 
NT3, is expressed throughout all stages of the OL lineage development, with NT3 
inducing the phosphorylation of mitogen-activated protein kinase (MAPK) to 
elicit its effect (Barres et al., 1993, 1994; Cohen et al., 1996). Brain-derived 
neurotrophic factor (BDNF), which acts through the trkB receptor, increases DNA 
synthesis in OPCs, differentiation of postmitotic OLs, and has a role in regulating 
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myelination (Figure 1.6). Knockout animals for BDNF show reduced OPC 
numbers at embryonic day 17 (E17), postnatal day 1 (P1), P14, and in the adult 
animal, as well as decrease myelin basic protein (MBP), myelin associated 
glycoprotein (MAG), and proteolipid protein (PLP), suggesting its importance in 
OPC development and differentiation (Vondran et al., 2010). Conditional 
knockout of the receptor TrkB on OLs also results in decreased myelin protein 
expression, as well as reduced myelination in the CNS during development 
despite normal numbers of OLs and myelinated axons, with myelin sheath 
thickness being significantly impacted, suggesting the role of BDNF in myelin 
ensheathment rather than axonal contact. Interestingly, these animals also 
showed increased OPC density and proliferation, suggestive of a modification of 
the proliferative potential of OPCs in conditional knockouts (Wong et al., 2013). 
In contused adult rat spinal cord, 10 weeks post-injury, transplants containing 
grafts of fibroblasts producing the neurotrophic factors NT3 and BDNF contained 
more axons than other grafts, including ciliary neurotrophic factor and basic 
fibroblast growth factor, and, importantly, enhanced myelinogenesis, which 
BrdU labelling was able to associate with increased expansion of OL lineage cells 
(McTigue et al., 1998). These highlight the role of neurotrophins, such as NT3 




In addition to growth factors, such as those discussed above, several chemotactic 
cytokines, or chemokines, which are regulatory molecules that modulate the 
inflammatory responses, have a role in modulating OL lineage cells. For example, 
growth-regulated-oncogene-α (GRO-α), which is released in part by a subset of 
spinal cord astrocytes, is a potent promoter of OPC proliferation and has a 
synergistic and localised influence on the mitogenic effects of PDGF in a 
developmentally regulated manner from the ventral to dorsal spinal cord white 
matter (Robinson et al., 1998). C-X-C Motif Chemokine Receptor 4 (CXCR4) and 
its chemokine ligand C-X-C Motif Chemokine 12 (CXCL12) also regulate OPC 
survival and migration (Figure 1.6). OPCs isolated from newborn mice 
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coexpressed CXCR4 and PDGFRα, and CXCR4 expression decreased with 
differentiation in vitro. Neonatal OPCs showed CXCR4- and CXCL12-dependent 
migratory behaviour in a concentration-dependent manner in chemotactic 
chambers, and CXCR4-defective mice showed decreased PDGFRα-expressing 
OPCs in the embryonic spinal cord with decreased indications of ventral to dorsal 
migration during development (Dziembowska et al., 2005). In studying the 
effects of another CXCR, CXCR7, the use of an in vivo EAE model and in vitro 
primary OPCs showed that CXCR4 was downregulated and CXCR7 upregulated 
with OPC differentiation and maturation, with CXCR4 being undetectable in the 
CNS of the EAE model. CXCL12 was also shown to promote the maturation of in 
vitro OPCs in a CXCR7-depenent manner through pharmacological inhibition 
(Göttle et al., 2010). Cumulatively, Dziembowska et al. (2005) and Göttle et al. 
(2010) highlight the role of various CXC receptors, specifically the CXCR4 and 
CXCR7, and their ligand CXCL12 on different stages of the OL lineage maturation. 
 
1.4.1.6.3 Extracellular Matrix (ECM) 
As discussed previously, ECM components such as TN-C and integrin play an 
important role in interacting with mitogens like PDGF to elicit their effect 
(Garcion, Faissner and ffrench-Constant, 2001; Milner et al., 1997). The ECM, 
comprised of a complex system comprised primarily of collagens, glycoproteins, 
and glycosaminoglycans, provides signals for growth, differentiation, and 
migration of cells, and are critical for the developmental organisation of the CNS 
(Novak and Kaye, 2000). In vitro, the purified ECM protein fibronectin enhanced 
the survival, proliferation, migration, and process extension properties above the 
PDL control, and above the purified ECM laminin and secreted ECM protein 
mixture Matrigel (Hu et al., 2009), showing the preference of OL lineage cells for 
certain ECM components. The integrins have also been shown to be important 
ECM components in OL development, particularly in the regulation of OL survival 
and death, with the absence of α6 integrin receptor for laminins in null animals 
resulting in increased apoptosis of myelinating OLs. The α6β1 integrins have been 
shown to activate a “switch” that is mediated via association with the Src family 
kinase (SFK) Fyn to change neuregulin signalling to increase dependence on the 
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more highly activated MAPK signalling pathway (differentiation) versus the PI3K 
pathway (proliferation) in survival signalling. Another SFK Lyn acts on the αvβ3 
integrin earlier in the lineage to promote OPC proliferation (Colognato et al., 
2002, 2004). The non-integrin ECM receptor, dystroglycan, which interacts with 
laminin, has also been shown to play an important role in regulating myelin 
formation. The absence of dystroglycan, either by antibody blocking or siRNA 
knockdown, lead to decreased differentiation and myelin-specific protein levels 
(MBP and CNP), and the loss of complex myelin membrane sheets production 
and nascent myelin sheath structure formation, suggesting its role in later stages 
of OL development (Colognato et al., 2007). 
In neuropathology, the CNS microenvironment has been shown to become 
perturbed and contain ECM components that are inhibitory to the regenerative 
process (Fitch and Silver, 2008). Of particular interest to MS, members of the 
chondroitin sulphate proteoglycans (CSPG) ECM family, which play a role in 
patterning cell migration and axonal growth guidance in development and in 
plasticity in adulthood (Laabs et al., 2005), have been shown to be upregulated 
and present at the borders of chronic lesions (Sobel and Ahmed, 2001), and 
inhibit OPC process outgrowth and differentiation in vitro which is reversible 
with Rho kinase inhibitor treatment (Siebert and Osterhout, 2011a). In addition, 
basement membrane components, predominantly associated with the 
vasculature in the normal CNS, have been shown to be expressed in active lesions, 
including laminin, collagen type IV, and heparin sulphate proteoglycans (HSPGs) 
(van Horssen et al., 2006; Van Horssen, Dijkstra and De Vries, 2007). In MS 
patient tissue samples and in the EAE mouse model, high molecular weight 
hyaluronan was shown to accumulate in chronic demyelinated lesions, with their 
presence inhibiting remyelination in lysolecithin-induced WM demyelination 
model, and shown in vitro to inhibit OPC maturation which degradation of this 
ECM component could improve (Back et al., 2005). Together, the inhibitory 
effect of upregulated ECM components in MS suggest their role in providing a 





1.4.1.6.4 Electrical activity 
OPCs have been shown to express a variety of neurotransmitter receptors, 
including those for glutamate (kainate, AMPA, and NMDA), GABA, and 
acetylcholine in serum-free cultures (Barres et al., 1990), in mouse hippocampal 
brain slices (Jabs et al., 1994; Steinhäser, Jabs and Kettenmann, 1994), and gene 
profiling (Patneau et al., 1994; Cahoy et al., 2008), and show brain region- and 
age-specific heterogeneous expression profiles of ion channels and neuronal 
activity sensitivity (Spitzer et al., 2019), suggesting their responsiveness to the 
demands of surrounding neurons. OPCs appear to be the only glial cells to 
directly form synapses with neurons to receive postsynaptic inputs, forming 
synapses with glutamatergic neurons throughout the grey and white matter 
which become more robust throughout maturation (Bergles et al., 2000; 
Káradóttir et al., 2005; Müller et al., 2009), and with GABAergic neurons in the 
grey matter which change to extrasynaptic signalling with age (Lin and Bergles, 
2004; Velez-Fort et al., 2010). Although the function of these synaptic inputs in 
OPCs are less clear than for neurons, AMPA and NMDA receptor expression has 
been shown to be rapidly down-regulated and the synapses removed with OPC 
differentiation (Biase, Nishiyama and Bergles, 2010; Kukley, Nishiyama and 
Dietrich, 2010), suggesting their role in communication with neurons at the 
precursor stage of migration and OL development (Gudz, Komuro and Macklin, 
2006; Yuan et al., 1998). Electrical activity has been shown to be important for 
OPC proliferation through influencing growth factor release (Barres and Raff, 
1993), and in inducing myelination through tetrodotoxin (TTX) blocking of 
neuronal firing (Demerens et al., 1996). More recently, stimulation of the neural 
circuit in adult animals have shown increases in OPC proliferation, OL 
myelination, and myelin sheath thickness (Wake, Philip R. Lee and Fields, 2011; 
Gibson, Purger, Mount, Goldstein, Lin, Wood, Inema, Miller, Bieri, Zuchero, B. A. 
Barres, Woo, Vogel and Monje, 2014; McKenzie et al., 2014), with the frequency 
of the neuronal firing itself, and not just its presence, seeming to affect OPC 
behaviour. The different patterns of neuronal activity modulates the 
neurotransmitter and synaptic profile at axon-OPC synapses through changes in 
glutamate release. The implantation of an electrode array into the corpus 
callosum of adult mice showed that the degree of stimulation of axons changed 
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the density of OPCs and pre-myelinating OLs, with testing of OPC behaviour at 
three different stimulation paradigms showing that 5 Hz seemed to be more 
efficient at affecting differentiation behaviour, whereas 25 Hz and 300 Hz 
triggered proliferative ones (Nagy et al., 2017). The ability to communicate with 
and detect neuronal signals, and the specific pattern of this signalling, therefore 
seems to play an important role in the ability for OPCs to develop and mature in 
the CNS. 
 
1.4.2 Oligodendrocyte Formation and Heterogeneity 
 
In order to form myelin sheaths, OPCs need to differentiate into OLs, with this 
transition being highly regulated by, for example, GABAergic signalling positively 
driving differentiation whilst negatively regulating proliferation, and its peak 
signalling being coordinated with onset of oligodendrogenesis (Orduz et al., 2015; 
Velez-Fort et al., 2010; Zonouzi et al., 2015). Differentiating OLs can be identified 
by marker proteins CNP (Poduslo and Norton, 1972), O4 (Schachner and Sommer, 
1981), and ectonucleotide pyrophosphatase/phosphodiesterase 6 (ENPP6) (Xiao 
et al., 2016), whilst more mature OLs express a range of myelin-specific proteins 
and transcription factors such as MBP (Sternberger et al., 1978), MAG 
(Sternberger et al., 1979), myelin/oligodendrocyte glycoprotein (MOG) 
(Linnington, Webb and Woodhams, 1984), PLP (Sobel et al., 1994), and myelin 
regulatory factor (MYRF, which is essential for differentiation of mature 
myelinating OLs and lack of expression leads to hypomyelination and OL 
apoptosis) (Emery et al., 2009). 
OLs are highly heterogeneous, including their morphological properties (Murtie, 
Macklin and Corfas, 2007; Vinet et al., 2010). A transgenic mouse line expressing 
membrane-associated EGFP expression under the control of MBP, labelling <1% 
of the myelinating cells so that individual OLs could be imaged and quantified, 
showed diversity with the number of myelin internodes formed per OL, with a 
range of 10 to 60, and sheath length, between 20 to 200 microns (Chong et al., 
2012). OLs from distinct regions have also been shown to have different 
properties including myelinogenic capabilities and myelination preference. In 
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the grey matter (GM), a high-throughput electron microscopy (EM) 
reconstruction technique to visualise myelination in the mouse neocortex 
showed distinct and variable distribution of myelin, with superficial layers 
showing higher diversity (Tomassy et al., 2014). Injection with attenuated rabies 
virus and adeno-associated virus to visualise individual OLs in WM, the corpus 
callosum, showed that 25% of OLs preferentially myelinated motor or sensory 
cortical axons, whereas 75% showed no preference (Osanai et al., 2017). 
Collectively, these suggest that the myelination properties of individual OLs are 
highly diverse, which may be linked to functional and regional diversity. 
Further evidence for diversity comes from homo- and heterotropic cell 
transplantation experiments of OLs from GM and WM of the adult mouse cortex 
that showed higher efficiency of WM-derived OLs in differentiating in either GM 
and WM environments in comparison to GM-derived OLs (Viganò et al., 2013), 
and from single-cell sequencing experiments have shown six different 
transcriptional profiles of myelin-forming OLs (Marques et al., 2016; Jäkel  et al., 
2019).  However the biological significance of this diversity remains unknown. 
 
1.4.3 Myelin Sheath Formation 
 
Once an oligodendrocyte is formed, the next step is myelin sheath formation. 
The exact mechanism by which a myelin sheath is constructed is not yet fully 
understood. One model, later called the “carpet crawler model” (Sobottka et al., 
2011), used electron microscopy data to suggest the outer myelin membrane is 
formed, followed by the inner layers migrating underneath in a “rolled up carpet” 
motion (Bunge, Bunge and Bates, 1989). More recently, the “liquid croissant 
model” was suggested, which addresses some of the limitations of previous 
models such as the high energy required to overcome the friction of pushing 
myelin layers underneath already formed ones in the “carpet crawler model”, or 
how the maximum thickness of the myelin at the middle of the internode is 
formed. In this study, high-resolution confocal microscopy was used to describe 
the process of myelin sheath formation as the creation of a triangular-shaped 
myelin sheet, with the “pouring out” of myelin proteins along the triangular 
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shaped OL process following initial axon contact in a bidirectional coiled manner, 
and sheath thickness and length increase occurring by subsequent layers 
“pouring” on top of previously formed inner layers and extending sideways in a 
“croissant” shape (Sobottka et al., 2011). Snaidero et al. (2014) found with 
fluorescent signal intensity analysis from confocal images of zebrafish in vivo and 
high-resolution three-dimensional reconstructions of the mouse optic nerve 
from electron microscopy that myelin sheath growth appears to initially be 
nonuniform in the growing myelin sheath, with more layers at the centre 
compared to the lateral edges. The inner tongue appears to extend around the 
axon underneath the previous membrane layer, with in vivo virus labelling of 
glycoprotein and electron microscopy data showing selective targeting of new 
membrane material at this active growth zone facilitated by cytoplasmic 
channels. Simultaneous lateral extension in the growing myelin sheath seems to 
lead to a more uniform thickness along the mature sheath. Collectively, these 
data support Sobottka et al. (2011)’s “liquid croissant model” of myelin sheath 
formation, with further evidence showing that the phosphoinositide 3-kinase 
(PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signalling 
pathway regulates the cytoplasmic channels in myelin growth regulation. 
The role of the actin cytoskeleton has been implicated as important for myelin 
wrapping (Figure 1.7). In this process, F-actin is redistributed and polymerised at 
the leading edge as a mechanical force to push out the myelin membrane and 
then disassembled, which triggers the myelin sheet to spread and adhere. Actin 
assembly in myelin wrapping appears to be mediated by the Arp2/3 complex in 
driving OL process growth and branching, with deletion early on in myelin 
formation resulting in myelination defects, although it is not required for 
subsequent wrapping (Zuchero et al., 2015). Subsequently, actin disassembly 
appears to be facilitated by ADF/cofilin1, with deletion resulting in an abnormal 
size of the inner tongue of the wrapping myelin sheet and impaired myelin 
growth and hypomyelination (Nawaz et al., 2015), and indirectly via MBP by 
binding to membrane PI(4,5)P2 to induce the release of actin disassembly 
proteins, with MBP and actin filaments occupying non-overlapping domains in 
differentiating OLs and knockdown of MBP resulting in abnormal actin filament 




Figure 1.7 Potential mechanism for myelin wrapping 
As described by Zuchero et al. (2015), myelin wrapping may occur in a two-step process by which 
ensheathment occurs due to an Arp2/3-dependent actin assembly, followed by its disassembly in 
the inner tongue for myelin wrapping to occur. 
Figure from Zuchero et al. (2015). 
 
Once wrapping has initiated, myelin sheaths elongate and compact in order to 
become mature myelin sheaths. Live in vivo studies in zebrafish show that in 
addition to its role in process retraction in axon selection, calcium plays an 
important role in sheath elongation. High frequency of intracellular [Ca2+] 
transients appear to promote sheath lengthening, with elongation occurring 
about 1 hour after calcium concentration being increased, with calcium buffering 
being sufficient to result in shorter sheath lengths (Krasnow et al., 2017; Baraban, 
Koudelka and Lyons, 2018). These changes in calcium may regulate the activity 
of proteins involved in the cytoskeleton or calcium-activated signalling pathways, 
such as the PI3K-AKT-mTOR pathway (Zonouzi et al., 2011). The generation of 
myelin appears to have a variety of signalling pathways that play a role, such as 
phosphatidylinositol 3,4,5-trisphosphate (PIP3) and extracellular signal-
regulated kinases (ERK)/mitogen-activated protein kinases (MAPK). Various 
mouse mutants to elevate the PIP3 signalling pathway, such as through the 
disruption of its antagonist phosphatase and tensin homolog (PTEN) (Goebbels 
et al., 2010) and constitutive activation of its downstream target AKT kinase 
(Flores et al., 2008), and transgenic mice with sustained ERK1/2 activation (Ishii, 
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Furusho and Bansal, 2013) showing increased myelin thickness, highlighting their 
roles in controlling myelination. The conditional mouse mutant of a highly 
evolutionarily conserved regulator of cell polarity, Scribble, showed decreased 
longitudinal myelin extension but increased myelin thickness (Jarjour et al., 
2015), suggesting that radial and longitudinal growth of myelin requires 
individual coordination of signals along both axis of growths to regulate 
cohesively. Myelin compaction is the final stage in the myelin sheath formation 
process by which the extracellular and cytoplasmic sides of adjacent myelin 
lamellae connect tightly, with compaction starting from the outside in (Snaidero 
et al., 2014). Although the exact mechanism through which this process is 
initiated is not yet understood, MBP (Raasakka et al., 2017) and CNPase (Yin et 
al., 1997) appear to play important roles.  
 
1.4.3.1 Regulation of Myelination - Intrinsic and Extrinsic Signals 
 
The mechanisms described above suggest an intrinsic programme driving sheath 
formation, a conclusion supported by the finding that when OPCs are cultured in 
the absence of axonal signalling, such as on paraformaldehyde-fixed axons 
(Rosenberg et al., 2008) and polystyrene microfibers (Lee et al., 2013), these 
OPCs are able to differentiate and form compact myelin sheaths. Importantly, 
spinal cord-derived OLs produced longer sheaths than cortex-derived OLs when 
cultured on poly-L-lactic acid (PLA) microfibers (Bechler, Byrne and ffrench-
Constant, 2015), with these lengths being comparable to their respective in vivo 
sheath lengths (Murtie, Macklin and Corfas, 2007; Bechler, Byrne and ffrench-
Constant, 2015), highlighting the origin of OPCs as determining their intrinsic 
myelinogenic potential. 
In addition to these intrinsic mechanisms, however, there is abundant evidence 
that myelination can be altered through extrinsic signalling, such as with 
experience and learning. A key signal here is thought to be axonal activity, as first 
suggested by experiments with mice reared in complete darkness showing 
decreased myelination (Gyllensten and Malmfors, 1963), the blocking of axonal 
potential with tetrodotoxin inhibiting myelination (Demerens et al., 1996), and 
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more recently by optogenetic stimulation of the premotor cortex in mice 
promoting oligodendrogenesis and increasing myelination (Gibson et al., 2014). 
In addition, socially isolated male rhesus monkey infants (Sánchez et al., 1998) 
and socioemotionally deprived children raised in orphanages (Eluvathingal et al., 
2006), with decreased social, cognitive, and emotional stimulation during 
development, were shown to have decreased white matter volume and cognitive 
and behavioural deficits. In mice, two weeks of social isolation immediately after 
weaning led to hypomyelination of the prefrontal cortex, with oligodendrocytes 
having reduced branching, sheath number and thickness, and deficiencies in 
behavioural tests, such as social exploration, which was irreversible with 
reintroduction to a social environment and suggests a critical window for myelin 
plasticity. This phenotype could be replicated by the loss of ErbB3 receptors in 
OLs, highlighting the neuregulin-1 (NRG1)/ErbB3 signalling pathway as a 
potential molecular mechanism through which this stimulation-dependent 
myelination occurs (Makinodan et al., 2012). 
Linked to the role of activity in influencing myelination, Mckenzie et al. (2014) 
conducted a study in which mice learnt a new complex motor task of running on 
a “complex wheel” in which rungs on the running wheel were removed at 
random positions. These mice showed an increase in OL formation, suggesting 
the effect of increased neuronal activity specifically from learning a new motor 
task in increasing myelination. However, interestingly, when Myrf was 
conditionally knocked out to prevent new OL development, deficits in the 
learning could be seen. This suggests both that increased neuronal stimulation 
through learning increases myelin formation, and that myelination is also 
required for this learning to occur (Mckenzie et al., 2014). 
A key question is how activity signals to the oligodendrocyte, and synaptic vesicle 
release has been shown to be one of the mechanisms through which this occurs. 
Vesicular release of glutamate from axons stimulate the local translation of MBP 
in OLs through the Fyn kinase-dependent pathway (Wake, Philip R Lee and Fields, 
2011), and tetanus toxin inhibition of axonal activity results in fewer myelinated 
axons, and vice versa with stimulated neuronal activity through the use of a 
GABA-A receptor antagonist (Mensch et al., 2015). Fyn signalling appears to be 
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important in modulating myelination as the activation and disruption of Fyn 
increases and decreases sheath number per OL, respectively (Czopka, ffrench-
Constant and Lyons, 2013), with its tyrosine kinase activity appearing to be 
important for myelination (Sperber et al., 2001).  
Activity-related signals might explain in part why the formation and degree of 
myelination progresses in a relatively fixed topographical and chronological 
sequence, which is generally hierarchical starting from regions controlling basic 
homeostasis to areas of increasing complexity, sensory systems usually before 
motor systems (Brody et al., 1987; Kinney et al., 1988), and axons being 
myelinated, partially myelinated, or unmyelinated (Tomassy et al., 2014). 
However, the question as to whether other cues on the surface of CNS axons 
play a role remains unanswered.  
Suggesting that such cues exist, OLs actively explore their surrounding 
environment using highly dynamic processes (Kirby et al., 2006; Ethan G Hughes 
et al., 2013), with cells determining whether to retract or stabilise and elongate 
the formation of myelin sheaths by mediation of intracellular calcium 
concentrations (Baraban, Koudelka and Lyons, 2017; Krasnow et al., 2017) in a 
relatively restricted time window (Czopka, ffrench-Constant and Lyons, 2013). 
Inhibitory molecules of myelination have been discovered, such as 
polysialylated-neural cell adhesion molecule (PSA-NCAM) on immature neurons 
(P Charles et al., 2000) and JAM2 on neuronal cell bodies (Redmond et al., 2016) 
in developmental myelination, and semaphorin 3A, which is elevated in active 
MS lesions, as an inhibitor of OPC recruitment and remyelination in pathology 
(Piaton et al., 2011; Syed et al., 2011). However factors such as NRG1 (Brinkmann 
et al., 2008; Taveggia et al., 2008) and integrin β1 (Câmara et al., 2009) that play 
a key role in PNS myelination have only been shown to play a role in modulating 
myelination in the CNS – they are not necessary for myelination. Thus, 
Brinkmann et al. (2008) created conditional mutant mice lacking NRG1 in almost 
all projection neurons in the forebrain. Surprisingly, these animals did not show 
abnormalities in myelination development or timing when knockout occurred in 
adults or in embryonic development. Double mutants for ErbB3 and ErbB4, the 
receptors for NRG signalling, also did not affect CNS myelination. The 
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overexpression of NRG1 type III isoform, conversely, led to hypermyelination and 
premature myelination, although "ectopic“ myelination of normally 
unmyelinated axons was not observed and it did not increase myelination in LPC 
lesions. However, Taveggia et al. (2008) found that haploinsufficient mice for 
NRG1 type III have myelination defects on DRG neurons and are hypomyelinated 
in the forebrain. Collectively, these studies suggest NRG1 acts as an axonal signal 
that promotes myelination, but is not sufficient or exclusive in driving its 
occurrence. Câmara et al. (2009), in addition, showed that dominant-negative β1 
integrin transgenic mice transiently required a higher axonal calibre for 
developmental myelination to occur, with a lower percentage of myelination of 
axons below 0.6 microns in diameter, and that oligodendrocytes derived from 
dominant-negative β1 animals formed fewer internodes in co-culture, 
suggesting an intrinsic signalling abnormality. . 
While the precise molecular cues that determine whether and where an axon 
will be myelinated has yet to be determined, the role for physical cues should 
also be considered. Oligodendrocytes ensheathing biologically inert polymer 
microfibers show a preference for larger diameter microfibres of above 0.4 
micron on whether ensheathment occurs and the length of the myelin sheath 
formed (Bechler, Byrne and ffrench-Constant, 2015; Lee et al., 2012), suggesting 
that physical cues such as axon calibre may play a role in this axon selection 
process. 
 
1.4.3.2 Differentiation vs. Myelination 
 
Whether differentiation and myelination occur in a one-step process, whereby 
the initiation of the signalling pathways that result in differentiation result in 
direct progression into myelination, or a two-step process, where the OL must 
receive two different signals for each step to occur, is highly debated. From a 
clinical perspective, the difference between these two theories are significant as 
the one-step theory suggests that a pro-differentiation drug is sufficient to result 
in myelination, whereas the two-step theory would mean that different pro-
differentiation and pro-myelination drugs are required. 
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A key study that suggests the differential signalling required to initiate 
differentiation and myelination looked at the temporal and spatial progression 
of these two developmental stages in the rat optic nerve. As summarised in 
Figure 1.8, OPCs differentiate into OLs from the optic chiasm towards the eyes, 
with the OPCs near the optic chiasm expressing markers of differentiation, 
mRNAs of MBP and PLP, 3 days before those near the eyes. Conversely, however, 
MBP and PLP proteins, as markers of myelination, were detectable firstly near 
the eyes and subsequently towards the optic chiasm in a reverse gradient to 
differentiation (Colello et al., 1995). Although OPC heterogeneity could be one 
possible explanation for the temporal difference between differentiation and 
myelination of the potential different sub-populations of OPCs along the optic 
nerve, the chronology of the two different events does, however, highlight that 
there appears to be two different signalling mechanisms to initiate 
differentiation, starting from the optic chiasm, and another one to initiate 
myelination, from the eyes, providing evidence towards the two-step theory. 
 
 
Figure 1.8 Uncoupling differentiation and myelination in the rat optic nerve 
OPCs (shown in green) differentiating into OLs (shown in red) occurs from the optic chiasm to the 
eye in the rat optic nerve. Myelination (shown in blue) occurs in the opposite direction from the 
eye to optic chiasm. 
(Figure from Rosenberg, Powell and Chan, 2007) 
 
In addition, in vivo and ex vivo imaging, EdU pulse-chase experiments, and cell 
fate mapping showed that in postnatal mouse brains, P8 animals exhibited a 
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critical temporal window of 3 to 4 days for a plateau to be reached in OPCs 
differentiating into OLs after cell division, and P21 animals of 7 to 8 days, but that 
OL maturation and myelination appeared to occur more gradually over an 
extended period of time (Hill et al., 2014). Live in vivo imaging in zebrafish has 
shown that there is a critical time window of 5 hours for new myelin sheaths to 
be generated and number of sheaths formed by the oligodendrocyte to be 
determined (Czopka, ffrench-Constant and Lyons, 2013), and co-cultures of rat 
retinal ganglion cells and OPCs showed a 12 hour critical window for OLs to form 
stable myelin segments after initiation after which continued interactions did not 
result in stable segment formation (Watkins et al., 2008). Collectively, these 
suggest two potentially distinct critical periods for differentiation and myelin 
sheath initiation to occur, highlighting that there may be two different 
mechanisms modulating these two processes. 
In supporting this idea, OPCs have been shown to be electrically excitable (Clarke 
et al., 2012), with expression of voltage-gated sodium channels and ionotropic 
glutamate receptors, and the ability to form synapses with glutamatergic 
neurons (Biase, Nishiyama and Bergles, 2010). However, as these OPCs 
transitioned into myelinating OLs, there was a decrease in synaptic input, and 
downregulation of the sodium channels and glutamatergic receptors, with a shift 
towards non-synaptic inputs for promoting myelin sheath formation such as 
vesicular release (Biase, Nishiyama and Bergles, 2010; Wake et al., 2015). 
Therefore, there is evidence to suggest that neuronal activity affects both 
transitional phases in the OL development independently, with synaptic 
mechanisms modulating differentiation, and non-synaptic mechanisms for 
myelination, and consequently that different pharmacological modulators of 
these two independent processes may be required to enhance myelination in 
the treatment of MS, with G protein-coupled receptor endothelin receptor B 
having been shown to have opposing responses in inhibiting and enhancing 





1.5 Reversing Remyelination Failure 
 
1.5.1 Ageing and remyelination 
 
Chronic demyelination and decreased remyelination is a defining characteristic 
of progressive MS, and potential causes of remyelination failure include extrinsic, 
such as increased inhibitory or insufficient pro-regenerative, and intrinsic factors, 
such as the impaired capacity of the OL. As a key intrinsic factor, ageing is an 
important consideration for both remyelination and MS. MS patients are often 
diagnosed in their 30s or 40s, and have a life expectancy of at least 25 years 
(Compston and Coles, 2002), making ageing a component of disease progression. 
The rate of remyelination slows throughout adult life, progressively impairing 
OPC recruitment and differentiation (Sim et al., 2002), with this decline being 
more rapid in the more efficiently remyelinating WM (Hampton et al., 2012; 
Pfeifenbring et al., 2015; Shields et al., 1999). There is also evidence for an 
accumulation of axonal damage resulting in permanent clinical deterioration, 
which may explain the transition from RRMS to SPMS (Irvine and Blakemore, 
2006). In fact, regardless of the initial age and pattern of MS at onset of disease, 
patients reached specific and similar levels of disability at the same age, 
suggesting there was an age-associated decline (Confavreux and Vukusic, 2006), 
with cellular senescence impairing remyelination (Nicaise et al., 2019) and MS 
patients potentially undergoing accelerated ageing (Confavreux and Vukusic, 
2006). This age-related decline in remyelination has been shown to be reversible 
through exposure to a “youthful systemic milieu” of blood-derived monocytes 
from young animals in a heterochronic parabiosis experiment (Ruckh et al., 2011). 
 
1.5.2 Extrinsic factors that inhibit remyelination 
 
Our now quite detailed understanding of oligodendrocyte biology and 
myelination has led to many studies examining the possible causes of poor 
remyelination seen in patients with MS. Myelin debris represents an important 
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extrinsic factor, as myelin contains inhibitors of OPC differentiation and 
maturation ( Trapp et al., 1997; Robinson and Miller, 1999; Plemel et al., 2012). 
In the intact CNS, with disrupted BBB aiding efficient myelin debris removal (Pohl 
et al., 2011), this mechanism prevents OPCs from undergoing differentiation and 
myelination in areas already containing myelin, or in areas where there are no 
exposed axons as this would result in apoptosis. However, in MS lesions, where 
myelin debris from the inflammatory attack on oligodendrocytes and myelin 
sheaths are present, this could prevent remyelination due to the presence of the 
inhibitory signals (Baer et al., 2009; Kotter et al., 2006; Lampron et al., 2015; 
Skripuletz et al., 2013). Therefore, activation of the immune system to promote 
myelin debris clearance from extracellular space by microglia (Baer et al., 2009; 
Kotter et al., 2006; Lampron et al., 2015; Skripuletz et al., 2013), as well as 
modulation by T cells to promote spontaneous remyelination (Bieber, Kerr and 
Rodriguez, 2003; Nielsen et al., 2011; Dombrowski et al., 2015), is required to 
achieve remyelination. 
Most studies, however, have focussed on the signalling pathways that regulate 
OPC and oligodendrocyte behaviour. From these, a number of additional 
inhibitors of remyelination have been identified (Figure 1.9). These have in turn 
led to candidate-led research programmes to develop therapies to enhance 
remyelination. One important inhibitor of remyelination is LRR and Ig domain-
containing, Nogo receptor-interacting protein (LINGO-1), a CNS-expressed 
transmembrane protein in the NgR1/p75 and NgR1/Taj(Troy) signalling 
complexes in regulating axon growth which is also expressed in OLs. LINGO-1 
antagonists, through lentivirus RNA interference and exogenous antagonist 
addition, resulted in increased OL differentiation and axonal myelination, 
including in demyelination/remyelination models (Lee et al., 2007; Mi et al., 2005; 
Mi et al. 2009). This resulted in the development of a potential remyelination 
enhancement therapy, Opicinumab, a human monoclonal antibody against 
LINGO-1 (Cadavid et al., 2019), that is currently in clinical trials (NIH U.S. National 
Library of Medicine, 2019). Other inhibitors in the extracellular matrix, such as 
chondroitin sulphate proteoglycans (Siebert and Osterhout, 2011b) and 
hyaluronan (Back et al., 2005), and fibrinogen (Petersen et al., 2017) have also 
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been shown to have inhibitory effects on OLs and remyelination and represent a 
promising approach to further experimental medicine programmes. 
An alternative approach to the discovery of pathways that reverse remyelination 
failure is the discovery of new molecules implicated in normal remyelination. 
One such molecule, Retinoid X receptor gamma (RXR-ɣ), was detected in OL 
lineage cells in remyelination in a rat focal demyelination model from a 
transcription-profiling screen and has been shown to be an accelerator of 
remyelination. Administration of an agonist, 9-cis-retinoic acid, and antagonism, 
through siRNAs, antagonists, and null mice, of this receptor in in vitro and in vivo 
studies were able to show increased remyelination and delayed differentiation, 
respectively (Huang et al., 2010). Subsequently, the vitamin D receptor was 
found to be one of the nuclear receptor binding partner of RXR-ɣ, which is of 
clinical interest as vitamin D is thought to be linked with MS prevalence (Mokry 
et al., 2015), and therefore may provide a therapeutic target of increasing 
remyelination through this signalling pathway. Other possible molecules will 
come from ongoing research – so, for example, with demyelinated axons being 
shown to be electrically active and form new synapses with OPCs, targeting of 
neuronal activity through the glutamate signalling pathway (Gautier et al., 2015) 




Figure 1.9 Positive and negative factors that regulate OLs 
Figure from Plemel, Liu and Yong (2017) 
 
1.5.3 At what stage does remyelination fail 
 
In about 30% of MS lesions, a failure of remyelination occurs due to lack of OPC 
recruitment, whereas in the remaining 70%, the block occurs at a later stage in 
OL development (Boyd, Zhang and Williams, 2013; Chang et al., 2000; Jäkel et al., 
2019; Lucchinetti et al., 1999; Wolswijk, 1998). However the exact stage at which 
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this block occurs in the 70% of lesions with OPCs and OLs within them remains 
undetermined. A block in OPC maturation in the majority of MS lesions has been 
supported by various studies, including Wolswijk (1998), who characterised post-
mortem MS tissue of patients at chronic stages of the disease, and found variable 
densities of O4+, GalC- OPCs (2.3 to 34 cells/mm2) in all 22 lesions investigated, 
with 15 of these lesions (~68%) showing almost complete absence of GalC+ 
oligodendrocytes and myelin at their centres. Using double-labelling with O4 
(OPC) and Ki-67 (active proliferating cells) antibodies, none of the ~7000 O4+ 
cells in the 15 lesions were positive for Ki-67, suggesting the presence of 
quiescent OPCs in these chronic MS lesions with little to no myelination. 
Lucchinetti et al. (1999) examined brain biopsy and autopsy specimens from 113 
early MS cases for a total of 395 lesions at various stages of demyelination, which 
was narrowed down to 56 cases with lesions extending from the periplaque WM 
to the active demyelinating edge and inactive plaque centre, and OLs were 
identified using PLP mRNA for immature and mature OLs synthesising and 
maintaining myelin, and MOG protein for terminally differentiated mature OLs. 
In their study, however, they found 39 of the 56 cases (~70%) showed increased 
OL numbers, suggesting their recruitment, in demyelinated and/or remyelinated 
areas compared to active lesions. They also found increased PLP+ MOG- cells in 
29 out of 43 cases (~67%) with inactive demyelinated or remyelinated areas, 
suggesting increased immature OLs in these lesions in early MS cases. Chang et 
al. (2002) obtained autopsy samples from 10 MS patients for a total of 48 chronic 
lesions, and used confocal microscopy images to quantify premyelinating OLs, 
determined as PLP+ cells with multiple processes that were not in contact with 
myelin internodes. They were able to identify premyelinating OLs in 34 out of the 
48 lesions (~71%) (Figure 1.10 A). 
Together these studies showing lesions lacking myelin but containing either OPcs 
or OLs suggest there may be blocks at different stages in differentiation and 
remyelination in MS. More recently, single-cell transcriptomic analysis of OL 
lineage cells from a mouse model of MS, the experimental autoimmune 
encephalomyelitis (EAE) model (Falcão et al., 2018), and post-mortem human 
tissue (Jäkel et al., 2019) support this conclusion by showing a change in the 
transcriptional profile of OLs in disease. In post-mortem human tissue, single-
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nucleus transcriptional analysis from the WM of control and MS brains showed 
a skewing of the heterogeneous subclusters of OLs, with a preference for 
immature and intermediate OL populations in MS (Figure 1.5 C and Figure 1.10 
B) (Jäkel et al., 2019). Collectively, these studies suggest that in 70% of lesions, 
the lack of sufficient OPCs is not the limiting factor for why there is a failure for 
effective remyelination, that there is a change in the developmental and 
transcriptional profile of the OLs present, and that this skew may be towards pre-
myelinating and immature OLs suggesting a maturation block in MS. 
 
 
Figure 1.10 Oligodendrocytes in MS 
A. Clusters of pre-myelinating OLs can be detected within MS lesions extending multiple 




(Figure from Chang et al., 2002) 
B. t-SNE projections of OL subclasses in control and MS post-mortem human brain tissue. 
Single-nuclear sequencing data on post-mortem human brain tissue show reduction in 
OPCs and intermediate Oligo6 populations, and a skewing of the OLs with a depletion in 
Oligo1 and enrichment in Oligo2, Oligo3, Oligo5, and ImOLG.  
(Figure from Jäkel et al., 2019) 
 
1.6 Why has drug discovery for remyelination in MS been so difficult? 
 
In this section I will review two principle causes as to why drugs for remyelination have not 
yet reached the clinic. These are, (1.6.1) the difficulties of drug discovery in the CNS in general, 
and (1.6.2) the challenges of extrapolating from the predominately animal-based studies 
above to human disease, as a result of which we still do not know which cell type drives 
remyelination in humans.  A third possible reason, that the screens thus far have not 
considered the differences in the regulation of oligodendrocyte differentiation and 
myelination, will be discussed at the end of this chapter. 
 
1.6.1 Brain Disorders across the piece have defied Drug Discovery 
 
Brain disorders have largely defied drug discovery efforts, with few to no drugs 
being available for a large number of the major conditions. In order to consider 
as to why this may be the case, I will (1.6.1.1) first compare brain disorders with 
other organs and tissues to establish comparative rates of failure and where in 
the pipeline these failures occur. Following this, I will then describe the major 
challenges for drug discovery in the brain that causes these low success rates: 
(1.6.1.2) the lack of biomarkers, (1.6.1.3) pharmacokinetics and drug metabolism, 




1.6.1.1 Drug discovery across organs and diseases 
 
Success rates in drug discovery vary widely between different disease areas and 
organs, with cardiovascular diseases having approximately 20% rate of success 
versus 5% and 8% for oncology and CNS disorders, respectively (Figure 1.11 A). 
When divided by the phase of development, the majority of attrition occurs later 
on in clinical development, around Phases IIb and III. The average failure rate for 
compounds for all disease areas is 23% at the registration stage, where the full 
time and cost burden of the drug discovery pipeline has already been incurred. 
CNS has the second highest failure rate after women’s health at above 30% 
(Figure 1.11 B) (Kola and Landis, 2004), and that it falls behind cancer and 
cardiovascular success rates in clinical trials (Figure 1.11 C) with CNS drugs taking 
longer to reach the market at 12 to 16 years compared to the 10 to 12 years of 
non-CNS drugs (Alavijeh et al., 2005; Srinivas, Maffuid and Kashuba, 2018). More 
recent data paints a similar landscape, with the likelihood of approval (LOA) for 
non-pain and non-psychiatric neurological drugs, of mainly neurodegenerative 
diseases, being 9.8% from phase I to II. For comparison, infectious diseases and 
autoimmune-immunology drugs, which had the two highest LOAs from the 
disease categories with sufficient sample size, had approval rates of 16.7% and 
12.7%, respectively, and the lowest being oncology at 6.7%, for the same clinical 
phase (Figure 1.11 D) (Hay et al., 2014). Across the drugs which went through 
FDA approval for new drug application (NDA) and biologic license application 
(BLA) across various disease areas between 2005 to 2011, drugs for all 
neurological diseases, including neurodegenerative, pain, and psychiatric 
disorders, had the lowest approval rate for the first review at 36% compared to 
highest for oncology at 71%. The cumulative NDA/BLA success rate for neurology 
was 78%, second from the bottom with cardiovascular diseases also being 78% 
and endocrine being lower at 71%, and the highest being infectious diseases at 
90% (Hay et al., 2014). Cumulatively, these two studies show that the rate of 
drug approval for CNS/neurological disorders is low compared to other disease 
areas, and that this has remained consistent across the decade difference 
between the publications of these two papers, with oncology being the only 




Figure 1.11 Clinical success rates by disease area 
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A. Clinical success rates from first-in-man to registration between 1991-2000 for ten big 
pharmaceutical companies in the United States and Europe divided by disease areas, 
with the overall rate being 11%. 
10 companies: AstraZeneca, Bistol-Myers Squibb, Eli Lilly, F. Hoffman-La Roche, 
GlaxoWellcome, Johnson & Johnson, Novartis, Pfizer, Pharmacia, Schering-Plough, and 
SmithKline Beecham. 
Figure from Kola and Landis (2004) 
B. Clinical success (left y-axis) and failure (right y-axis) rates divided by phase of 
development, with significant attrition rates occurring later on in the pipeline. 
Figure from Kola and Landis (2004) 
C. Cumulative success rate by phase of clinical development by disease area. 
Figure from Alavijeh et al. (2005) 
D. Success rate and LOA by clinical phase per disease area. Neurological disorders, including 
pain, psychiatric, and neurodegenerative diseases, consistently performed at or below 
the total average. 
Comparing only non-psychiatric non-pain neurological diseases, the phase success was 
9.8%, 36.6%, 55.9%, and 81.4%, and the phase LOA as 9.8%, 16.7%, 45.5%, and 81.4%. 
The percentages were therefore higher than for the total for both at the phase 2 to phase 
3 stage only. 
Figure from Hay et al. (2014) 
 
1.6.1.2 Lack of disease biomarkers 
 
Contributing towards the difficulty in drug discovery in brain disorders is the lack 
of clinical biomarkers for neurodegenerative diseases. Biochemical, genetic, and 
neuropathological biomarkers are important tools for assessing and monitoring 
the changes in neurobiological and neuropathological processes that are 
associated with disease onset and progression and after administration of 
potential therapeutic agents in clinical trials to monitor the response, and should 
ideally be specific to the disease and reliable. A small number of biomarkers for 
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neurodegenerative conditions are available from neuroimaging, such as 
diffusion tensor imaging (DTI)-detected changes in WM and GM integrity in MS 
and indirectly through [18F]FDG measurements for glucose metabolism from 
PET scans for various neurodegenerative diseases, biochemical approaches like 
phosphorylated tau levels in Alzheimer’s disease (AD), and genetic biomarkers 
for common familial and sporadic genetic mutations to predict disease onset, 
like amyloid precursor protein gene mutation in AD and the number of CAG 
repeats on the IT15 gene on chromosome 4 for Huntington’s disease. However, 
the available biomarkers are either non-specific for the disease being studied, do 
not have the resolution required to accurately follow disease progression and 
detect small changes, or are predictive for diagnosis due to specific genetic 
mutations, and the current gold standard for neuropathological diagnosis is with 
an autopsy on post-mortem tissue, when it is too late to understand disease 
progression or treatment effects (Rachakonda, Pan and Le, 2004; Risacher and 
Saykin, 2013; Shi, Caudle and Zhang, 2009). In contrast, oncology has made 
further strides in the discovery of stratification or predictive biomarkers for 
subpopulations of the heterogeneous disease patient population, many of which 
are direct drug targets for their respective treatment, including the kinase 
biomarkers EGFT, HER2/neu, PDGFR, and estrogen receptor, as well as immune 
cell surface receptors such as CD20 and CD25, and range from genetic, 
transcriptomic, protein, microRNA, and metabolic biomarkers (Deyati et al., 
2013). Therefore, despite the similarly low rates of clinical trial success for 
oncology as for brain disorders (Kola and Landis, 2004; Hay et al., 2014), there 
have been more activity and overall number of successes in the drug discovery 
for oncology due to the ability to detect whether a drug has worked in clinical 
trials, whereas treatments that only have small effects are missed in 
neurodegenerative diseases due to our inability to detect them with the lack of 






1.6.1.3 Pharmacokinetics and drug metabolism (PKDM) 
 
One of the barriers to drug discovery in brain disorders is in the pharmacokinetics 
of getting the drug delivered to the brain. The brain, as part of the CNS, is a 
sanctuary site with protective barriers, specifically the blood-brain barrier (BBB), 
which is highly neuroprotective, and is constituted by endothelial cells in the 
capillaries with three levels of barrier formation for physical, transport, and 
metabolic (Alavijeh et al., 2005; de Boer and Gaillard, 2007; Gaillard et al., 2012). 
The poor BBB penetration for drugs prevents 98% of small molecules and almost 
100% of large molecules not making it across to the brain, especially if they are 
hydrophilic, and compounds may still be targeted for degradation by 
endosomal/lysosomal or ubiquitin/proteasomal systems once across the BBB (de 
Boer and Gaillard, 2007). Alternative strategies to increase drug delivery to the 
brain include highly invasive direct injection of the drugs into the CSF, potentially 
permanently damaging non-specific and non-selective transient disruption and 
increased permeability of the BBB, the modification of the compound with a 
homing device for the specific and selective targeting of endogenous transport 
mechanisms, and other mechanisms to improve the absorption, distribution, 
metabolism and excretion (ADME) properties of the compound such as 
lipophilicity and hydrogen bonding (de Boer and Gaillard, 2007; Gaillard et al., 
2012). In addition, the difference in the BBB permeability, and the drug 
metabolising enzymes and transporters between animal models, where in vivo 
assessment of brain penetration by ventricular CSF sampling and tissue 
microdialysis can be routinely performed over time (Alavijeh et al., 2005; Srinivas, 
Maffuid and Kashuba, 2018), compared to human patients mean that 
pharmacokinetic predictors of the degree of drug penetrance in the CNS are not 
necessarily predictive of human drug exposure. Measurements of drug 
concentration and exposure in the CNS in human patients can be performed by 
techniques such as (1) positron emission tomography (PET), which is restricted 
by the cost, use of radioactivity, and inability to distinguish between the drug 
and its metabolites, (2) microdialysis, which is only available during 
intraoperative procedures, or (3) lumbar punctures, with medical risks, not 
performed routinely, as well as the measurement being location and time 
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dependent, and therefore the data not always available or predictive even when 
taken in human patients (Deo, Theil and Nicolas, 2013; Markou et al., 2009; 
Srinivas, Maffuid and Kashuba, 2018). Although the BBB functions to maintain 
the brain’s homeostasis, this also sometimes prevents potential drugs for 
treatment from reaching the area in sufficient quantities for the length of time 
required for its therapeutic function (Alavijeh et al., 2005), and therefore adds 
complexity to the pharmacokinetic properties of the drugs that are appropriate 
for the treatment of brain disorders even if they were efficient in pre-clinical 
studies of in vitro and ex vivo models. 
A commentary by Aronson (2007) highlighted the lack of pharmacodynamics 
reports in drug development, with concentration-effect relationships being 
quantified in animal models with limited ability to predict the human disease and 
efficacy (Markou et al., 2009). Pharmacodynamics for the CNS is measured using 
various endpoints, including (1) receptor occupancy/binding affinity as in vitro 
and in vivo measurements of the ligand-receptor complex formation, 
respectively, but is limited by species translatability despite its benefit as a direct 
measure of drug efficacy, as well as discrepancies between in vitro and in vivo 
data in complicating interpretations, (2) behavioural symptom changes and 
clinical ratings scales, which is clinically easy to understand and perform 
longitudinal studies tracking, but is rarely translatable between animal models 
and humans, and can create difficulties with translation, and (3) neuroimaging 
markers, such as PET scans and functional magnetic resonance imaging (fMRI), 
but are generally expensive, and lead to exposure to radioactivity or high-
intensity magnetic fields, respectively (Srinivas, Maffuid and Kashuba, 2018). The 
location of and the heightened immune protection provided to the brain 
therefore restricts our ability in being able to take direct samples and 
measurements routinely over a long period of time, and limits the applicability 
of animal models to human patients, making understanding the 
pharmacodynamics properties of compounds in drug discovery for brain 
disorders more complex than organs that are more easily accessible. 
In addressing some of these issues, the development of an in vitro Madin-Darby 
canine kidney (MDCK) cell line assay that express multidrug resistance protein 1 
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(MDR1), MDR1-MDCK, or breast cancer resistance protein (BCRP), BCRP-MDCK, 
which are 2 major efflux transporters of the BBB that actively eliminate 
compounds from the brain, were validated to be able to better predict brain 
penetration of compounds in vivo. This highlighted the role of in vitro models of 
brain penetrance as physiologically based pharmacokinetic models in simplifying 
complex organisms to quantitative systems (Feng et al., 2019). Trapa et al. (2019) 
were also able to compare the efflux activity of two key transporters in vitro, 
BCRP and P-glycoprotein (P-gp), to in vivo unbound brain-to-plasma 
concentration ratio using approaches that took into account the scaling 
differences between in vitro models to in vivo organisms. They were able to 
validate that in vitro efflux data is able to accurately predict the degree of brain 
penetration across three preclinical species within their physiologically based 
pharmacokinetic framework, and therefore support that extrapolating the 
degree to which a compound could cross the BBB in vivo from in vitro models 
could improve pharmacokinetic predictions of brain drug discovery. 
In silico simulations and predictions may further allow us to screen for 
compounds with the correct physiochemical features that allow them to be used 
in treating CNS conditions by crossing the BBB and having an effect on the 
relevant biological systems. Pajouhesh and Lenz (2005) described a classification 





Table 1.1 Characteristics of a successful CNS drug 
Table from Pajouhesh and Lenz (2005) 
 
Overall, molecules for brain disorders tend to be more lipophilic for BBB 
penetration, be less polar and less flexible, and have lower molecular weights 
and be smaller than compounds used for other therapeutic areas. As adjusting 
for one attribute affects others, medicinal chemistry to design compounds of the 
right physical chemistry properties will require a balance of the structure and 
activity, with guides such as the Pajouhesh and Lenz (2005) system aiding in the 
design of CNS therapeutics. 
Improvements in in vivo imaging techniques may aid in understanding the 
pharmacokinetics in the distribution of drugs in a whole organism or even in 
human patients. Magnetic resonance (MR) spectroscopy and spectroscopic 
imaging are non-invasive techniques, therefore allowing repeat measurements 
and long-term follow-up in healthy subjects and patients, for evaluating the 
body’s metabolism using predominantly the proton in 1H-MR spectroscopy for 
the brain and has been used in the research of psychiatric brain conditions 
(Mason and Krystal, 2006; Zhu and Barker, 2010). As it is relatively low sensitivity, 
it can only detect millimolar quantities of small, mobile molecules in vivo, with 
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commonly used field strengths and long echo times only being able to pick up 
signals from choline, creatine, and N-acetylaspartate in normal conditions, and 
potentially lactate, alanine, and other compounds in elevated concentrations in 
pathological conditions. Short echo times allow the detection of other structures 
including glutamate, glutamine, myo-inositol, lipids, and macromolecules. The 
signal is localised to the voxel by using the intersection of three orthogonal slice-
selective selections, with voxel sizes for the human brain being 4 to 8 cm3. MR 
spectroscopic imaging especially, despite its longer time compared to MR 
spectroscopy, can be used to measure multiple locations simultaneously for 
increased spatial variation information on the distribution of metabolites, with 
multiple approaches being implemented to improve its speed, each with its own 
benefits and caveats (Zhu and Barker, 2010). Despite its current limitations, MR 
spectroscopic imaging provides a promising in vivo imaging technique to detect 
in animal models and in humans the localisation of the drug metabolites in 
studying the pharmacokinetics of the drug distribution. However, its low 
resolution does mean that it is currently difficult to distinguish between the 
various brain regions, and between the brain region and perivascular space, 
which may be remedied by the development of novel variations of this imaging 
technique in the future. 
 
1.6.1.4 Access to brain samples 
 
The limited access to human brain samples, especially during active disease 
progression (Denic et al., 2011), also limits our current understanding of brain 
disorders. As discussed in detail later, Brain Banks have given us access to post-
mortem human brain tissue from generous donors and their families (Ravid, 
2008). However, these samples, due to the nature of the tissue collection being 
post-mortem, are all end-stage disease, containing mostly chronic lesions in MS 
brain tissue (Wolswijk, 1998; A Chang et al., 2002), and therefore limits our 
ability to study disease progression. Although brain biopsies have been used to 
study MS lesions previously (Lucchinetti et al., 1999), such tissue are rare to 
access unless the patient is already undergoing surgery for another brain-related 
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medical condition. Due to this lack of access for direct histological analysis, 
studies and clinical trials for MS have relied upon various proxy outcome 
measurements for tissue repair by, for example, measuring the shortening of 
P100 latency delay on full-field, pattern-reversal, visual-evoked potentials, or 
through imaging techniques such as MRI, which allows detection in gross 
changes to lesion size and location but doesn’t have the resolution to allow these 
to be studied at a cellular level (Ari J. Green et al., 2017). Conversely, other 
organs such as the liver allow for regular biopsies, permitting long-term follow-
up studies to be performed, such as one on non-alcoholic fatty liver disease 
(NAFLD) where they correlated biopsy-proven NAFLD with BMI to conduct a 
follow-up study ranging up to 40 years in length (Hagström et al., 2018). We are 
therefore limited in our ability to follow the progression of the active disease in 
patients, and therefore rely on in vitro human or animal-derived cells, ex vivo 
animal model brain slices, or in vivo animal models to predict the clinical 
development. 
 
1.6.1.5 Disease modelling  
 
Another important factor hindering drug discovery in this therapeutic area is the 
lack of predictive animal models, making preclinical studies for efficacy less 
translatable at the clinical trial stage (Kola and Landis, 2004; Markou et al., 2009). 
Unlike fields such as haematopoiesis which has benefited from humanised 
mouse models as a powerful tool to more accurately study diseases like 
leukaemia (Lysenko et al., 2017), animal models in MS research, whilst they have 
been extremely valuable in contributing to our understanding of the disease, 
have been restricted to the ability to model only specific aspects of this complex 
disease. Multiple models of the demyelinating phase of MS are available, 
including the experimental autoimmune encephalomyelitis (EAE), virus-induced 
demyelination, and toxic models such as dietary administration of the copper 
chelator cuprizone for global demyelination and lysophosphatidylcholine (LPC) 
injection for focal lesion formation. However, EAE, the oldest animal model of 
MS, only recapitulates the autoimmune phase of the disease while being a poor 
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predictor of the remyelination phase in drug efficacy studies. The virus-induced 
model best represents demyelination following viral infection, such as 
encephalitis, but its pathogenesis does not accurately represent that of MS. 
Whilst the toxic models allow remyelination to be modelled, and allows the 
timing of both demyelination and remyelination to be controlled more precisely, 
the complexity of the cuprizone model makes interpretation of the responses of 
the various cell types involved more difficult, and is limited in applicability to 
certain breeds and genders of mice with female mice in certain strains being 
resistant. The LPC injection model, whilst having been valuable in examining 
cellular and molecular determinants of remyelination and allows precise control 
of the location of focal demyelination, does not recapitulate the ongoing 
immune activity seen in MS with its single dose of injection for lesion formation 
(Denic et al., 2011; Plemel, Liu and Yong, 2017; Ransohoff, 2012). There is 
therefore no “magic bullet” animal model that can fully recapitulate all aspects 
of complex and heterogeneous diseases as described here for MS but are 
common patterns in other brain disorders. Each of the currently available animal 
models for brain disorders must therefore be selected for their value in studying 
the aspect of the disease that they are able to represent, and the compound of 
interest studied in this model within the perspective of the purported 
therapeutic use (Markou et al., 2009), whilst needing to acknowledge their 
limitations in clinical translation in making successful drug discovery for brain 
disorders more difficult. 
One of the methods to overcome the limitations in the availability of clinically 
representative models of the brain in drug discovery is the development of 
physiologically-relevant in vitro models. For example, as also discussed later, the 
advancements in stem cell technology has allowed human OPCs to be modelled 
in vitro using human ESCs (Wilson, Onischke and Raine, 2003; Biswas et al., 2019) 
and human iPSCs (Livesey et al., 2016; Ehrlich, Mozafari, Glatza, Starost, 
Velychko, A.-L. Hallmann, et al., 2017; Rodrigues et al., 2017a; Biswas et al., 
2019), with patient-derived iPSCs allowing patient-specific disease mutations to 
be studied in vitro (Livesey et al., 2016). However, the two-dimensional nature 
of these cell cultures limit their applicability in understanding the three-
dimensional interactions between the various cell types present in the CNS. Brain 
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organoids, which are three-dimensional aggregates that resemble the cell type 
population and cytoarchitecture of human embryonic brains, have added a 
valuable layer of in vitro  complexity to our ability to mimic brain structures in 
vitro whilst overcoming the species differences of using animal models (Qian, 
Song and Ming, 2019). For example, Choi et al. (2014) were able to form human 
neural stem cell-derived three-dimensional cultures with familial Alzheimer’s 
disease (fAD) mutations in β-amyloid precursor protein and presenilin 1 that 
recapitulated both the extracellular amyloid β plaque formation and 
phosphorylated tau aggregates and filaments, the two key pathological features 
of AD. In previous models of fAD, the amyloid β plaques and neurofibrillary 
tangles were not seen in 2D AD patient-derived neurons despite the presence of 
toxic amyloid β and phosphorylated tau (Choi and Tanzi, 2012; Israel et al., 2012), 
and mouse models represented the amyloid β pathology and behavioural 
memory deficits, whilst lacking the neurofibrillary tangle pathology (Chin et al. 
2010). Accumulatively, the developments in stem cell technology and in vitro 3D 
modelling will advance our ability to model brains “in a dish” to study them in 
physiologically- and disease-relevant cellular models. 
Despite their advantages over non-human cell models, neither 2D nor 3D in vitro 
human cell models are able to fully recapitulate the complexity of the whole 
organism as with in vivo animal models, whilst many of these models only 
represent aspects of the complex human brain disorders, such as MS rodent 
models primarily inducing an inflammatory response to cause demyelination as 
described above. However, this only represents one aspect of the 
neuropathology of MS and assumes the “outside-in” hypothesis as the cause of 
demyelination, with the absence of remyelination being another important 
aspect to be able to model in vivo. Shiverer mice have an autosomal recessive 
mutation that results in the lack of MBP, and therefore the inability to form 
compact myelin in the CNS, with a shivering phenotype being visible in the 
mutant animals (Molineaux et al., 1986; Readhead and Hood, 1990). 
Differentiated human cells, such as neural stem cells derived from iPSCs 
differentiated into OLs (Biswas et al., 2019), are able to be transplanted into 
these shiverer mice to study whether they are able to form compact myelin 
sheaths in vivo when no endogenous myelination should be present. The 
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transplantation of human neural stem cells into shiverer-immunodeficient mice 
have shown preferential differentiation into OLs, which formed functional 
compact myelin with normal nodal organisation and physiological properties 
(Uchida et al., 2012). The combination of the human-derived OLs and the in vivo 
animal model provide an approach that both combines being able to study and 
model myelin sheath formation by human OLs prior to the end-stage of the 
disease as seen in post-mortem human tissue and the lack of an in vivo system 
to be able to study the role of OLs in a hypomyelinating environment. 
Just how significant the problem of poor models of disease-relevant cells may be 
in contributing towards the poor drug discovery rates in discovering treatments 
for the remyelination phase of MS is clear from the work of Scannell and Bosley 
(2016). These authors constructed a quantitative classifier model (Figure 1.12) 
that represents the predictive validity (PV) of a model in decision-making. The 
decision threshold, yt, is a measure of the throughput, attrition rate, and rigor of 
the decision-making, and molecules that exceed the decision threshold classified 
as a positive hit for further investigation, with the higher the threshold value, the 
more compounds need to be screened (i.e. increased throughput) for each hit. A 
hit is only a true positive if it also surpasses the reference threshold rt on the 
reference variable R. As represented in these models, a good model will yield a 
better ratio of true positives, with fewer false positive hits costing more R&D 
costs, and fewer losses as false negatives, whereas worse models have lower 
predictive validity and therefore detect fewer true positives, with more false 
positives and false negatives. The positive predictive value, PPV, is a measure of 
decision quality in R&D, calculated as PPV = 
#𝑇𝑃
#𝑇𝑃+#𝐹𝑃
 = 1 – FDR, where # 
represents number of, and FDR stands for false discovery rate. Thus maximising 
of PPV reduces the cost of the R&D process per each therapeutic candidate, with 
better models with higher PV and/or the application of high yt thresholds to 





Figure 1.12  The quantitative classifier model 
Probability density function diagrams based on the correlation, ρY,R, between the decision variable 
Y, the measure on which the classification decision is based, and reference variable R, the test of 
the performance of the decision process. The colours indicate probability density of candidate 
molecules, with light being high and dark being low. The axis units are one standard deviation, 
and the yt and rt are decision and reference thresholds, respectively. PV is the predictive validity, 
calculated as the Pearson correlation coefficient between Y and R in this model. 
TP = true positives, FP = false positives, and FN = false negatives 
(Figure from Scannell and Bosley (2016)) 
 
Scannell and Bosley (2016) and Horvath et al. (2016) also predict the continued 
presence of poor disease models with low PVs in diseases that represent major 
global health problems and  urgent areas of unmet medical need, and the interest 
in such reductionist models for simplicity, ease of use, “tradition”, and ‘brute-
force’ efficiency. The validation of good reductionist models requires time, effort, 
innovation, and “guess-work” to verify they fit within “domains of validity”, a 
term used in physics to refer to the parameter in which a model is valid, resulting 
in the reluctance in their adoption despite the potential for improved clinical 
relevance and success. The development, verification, and use of 3D cell-based 
models of disease provides additional challenges to overcome in comparison to 
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the relatively simpler 2D models (Horvath et al., 2016; Carragher et al., 2018), 
including increased cost, sample processing, imaging, data generation and 
storage, and analysis. However, with the continuing development of better high-
throughput liquid-handling machines, more 3D-compatible high content imaging 
platforms and analysis software, and the decreasing cost and improved capacity 
for larger datasets, along with the continued poor success at discovery of pro-
remyelination treatments for progressive MS, there is a need to overcome the 
‘basic research-brute force’ bias and improve the in vitro cell model for MS. 
 
1.6.2 The challenges of extrapolating from animal-based studies to human disease 
 
1.6.2.1 Limitations of cell culture approaches 
 
Stem cell technology has allowed us to model human OPCs in vitro using human 
embryonic stem cells (ESCs) (Biswas et al., 2019; Wilson, Onischke and Raine, 
2003) and human induced pluripotent stem cells (iPSCs) (Biswas et al., 2019; 
Ehrlich et al., 2017; Livesey et al., 2016; Rodrigues et al., 2017), and therefore 
overcome the constraints of limited access to human OLs in research. These 
human cell-derived OPCs have been shown to have similar properties to rodent-
derived ones, such as the markers expressed (Livesey et al., 2016; Wilson, 
Onischke and Raine, 2003), the growth factors that promote maturation (Wilson, 
Onischke and Raine, 2003), and their physiological characteristics such as the 
expression and activity of electrophysiological channels and receptors (Livesey 
et al., 2016). Patient-derived iPSCs can also be cultured, allowing disease-
relevant mutations to be studied in vitro (Livesey et al., 2016), human OPCs 
genetically manipulated using techniques such as CRISPR/Cas9 (Rodrigues et al., 
2017b) and retroviral vectors (Biswas et al., 2019), and the ability to produce 
these human iPSC-derived OPCs in a defined, efficient, and scalable manner 
means that they may be suitable for high-throughput screens for drug discovery 
(Ehrlich et al., 2017; Rodrigues et al., 2017b). These human cell-derived stem 
cells are therefore highly valuable in studying and understanding the role of OLs 
in biology and disease in a controlled and defined environment in vitro. However, 
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despite these invaluable benefits as technical and biological tools in studying 
diseases such as MS, they are poor models for studying the complexity of the 
disease in vivo, limited by the nature of their development in a strictly defined 
and artificial environment in cell culture. It is therefore important to not over-
estimate the conclusions drawn from cell culture studies, and put them in the 
wider context of the disease using methods such as those described below. 
 
1.6.2.2 Limitations of post-mortem human brain tissue pathology 
 
Access to post-mortem human brain tissue has allowed us to develop an 
understanding of the pathology of MS in the context of human disease rather 
than within the scope and limitations of animal models, with findings such as the 
quantification of the heterogeneity of MS lesions (Lucchinetti et al., 1999), and 
the presence of quiescent OPC populations (Wolswijk, 1998) and differentiated 
but non-myelinating oligodendrocytes (Ansi Chang et al., 2002) in chronic lesions. 
Brain Banks have been instrumental to the collection, classification, preservation, 
and distribution of post-mortem human brain tissue samples for researching 
diseases of the nervous system in an ethically and legally regulated manner 
(Ravid, 2008). 
The histological classification system for MS lesions in post-mortem human brain 
tissue have been described initially by Lucchinetti et al. (2000), and more 
recently in an updated version by (Kuhlmann et al., 2017). (Lucchinetti et al., 
2000), following on from observations of distinct patterns and heterogeneity in 
MS pathology (Lucchinetti et al., 1996), defined 4 distinct patterns of 
demyelination based on myelin protein loss, the size and shape of the plaque, 
the pattern of demyelination, and the immunological response. They described 
Patterns I and II of suggesting T-cell and T-cell and antibody-mediated 
autoimmune pathology, and Patterns III and IV of being primary OL damage 
(Figure 1.13 A). The more recent (Kuhlmann et al., 2017) classification combines 
the inflammatory activity based on macrophages/microglia (Figure 1.13 B) with 
the demyelinating activity present in lesions to propose a more unifying 
classification system, as summarised in Figure 1.13 C. In short, active lesions 
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contain macrophages/microglia throughout the lesion, whereas mixed 
active/inactive lesions compose of a hypocellular centre and border of 
macrophages/microglia, with inactive lesions lacking these inflammatory cells. 
Active and mixed active/inactive lesions are further classified based on the 
degree of demyelination. These classifications highlight the lack of consensus 
within the field when studying neuropathology using post-mortem human brain 
tissue in determining the lesion types being analysed. Further complications 
arise due to: (1) post-mortem tissue sample preparation, (2) their strong bias as 




Figure 1.13 Tables of MS lesion classifications 
A. Features of different patterns of active MS lesions, with values given as cells/mm2. 
#OG = density of OLs in inactive demyelinated plaque centre, DNA frag in OG = OLs 
showing nuclear DNA fragmentation, OG apoptosis = OL apoptosis in active lesion, MAG 
= myelin-associated proteins, PPWM = DNA fragmentation in OLs in periplaque WM 
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Table from Lucchinetti et al. (2000) 
B. Histological characteristics of various MS lesion types. 
LFB = luxol fast blue, MBP = myelin basic protein, PLP = proteolipid protein, CNP = 2’,3’-
cyclic-nucleotide 3’-phosphodiesterase, MOG = myelin oligodendrocyte glycoprotein 
Table from Kuhlmann et al. (2017) 
C. Schematic diagram of the temporal development of MS lesions starting from active 
demyelinating to inactive. The re-introduction of subsequent waves of 
macrophages/microglia may result in a mixed active/inactive or inactive lesion to become 
active again. 
Figure from Kuhlmann et al. (2017) 
 
1.6.2.2.1 Post-mortem tissue sample preparation 
Due to the nature of the tissue sample collection happening after death, there 
are numerous factors that contribute to the quality, or lack thereof, of the 
samples. For example, pre-mortem events that prolong damage to the brain 
during the process of death, like an inflammatory response, hypoxia, or fever, 
may result in non-neurodegenerative disease-related injury to the sample 
collected. Post-mortem delays between death and sample collection, which 
varied as widely as just under 4 hours to close to 10 hours in Wolswijk (1998)’s 
paper, the temperature of storage of the cadaver and the removed brain samples, 
and the methodological framework and solutions used in the preservation of the 
sample, like the fixative used or variability in the process of freezing, may 
contribute towards post-mortem degradation of the brain samples. 
Unpredictable case-to-case and brain region-to-region variability despite 
otherwise similar parameters of preservation further complicate and limit the 






1.6.2.2.2 End-stage disease 
In addition to the variability in tissue quality, due to the nature of the timing of 
the sample collection being post-mortem, the samples that can be studied are 
end-stage tissue of predominantly chronic lesions (Wolswijk, 1998; Ansi Chang 
et al., 2002). Furthermore, these tissue samples, although extremely valuable in 
our ability to study and understand the disease in human patients, only provide 
a single time snapshot of the disease at the moment of death of the patient 
donor, making it difficult to infer the processes involved in disease progression. 
For example, 8 out of the 10 patients and lesions studied in Chang et al. (2002)’s 
paper were of secondary progressive patients with the duration of disease 
ranging from 9 to 44 years, and only 1 patient having relapsing-remitting MS with 
less than 1 year since disease diagnosis, and therefore the study being 
representative of mostly late-stage MS. As the proportion of lesions with pre-
myelinating oligodendrocytes appeared to decrease with an increase in the 
duration of disease in this small sample of MS patients, the limitations in being 
able to focus on only one time-point of the disease progression is highlighted as 
it is not possible to study whether there are changes as the disease progresses 
that makes chronic lesions less favourable to the presence of pre-myelinating 
oligodendrocytes, or whether this difference is due to patient heterogeneity.  
Although it is possible to obtain brain biopsies at earlier stages of the disease 
progression, such as in Lucchinetti et al. (1999)’s paper, the highly invasive 
nature of obtaining biopsies from the brain compared to other organs, such as 
the liver or kidneys, means that it is rare to be able to obtain samples in this 
manner, almost impossible to repeat at different time-points of the disease due 
to practical and ethical reasons, and the influence of the medical condition that 
led to requiring a biopsy cannot be excluded in whether a sample is appropriate 







1.6.2.2.3 Lack of markers 
A significant contributor to the difficulty in understanding and classifying post-
mortem human brain tissue is the limited number of markers available. These 
are broadly limited to histological dyes with low resolution and non-specific for 
markers, such as Luxol Fast Blue (LFB) to stain for myelin (Lucchinetti et al., 1999), 
or in situ hybridisation and immunohistochemistry with antibodies that are 
specific for markers that distinguish between OPCs, such as NG2 (Wolswijk, 1998; 
Ansi Chang et al., 2002) and, more commonly, Olig2+ (marker for all OL lineage 
cell bodies) NogoA- (more mature OL cell bodies) cells (Kuhlmann et al., 2017), 
and differentiated OLs that are both non-myelinating and myelinating, like PLP 
and MBP (Wolswijk, 1998; Lucchinetti et al., 1999), with MOG, MAG, and CNP 
being helpful in determining early or late lesion formation (Kuhlmann et al., 
2017), which limit the ability to distinguish between the various stages of OL 
development. Recent advances in RNA sequencing techniques have expanded 
our ability to study the heterogeneity of the oligodendrocytes present within 
human MS brain tissue while overcoming the limitations of restricted markers 
available, as discussed below. 
The difficulty in analysing post-mortem human brain tissue is highlighted by the 
14C-dating research, published by the Frisén Lab in Nature in 2019 (Maggie S. Y. 
Yeung et al., 2019). In their paper, they measured the integration of 14C into DNA, 
as correlated to the changes in atmospheric levels due to historic nuclear testing, 
to assess oligodendrocytes in post-mortem multiple sclerosis patient brain 
samples. They concluded that in “shadow plaques”, regions where thin myelin 
sheaths from remyelination have formed following demyelination, the 14C levels 
indicate that the oligodendrocytes present were not newly formed, suggesting 
that remyelination occurs due to pre-existing oligodendrocytes forming new 
myelin sheaths in MS lesions. This understanding of the dynamics of 
oligodendrocyte generation may have had significant consequences for 
remyelination therapies in drug discovery, as this would suggest that pro-
remyelination drugs would have to predominantly, if not solely, promote myelin 
sheath formation to be of therapeutic value in MS, rather than a combination of 
enhancing differentiation and myelination. However, more recent views in the 
field suggest that the “shadow plaques” studied in the post-mortem brain 
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samples in this paper may potentially have been sites of cerebral oedema, and 
therefore not be sites of demyelination and subsequent remyelination, which 
may explain why no newly formed oligodendrocytes were present. This 
emphasises the difficulty in assessing post-mortem brain tissue, even by 
researchers with experience and expertise, in classifying the types of lesions 
present accurately. 
 
1.6.2.2.4 Caveats of single-nucleus RNA sequencing of post-mortem human brain tissue 
As mentioned previously, recently, Jäkel et al. (2019) were able to perform 
single-nucleus RNA sequencing (snRNA-seq) on the WM of post-mortem human 
brain tissue of both control and progressive MS patients using the Chromium 10x 
Genomics and Illumina next-generation sequencing pipeline. They were able to 
isolate nuclei from NAWM, active, chronic active, chronic inactive, and 
remyelinated lesions within the WM of the same MS patient, and identify several 
clusters and subclusters of cells types, including seven subclusters of OLs and 
clusters of OPCs and committed oligodendrocyte precursors (COPs). Using this 
method, they were able to compare the proportion of the various OL lineage cell 
populations and subclusters in MS compared to control brains, including a 
reduction in the intermediate Oligo6 cells and the skewing in the subclusters of 
mature OLs. Although the same limitations in tissue preservation and quality as 
when analysing neuropathology still apply, with additional variables in the 
preservation of the integrity of RNA (Ferrer et al., 2008), as well as the samples 
representing a single time-point end-stage disease state, snRNA-seq avoids the 
need for existing markers to identify the different populations of the OL lineage 
cells and therefore allows the exploration of the wider scope of the 
heterogeneity of the various stages and subclusters of OL development. In 
addition, the use of sequencing technology has allowed differential gene 
expression analysis to be performed in the context of disease, and opens up the 
potential to be used to classify lesion types through the detection of unique 
biological markers, which may also improve clinical accuracy in diagnosing 
patients beyond research purposes. Although immunohistochemistry and in situ 
hybridisation is still the gold standard in confirming the results obtained in this 
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novel application of snRNA-seq for the neuropathological analysis of MS, this 
technology provides great promise in enhancing our ability to understand the 
human disease without being restricted to available markers. Through this 
identification of new markers and increasing our understanding of the 
transcriptional profile differences of the various subclusters of OLs, snRNA-seq 
also has the capability to improve the relevance of neuropathological analysis of 
post-mortem human brain tissue and the application of human stem cell cultures 
in human MS research. 
 
1.6.3 Which cell type drives remyelination - OPCs or OLs?  
 
The clearest evidence as to the difficulties of extrapolating from animal models 
to human disease comes from the ongoing debate as to whether myelin sheaths 
in human remyelination are formed by differentiating OPCs or differentiated OLs. 
There is conflicting evidence, with the traditional view based on animal work 
being that once myelin sheaths have formed, these OLs becomes structurally 
fixed. In supporting this, gene expression profiling of neonatal and adult mice 
OPCs suggest that following demyelination, the activated OPCs revert to an 
immature neonatal-like state (Moyon et al., 2015), suggesting priming to 
enhance their contribution to the regenerative process of remyelination. In 
addition, fate map tracing of OPCs in transgenic mice (Zawadzka et al., 2008) and 
tamoxifen-induced YFP expression in OPCs in the EAE model (Tripathi et al., 2010) 
suggest that it is the OPCs that populate lesions and differentiate to form the 
new myelin sheaths in remyelination. Membrane-bound GFP labelled mature 
OLs in a focal demyelinating mouse model also showed no evidence of the 
mature OLs contributing to remyelination (Crawford et al., 2016). 
However, in both complementary models of a food-induced demyelination in 
cats and the spinal cord of B12-deficient rhesus monkey with extensive 
demyelination but OL survival, evidence of adult OLs ensheathing axons and 
remyelinating were observed (Duncan et al., 2018). Also, constitutive activation 
of Akt in the PI3K-AKT-mTOR pathway (Flores et al., 2008), sustained activation 
of ERK1/2 in pre-existing OLs (Jeffries et al., 2016), optogenetic stimulation of 
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axonal activity (Gibson et al., 2014), and social re-integration and enrichment 
following social isolation (Liu et al., 2012) all show increase in myelin formation, 
mainly in increased myelin thickness. This adaptive myelination in differentiated 
OLs suggest that these myelinating OLs are not as fixed as conventionally thought, 
and therefore potentially may be able to show plasticity in remyelination. 
Recently, the changes in atmospheric carbon-14 (14C) integration into genomic 
DNA due to nuclear bomb testing during the Cold War was used to assess the 
dynamics of OL generation in shadow plaques of MS. The 14C levels in the OLs of 
these remyelinated lesions suggested that the OLs present were pre-existing OLs, 
rather than new ones (Yeung et al., 2019). Although caution must be taken in 
interpreting such data, especially due to questions about 14C incorporation and 
stability of their levels over time, as well being able to interpret their levels with 
such precision across relatively short time scales, this data suggests that there is 
potential for remyelination to occur from pre-existing OLs, rather than direct 
differentiation and myelination by new OLs. 
 
1.7 Current phenotypic cell-based drug screens for regenerative and 
remyelination therapies. 
 
The studies reviewed thus far have informed us that in order to increase myelin sheath 
formation as a therapeutic strategy for progressive multiple sclerosis, we need to target 
increasing myelination directly rather than relying on increasing differentiation. In order to 
be able to study myelin sheath formation directly, two main challenges need to be addressed: 
(1.7) creating a system that enables myelination to be studied in vitro, and (1.8) imaging the 
myelin sheath formation. The strategies to tackle these two issues will be addressed in the 






1.7.1 Two-dimensional cultures 
 
1.7.1.1. Single oligodendrocyte cultures 
 
Oligodendrocytes can be purified and cultured in isolation, allowing for well-
defined cell populations to be studied in vitro. For example, from the rat cerebral 
cortex, oligodendrocytes can be isolated using an orbital shaker for mechanical 
purification from mixed glial cultures prepared from animals of or less than 
postnatal 2 days (P2) of age with >95% purity (Figure 1.14 A) (McCarthy and de 
Vellis, 1980), or by immunopanning using a series of negative selections against 
contaminating cells and positive selection using O4 for OPCs using P7 animals for 
a purer population (Figure 1.14 B) (Barres et al., 1992a; Foo et al., 2011), among 
other techniques such as fluorescence-activated cell sorting (McMorris et al., 
1986; Behar et al., 1988). These isolated OPCs, in the absence of axons, extend 
flat 2D membranes, and express markers of differentiated OLs, such as MBP, 
allowing them to be valuable in the study of compounds that increase the rate 
of differentiation, like using rat optic-nerve-derived progenitor cells by 
Deshmukh et al. (2013), mouse epiblast stem cell (EpiSC)-derived OPCs by Najm 
et al. (2015), and using O4 immunopanned OPCs by Lariosa-Willingham et al. 
(2016). Although the simplicity of this model is of great value to the field, with 
differentiation drug screens culturing OPCs being able to be performed in under 
7 days (Deshmukh et al., 2013; Lariosa-Willingham et al., 2016; Najm et al., 2015), 
the lack of myelin sheath formation limits their physiological representation and 
their applicability to look beyond OPC proliferation, migration, survival, and 





Figure 1.14 Isolated two-dimensional oligodendrocyte cultures 
A. Phase contrast image of oligodendrocyte culture isolated using the mechanical shaking 
method. 
Scale bar = 50μm 
Figure from McCarthy and de Vellis (1980) 
B. Immunofluorescence image of oligodendrocyte culture isolated using the O4 
immunopanning method and cultured in the presence of T3 for 4 days. 
Scale bar = 200μm 
Figure from Lariosa-Willingham et al. (2016) 
 
1.7.1.2 Myelinating cultures 
 
Neurons, such as dorsal root ganglion cells (DRGs) (Svenningsen et al., 2003; 
Wood, Okada and Bunge, 1980) and retinal ganglion cells (RGCs) (Goldberg et al., 
2004), can be isolated from embryonic or postnatal rodents and cultured with 
separately isolated OPCs in myelinating co-cultures (Figure 1.15). The use of 
neuron-oligodendrocyte co-cultures have been instrumental to studying myelin 
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sheath formation, like the signals involved, i.e. the role of integrin and contactin 
in controlling Fyn activity in regulating myelination (Laursen, Chan and ffrench-
Constant, 2009), the role of neuronal activity, such as glutamate released 
through synaptic vesicles on axons increasing myelination also through a Fyn 
kinase-dependent signal (Wake, Philip R. Lee and Fields, 2011), and mechanical 
stimulation by the axon influencing the fate of the OLs (Rosenberg et al., 2008). 
Although valuable in allowing us to study myelin sheath formation in vitro, the 
technical challenges from the low yield of neurons in the co-cultures (Lariosa-
Willingham et al., 2016b), as well as the inability to separate the effect of 
compounds on axons and OLs limit their applicability for our purposes. 
 
 
Figure 1.15 DRG-oligodendrocyte myelinating co-cultures 
A. DRG neurons (red) 
B. MBP-expressing oligodendrocytes (green) 
C. Overlay of OLs myelinating DRG neurons. 
Scale bar = 50μm 
Figure from Swire and ffrench-Constant (2019) 
 
More complex myelinating cultures have also had significant contributions to our 
ability to study the interactions of OLs with neuronal and other non-neuronal 
cells in vitro. For example, primary embryonic (E18) rat cortical cells have been 
shown to be compatible in a 96-well plate format for high-throughput screening 
for the detection of promoters of myelination (Lariosa-Willingham et al., 2016b), 
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and E13 mouse spinal cords shown to recapitulate in vivo electrical and microglia 
phagocytosis activity as well as being compatible with adaption into a 96-well 
plate format for screens (Bijland et al., 2019). Despite the value of these 
heterogenous myelinating cultures in more accurately depicting the interactions 
between the various cell types in vivo, the difficulty, as with the neuron-OL co-
cultures, in extricating the cell types through which pro-myelination effect may 
be occurring, and the risk of variability in the proportion of the various cell types 
present in each isolation, may restrict our ability to understand the mechanism 
through which potential pro-remyelination compounds are having their effect, 
and their applicability in high-throughput formats to screen for compounds. 
 
1.7.2 Three-dimensional cultures 
 
1.7.2.1 Single oligodendrocyte cultures 
 
Three-dimensional cultures may allow us to study the oligodendrocyte-specific 
effects of compounds in the absence of neuronal influences whilst also studying 
beyond differentiation into their effects on myelination. One such assay 
developed for screening is the ‘binary indicant for myelination using micropillar 
arrays’, or BIMA (Mei et al., 2014a). In this system, cones, or micropillars (Figure 
1.16 A), made out of silica were compressed into a 96-well plate format. These 
micropillars are representative of freestanding fibres, which are described below, 
around which immunopanned O4+ rodent OPCs could wrap their concentric 
membranes as a “binary indicator” for myelin sheath formation (Figure 1.16 B) 
in a method that is high content-compatible for imaging (Figure 1.16 C) and 
analysis. Although they described that the MBP+ membrane were thicker than 
the PDGFRα+ membrane, suggesting increased wrapping with differentiation, as 
can be seen on Figure 1.16 C, both OPCs and OLs form rings around the 
micropillar, and therefore making their expression of PDGFRα versus MBP the 
main output to detect pro-differentiation compounds. Although the BIMA 
platform has increased our ability to study compounds that increase OPC 
differentiation in a more 3D nature in an OPC-specific manner, due to it still 
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quantifying the extension of membrane across a surface rather than the 
formation of multiple complex myelin sheaths by a single OL, there is a limit to 
its applicability as a myelination assay rather than a differentiation one. 
 
 
Figure 1.16 The Binary Indicant for myelination using Micropillar Arrays (BIMA) 
A. SEM image of OPCs and OLs interacting with and wrapping the micropillars. Arrows 
indicate multiple OPCs interacting with a single micropillar, and arrowheads indicate OLs 
interacting with a single micropillar. 
Scale bar = 10μm 
B. Compressed z-stack image and orthogonal views of an MBP+ OL and PDGFRα+ OPC 
obtained using the Zeiss LSM-700 confocal microscope. 
Scale bar = 10μm 
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C. PDGFRα-positive green OPCs and MBP-positive red OLs interacting with micropillars, 
imaged using the Zeiss microscope, and visualised in 2D from a compressed z-stack image 
to view the rings from the membrane wrapping. 
Scale bar = 25μm 




Organoids or spheroids allow the 3D environment, including spatial complexity, 
between CNS cell types to be replicated in vitro. These 3D structures are formed 
from the aggregation of dissociated neuronal cells under constant rotation, and 
have been shown to recapitulate some of the patterns of biochemical 
differentiation as in vivo such as with acetylcholine activity in embryonic mouse 
reaggregates (Seeds, 1971), and be used to study demyelination and 
remyelination in vitro using anti-MOG, IFNɣ, or LPC-induced demyelination in rat-
derived spheroid cultures (Diemel et al., 2004; Loughlin et al., 1994; Vereyken et 
al., 2009) including the influence of macrophages on the remyelination process 
(Diemel et al., 2004; Loughlin et al., 1994). More recently, human organoids with 
myelinating oligodendrocytes, including oligocortical spheroids (Figure 1.17 A 
and B) (Madhavan et al., 2018), human oligodendrocyte spheroids also 
containing neurons and astrocytes (Marton et al., 2019), forebrain organoids 
with OLIG2/GFP reporter lines (Kim et al., 2019), have been described that have 
been derived from human pluripotent stem cells. Oligocortical spheroids 
especially addressed the lack of OPCs and oligodendrocytes in the previously 
established neurocortical spheroids by treating the spheroids with PDGF-AA, IGF-
1, and T3 at various stages of the spheroid development (Figure 1.17 C), and 
could recapitulate the disease phenotype of the subject from whom the spheroid 





Figure 1.17 Generation of human oligocortical spheroids 
A. and B. Fluorescent images of Week 20 oligocortical spheroids expressing mature OL markers. 
Scale bar = 50μm 
C.    Schematic of neurocortical and oligocortical spheroid generation, including the adaption to 
the culture media required to increase the OPC/OL generation. PDGF-AA and IGF-1 treatment 
were from days 50 to 60, and T3 from days 60 to 70. 
Magenta = neurons, red = astrocytes, green = OPCs/OLs 
Figures from Madhavan et al. (2018) 
 
These organoids provide a platform for investigating cellular interactions and 
organisation of oligodendrocytes in a more physiologically-relevant 3D structure 
in vitro, which are accessible to exposure to experimental conditions due to their 
spherical shape and small diameter, without the need for in vivo animal models 
which limit the number of conditions that can be tested to one per animal 
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(Vereyken et al., 2009). However, despite their ability to recapitulate the 
complexity of the physiologically-relevant in vivo system, the cellular 
composition of the spheroids can be varied (Diemel et al., 2004), the influence 
of the other cell types, especially the neuronal cells required for myelin sheath 
formation, cannot be separated in understanding the mechanism of action of 
potential pro-remyelination therapies, and the complexity of miniaturising them 
makes them less compatible for high content purposes. 
 
1.7.2.3 Neuron-free microfibre system 
 
A method for studying myelin sheath formation in 3D without the need for 
neurons was described by (Lee et al., 2012). In their paper, they substituted 
axons for biologically inert electrospun fibres made out of polystyrene and poly-
L-lactic acid (PLA), to uncouple the effects of fibre diameter from axonal signals, 
with glass and vinyl fibres having previously been shown to also be permissive to 
myelination (Bullock and Rome, 1990; Howe, 2006). They showed that 
myelination occurs in the absence of axonal signalling, the diameter of the fibres 
influence oligodendrocyte behaviour (Figure 1.18 A and B), and that these 
artificial axons can be used to study myelination with concentric wraps being 
formed around the fibres (Figure 1.18 C and D). Bechler, Byrne and ffrench-
Constant (2015) further showed evidence of complete ensheathment of 
electrospun PLA microfibres by the myelin membrane by confocal microscopy 
(Figure 1.18 E) and electron microscopy, with distinct, multiple compact 
membranes clearly being evident after 14 days (Figure 1.18 F). More importantly, 
they showed that: 1) the sheath lengths formed on these fibres were comparable 
to in vivo cortex distribution (Murtie, Macklin and Corfas, 2007), and 2) that 
differences in myelin sheath formation could be detected and quantified, such 
as between cortical vs. spinal cord, smaller vs. larger diameter, and PDL vs. 
laminin-coating of the fibres. The electrospun microfibre platform therefore 
provides a 3D in vitro system that is capable of distinguishing oligodendrocyte-
specific mechanisms of myelin sheath formation in drug discovery without 




Figure 1.18 Myelin sheath formation on biologically inert electrospun microfibres 
A. 0.2-0.4µm diameter fibres with differentiated but unmyelinating oligodendrocyte. 
         Scale bar as shown on B. 
B. 2-4µm diameter fibres with differentiated and myelinating oligodendrocyte. 
         Scale bar as shown on figure. 
C. Electron micrograph of an oligodendrocyte wrapping a polystyrene fibre. 
         Scale bar as shown on figure. 
         Figures A-C from Lee et al. (2012) 
D. Higher magnificent image of the inset box from C) with concentric wrapping highlighted 
with arrows. 
         Scale bar as shown on figure. 
E. 1-2µm diameter fibre with a myelin sheath-forming oligodendrocyte. The magnified and 
cross-section (XZ) images show the wrapping of the myelin sheaths completely around the 
fibres. 
         Scale bar = 10µm 
F. Electron micrograph of multi-layered membranes formed by an oligodendrocyte around a 
microfibre after 14 days. 
         Scale bar = 200nm 
         Figures E-F from Bechler, Byrne and ffrench-Constant (2015) 
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However, neurons are not the only potential cell types that may have indirect 
effects on myelination, and contaminating astrocytes are present in 
oligodendrocyte microfibre cultures. As reviewed by Barnett and Linington 
(2013), astrocytes play a significant role in oligodendrocyte myelination and in 
MS. Bhat and Pfeiffer (1986), Noble et al. (1988), and Raff et al. (1988), and 
others have shown that astrocytes release mitogens and other factors that 
influence OPC self-renewal and differentiation, including PDGF. In fact, Sorensen 
et al. (2008) showed that myelin sheath formation, including the formation of 
nodes of Ranvier, from embryonic rat spinal cord-derived OL-CNS axon cultures 
were best when plated on a monolayer of neurosphere-derived astrocytes (NsAs) 
compared to a layer of olfactory ensheathing cells (OECs) or Schwann cells, and 
that conditioned medium from NsAs promoted myelination when the OL-axons 
were cultured on OEC monolayers. Although contaminating astrocytes are 
present in the neuron-free electrospun microfibre platform, and therefore 
indirect effects via mechanisms acting through these non-OL cell types cannot 
be completely excluded, the evidence seems to suggest that a low level of 
“contaminating” astrocytes may actually improve baseline myelin sheath 
formation. Although not completely free of contaminating cells, the electrospun 
microfibre platform provides an alternative in vitro 3D system to be able to study 
myelination in the absence of confounding axonal effects. 
 
1.8 How we can image these different ways of examining myelination in vitro? 
 
In order to conduct any screen for remyelination strategies, a microscopy technique with the 
capability to image and confirm the multi-layered wrapping and compaction of myelin 
sheaths is required. As described below, conventional optical imaging and electron 
microscopy techniques, for different reasons, are not suitable for these purposes, and 
therefore novel imaging strategies are required. I will now illustrate the strengths and 
weaknesses of the traditional methods of myelin imaging, including electron microscopy, 
histological dyes, confocal and super-resolution microscopy, and then go on to propose the 
nonlinear optical imaging technique of Coherent anti-Stokes Raman Scattering (CARS) 
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microscopy as the solution I tested, along with how an alternative technique, Spectral 
confocal reflectance microscopy (SCoRe), may also be appropriate. 
 
1.8.1 Electron Microscopy 
 
Electron microscopy (EM), which generates high resolution images by using 
electrons with very short wavelengths as the source of illumination, has been 
used to study the axonal components from as early as the 1940’s with Richards, 
Steinbach, and Anderson looking at the axoplasm of the giant fibre of the squid 
in 1943 and de Robertis and Schmitt studying nerve types of various crustaceans, 
squid, amphibians, and mammals in 1948 (de Robertis and Schmitt, 1948), with 
Fernández-Morán first visualising the organisation of the myelin sheath layers 
using osmium tetroxide-fixed, freeze-sectioned tissue in 1950 followed by 
Sjöstrand using methacrylate-embedded thin sections for more detailed 
visualisation in 1953 (Mcalpine and Finean, 1961). EM still remains to this day 
the gold standard for myelin imaging for the acquisition of ultrastructural data, 
such as myelin thickness in detecting sites of remyelination in MS and relevant 
animal models, and confirm compact myelin sheath formation. As such, this 
technique has been used to study myelin-related mutations, such as in the 
transgenic shiverer mice where compact myelin is absent (Readhead and Hood, 
1990), as well as the confirmation of myelin sheath formation in novel in vitro 
systems, such as for the micropillar array in showing myelin membrane extension 
and wrapping (Mei et al., 2014b) and electrospun PLA microfibres in the 
confirmation of compact multi-layered myelin membrane formation around the 
polymer fibres (Bechler, Byrne and ffrench-Constant, 2015), and to study the 
maturation of oligodendrocytes in human cell-derived organoids (Madhavan et 
al., 2018). Immunoelectron microscopy, an adaptation of the conventional EM 
technique, uses markers such as gold-conjugated antibodies to gain additional 
information about the abundance and localisation of the protein of interest (Weil 
et al., 2019). Although the gold standard, the conventional sample preparation 
relies on chemical fixation, which results in artefacts that may be difficult to 
discriminate from the effects of the animal model mutation in the myelin 
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architecture being studied. The application of high-pressure freezing improves 
tissue preservation and decreases fixation artefacts, particularly due to the 
sensitivity of the lipid-rich myelin structure to chemical fixation, by freezing the 
tissue in milliseconds at 2000 bar pressure (Möbius, Nave and Werner, 2016; 
Weil et al., 2019). Due to the highly intensive sample preparation (Weil et al., 
2019), as well as the low-throughput of the image acquisition speed, this 
technique is most suitable for detailed ultrastructural imaging of myelin. 
 
1.8.2 Histological dyes 
 
Another method of visualising myelin is through the use of histological dyes. 
Toluidine blue, or tolonium chloride, is an acidophilic (basic) thiazine 
metachromatic dye that was discovered in 1856 by William Henry Perkin. It 
selectively stains acidic tissue components, such as sulphates, carboxylates, and 
phosphate radicals, and therefore has a high affinity for nucleic acids. Its 
metachromatic property means that it is highly selective in the tissue structures 
that it stains, and absorbs light at different wavelengths depending on its 
surroundings and concentration due to the stacking of cations from the dye at 
the tissue where there are a high density of anionic groups. Toluidine blue 
staining allows the visualisation of individual myelinated nerve fibres in resin 
embedded semi-thin sections, with osmium tetroxide post-fixation improving 
the resolution of the image (Feirabend, Choufoer and Ploeger, 1998; Ghnenis et 
al., 2018; Sridharan and Shankar, 2012). Luxol Fast Blue (LFB) is one of the most 
commonly used myelin histological dye discovered by Kluver and Barrera in 1953. 
It is a copper phthalocyanine dye that is attracted to the bases found in 
lipoproteins, and therefore stains myelin and myelinated axons on fixed and 
paraffin-embedded or frozen tissue sections in blue, although not to a single 
axon resolution (Scholtz, 1977; Ineichen et al., 2017). Another example of a 
histological dye used to visualise myelin is sudan black, an oil-soluble dye that 
stains the lipid phase of myelin. It has been shown to distinguish myelin 
morphology and detect demyelinated versus remyelinated axons with 
comparable results to the gold standard histological dye toluidine blue but is less 
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labour intensive and less toxic (Ineichen et al., 2017; Schmued, 1990). Although 
these dyes have been and are instrumental for detecting demyelinated and 
remyelinated lesions in tissue sections, their lack of specific markers means that 
they are non-specific for myelin, data collection is hindered by inefficient 
diffusion of the dye, and the images are relatively low resolution in our ability to 




Immunofluorescence microscopy is the use of fluorescently tagged molecules to 
allow for the visualisation of the localisation and expression levels of proteins of 
interest. An antibody targeted against the protein is fluorescently labelled, 
allowing for the location of the antibody, and hence the protein it is bound to, to 
be determined by fluorescence microscopy (Asai 2015; Shakes, Miller and Nonet, 
2012). Antibodies against proteins in oligodendrocytes and myelin sheaths have 
long been used to study their development and function, including antibodies 
against cell surface markers O1 and O4 or intracellular MBP and CNP to study 
their expression patterns and role in OL differentiation (Bansal, Gard and Pfeiffer, 
1988; Bansal et al., 1990; Schachner and Sommer, 1981), to more recent markers 
against MYRF to examine their role in myelination (Bujalka et al., 2013). These 
fluorescence microscopes encompass more simple systems such as 
epifluorescence microscopes, to more complicated designs that allow more 
detailed structures to be examined, such as through the use of confocal 
microscopy as discussed next. 
 
1.8.4 Confocal microscopy 
 
Confocal microscopy is an optical imaging technique pioneered by Marvin 
Minsky in 1955 at Harvard University. It uses a spatial pinhole at the image plane 
to increase the optical resolution and contrast of the signal generated by 
blocking out-of-focus light from reaching the detector and creating a focused 
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region of light. This focused spot of illumination is then scanned across the 
specimen using a set of two mirrors moving in the x- and y-axis, and paired with 
a motorised z-axis, in order to build up a precise 3D image. Combined with the 
development of spectral detection systems that allow precise separation of the 
growing library of available fluorescence signals with overlapping emission 
spectra through the use of multi-element photomultiplier tubes (PMTs) and 
Hybrid Detectors (HyDs), and the exploitation of antibody binding specificity to 
target specific antigens and proteins in cells or tissue through 
immunohistochemistry like PLP and MBP for differentiated oligodendrocytes 
and myelin imaging (Agrawal et al., 1977; Hartman et al., 1982), confocal 
microscopy can be used to detect and separate even closely matched 
fluorophores in increased spectral resolution with increased sensitivity and 
specificity. The use of the spinning disk, which incorporates a pattern of pinholes 
or slits onto a disk, paired with cameras for detectors, results in decreased 
resolution but increased speed of data acquisition for improved temporal 
resolution and decreased photobleaching and phototoxicity to the sample 
(Semwogerere and Weeks, 2005; St Croix, Shand and Watkins, 2005). 
Immunohistochemistry-based high content microscopy techniques will be 
explored in order to achieve the high-throughput screening aspect of this thesis. 
Advances in super-resolution microscopy has advanced our ability to directly 
visualise how cells function and are morphologically structured, as well as how 
molecules interact, by changing the optical resolution previously visible from 
250nm in the x- and y-axis and 450 to 700nm in the z-axis of conventional light 
microscopy to as small as 10nm. The conventional limit of resolution is 
determined by the point-spread function (PSF), which is the fixed size of a single 
point of light that is diffracted through the microscope. Any object smaller than 
the PSF appears to be the same size as the PSF, and any collection of objects that 
are less than the PSF apart in distance cannot be distinguished. In super-
resolution microscopy, the excitation or activation of light is temporally or 
spatially modulated in order to overcome this diffraction limit. Two commonly 
used techniques include the saturation of the fluorophore emission to a transient 
dark state that either bleaches it, such as with stimulated emission depletion 
(STED) microscopy (Hell and Wichmann, 1994), or leads to the emission of light 
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on a microsecond or millisecond time scale rather than nanosecond, or induce 
photochemical reactions to stochastically switch between on and off states or 
change colours in a subset of photoswitchable or photoactivatable fluorophores, 
respectively, that are spatially separated by the distance of the PSF, like 
photoactivation localisation microscopy (PALM) and fluorescent PALM (fPALM) 
(Hess, Girirajan and Mason, 2006), or stochastic optical reconstruction 
microscopy (STORM) (Rust, Bates and Zhuang, 2006) and direct STORM (dSTORM) 
(Heilemann et al., 2008) (Galbraith and Galbraith, 2011; Sydor et al., 2015; 
Thompson, Larson and Webb, 2002). 
Super-resolution microscopy has been used to better understand 
oligodendrocyte biology and myelin sheath formation such as through the use of 
the super-resolution microscopy technique structured illumination microscopy 
(SIM), which overcomes the limitations of lateral resolution by illuminating the 
sample with spatially structured excitation light in a series of images that are 
reconstructed to extract the additional lateral information (Gustafsson, 2000), to 
understand the interaction of MBP and actin filament formation and disassembly 
during differentiation and membrane extension (Zuchero et al., 2015). STED 
microscopy, which reduces the diameter of the PSF by surrounding the focal 
excitation point with longer wavelengths of light at a high intensity to saturate 
the surrounding fluorophores (Hell and Wichmann, 1994), has also been used to 
pick apart the ultrastructural anatomy of the nodes of Ranvier in teased sciatic 
nerve fibres to a nanoscale resolution, such as the cytoskeletal proteins and 
sodium and potassium channels organisation, with implications for the 
mechanism through which paranodal junctions and nodal gaps function and have 
roles in health and disease (D’Este et al., 2017). The degree of detail and 
resolution obtainable through these super-resolution techniques come at the 
cost of the speed of image acquisition as they use conventional microscope 
optics and hardware to achieve these higher resolution images (Galbraith and 
Galbraith, 2011), with a 2.5 by 1.8μm field-of-view at a 2D resolution of 62nm 
taking a reported 35 seconds to image (Westphal et al., 2008), with the length of 
image acquisition accumulating with larger fields-of-view and the trade-off 
between resolution and speed becoming even larger in single-resolution super-
resolution microscopy techniques due to the need for stochastic excitation to 
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overcome the PSF limitations. Therefore, current applications of super-
resolution microscopy is limited to low temporal and high spatial resolution 
microscopy requirements rather than the types of high content imaging required 
for screening in drug discovery or hit validation. In the next section, I will discuss 
a technique which could balance the ability to detect myelin sheaths with a 
similar acquisition speed to the conventional confocal microscopy to give the 
required spatial and temporal resolution, and act as a non-fluorescent-based 
label-free imaging technique for the orthogonal screen of the drug screening 
cascade in hit validation. 
 
1.8.5 Non-linear optical imaging 
 
Optical imaging is the use of light to investigate cellular and molecular functions 
in a non-destructive manner, with images being generated using photons of light 
in the ultraviolet to near infrared wavelength range. Conventional linear 
microscopy techniques are limited by the mean free path (MFP) of a photon, 
which describes the average distance that a photon is able to move between two 
consecutive scattering events, with scattering being particularly strong in the 
near-infrared and especially visible and ultraviolet spectral regions, and limiting 
the depth of penetration of light to allow imaging. The improvement of optical 
imaging and advanced microscopy has increased the depth of imaging from 10 
to 20μm to up to several hundreds of micrometres due to the physical parameter 
set by the transport mean free path (TMFP), which combines MFP with the 
average angle of photons being scattered in a single scattering event to indicate 
the distance that a photon can travel into a tissue before it loses its initial 
propagation direction, with this value typically being 10 times larger than MFP 
(Farrar et al., 2011; Ntziachristos, 2010). 
Coherent anti-Stokes Raman Scattering (CARS) microscopy, as discussed in more 
detail in Chapter 7, is an optical imaging technique that uses a four-wave mixing 
process of combining a tuned pump field Ep (ωp) and Stokes field Es (ωs) to 
generate an anti-Stokes field Eas that matches the intrinsic vibration of a 
molecular bond to create a 3D image that coincides with the spatial location of 
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the molecular bond of interest in the sample in a label-free manner. Due to the 
nonlinear nature of this imaging technique, the signal is only produced from a 
small focal volume which increases the resolution of the image generated (Fu et 
al., 2008; Wang et al., 2005). By using the CH2 bond that is abundant in lipid, 
CARS has been shown to be able to produce images of myelin in ex vivo whole 
brain slices and in vivo in the subcortex white matter in mice (Fu et al., 2008), 
and in the live spinal cord tissue of guinea pigs (Wang et al., 2005). CARS 
increases our ability to visualise myelin sheaths without the need for 
endogenous transgenic or exogenous labelling of myelin to simplify sample 
preparation, while also avoiding the effects of photobleaching and non-specific 
binding, and is able to provide images with sharp contrast for subcellular 
resolution imaging that allows quantitative analysis to be performed upon, such 
as volume, density, and orientation of myelin. However, despite its advantages 
and value in advancing myelin imaging, as shown in Chapter 7, CARS microscopy, 
like other optical imaging techniques, is limited by two main constraints. Firstly, 
despite the subcellular resolution provided, the thickness of myelin is still below 
the threshold of the resolution. Wang et al. (2005) quantified the value of g ratio 
in his publication as 0.68 and 0.63 based on whether forward- or epi-detected 
CARS measurements were used, which differs from the gold standard EM 
technique of 0.81. Although they argued that this was due to the intense sample 
preparation and dehydration involved in EM, this difference is likely due to the 
resolution limitations of the technique. The other limitation in optical imaging 
and CARS microscopy is the difficulty of live in vivo imaging due to the thickness 
of the skull and the size of the animal and its brain, although longitudinal in vivo 
imaging of the spinal cord has been shown due to its easier access (Shi et al., 
2011). On the other hand, while Wang et al. (2005) demonstrated in vivo brain 
imaging of a live mouse, they removed the grey matter to be able to access the 
white matter, which is less than ideal for in vivo imaging. However, the 
combination of labelling-independent myelin sheath detection with the speed of 
image acquisition were attractive characteristics in the exploration of this 
technique. 
Although not discussed further as part of this thesis, other optical imaging 
methods include third-harmonic generation (THG), which is a nonlinear optical 
90 
 
process in which the frequency of the light source is tripled as it passes through 
a non-linear medium as three photons of the same frequency are upconverted 
to a photon at the third harmonic (Farrar et al., 2011), and optical coherence 
microscopy (OCM), a label-free imaging technique based on optical coherence 
tomography (OCT) that is based on the intrinsic contrasting of back-scattered 
coherent light to provide 3D reconstructions in the absence of fluorescent 
labelling (Ben Arous, 2011). THG has been shown to predominantly image myelin 
in fixed mouse CNS tissue, as well as in vivo mouse spinal cord, and an adaptation 
of OCM, called deep-OCM, was used to quantify the density of myelinated fibres 
in the rat cortical grey matter and sciatic nerve. The signal produced in THG is 
only in a focal volume, providing advantages in imaging in scattering tissue, and 
has increased depth of penetration to CARS, and OCM shows promise as an 
alternative non-invasive method for imaging individual myelin sheaths with 
increased depth of penetration of up to 300 microns. Although both optical 
imaging techniques are of value in imaging myelin and provide benefits 
compared to other microscopy techniques in being label-free, and therefore 
requiring less sample processing, and potentially non-invasive, similar to the 
limitations of CARS microscopy, they are still restricted by the depth that light 
can penetrate to restrict live imaging, with OCM still requiring a craniotomy to 
thin the skull and the dura mater removed in some cases to visualise the 
underlying somato-sensory cortex, and have limited resolution, with individual 
myelin sheaths being visible but their thickness and sub-micron structures still 
being below their threshold (Ben Arous, 2011; Farrar et al., 2011). A more novel 
imaging technique, although not explored as part of this thesis, Spectral confocal 
reflectance microscopy (SCoRe), may also provide a method of label-free imaging 
of myelin sheaths with similar temporal resolution to conventional confocal 









Spectral confocal reflectance microscopy, or SCoRe, is a high-resolution in vivo 
imaging technique described by Schain, Hill and Grutzendler (2014) for 
visualising myelinated axons. SCoRe relies on the use of a conventional laser-
scanning confocal system with tunable wavelength detection capabilities 
without the need for fluorescent labelling by using the high refractive index of 
lipid-rich myelin to create a composite image of individually generated 
discontinuous segments from multiple confocal lasers (488, 561, 633 nm) to 
visualise continuous myelin sheaths. By labelling myelin with fluoromyelin dye 
through a craniotomy for in vivo imaging of Thy1-YFP mice with a subset of layer 
V cortical pyramidal neurons labelled with YFP, they were able to confirm that 
only fluoromyelin-labelled myelinated fibres were reflective, whereas YFP-
labelled dendrites, unmyelinated axons, astrocytes, and microglia were not, and 
this reflective signal was reduced in shiverer mice with an absence of compact 
myelination. Due to the highly reflective nature of the lipid in myelin, they were 
able to reach a depth of 400μm even with low laser intensities, a depth of 
penetration not easily reached by other optical imaging techniques. With this 
system, longitudinal imaging of the same region was feasible, could be used to 
detect myelin pathologies in vivo, and even showed potential in human tissue 
myelin imaging. This technique was recently independently applied to quantify 
compact myelin on fixed frozen brain sections in a cuprizone model of 
demyelination by Gonsalvez et al. (2019) to quantitatively and qualitatively 
assess compact myelin integrity in control and injury mouse model of 
demyelination. Although still limited in its use thus far, SCoRe represents a 
promising in vivo label-free optical imaging technique to study compact myelin 






1.9 Project Rationale – the need for new screening assays. 
 
The work above emphasizes the need for new drugs to enhance remyelination.  Traditional 
drug discovery has relied on molecular target-based screens (Zheng, Thorne and McKew, 
2013). However, there are limitations to the application of this type of drug screen for MS 
due to our incomplete understanding and the complexity of the biology of the myelination 
and remyelination process. For example, both NRG1 (Brinkmann et al., 2008) and integrin β1 
(Câmara et al., 2009) have been shown to be axonal signals that modulate myelination, but 
are not sufficient to “force” myelination to occur, and therefore their target biology may be 
more complicated to develop treatments against. In addition, there are limitations to the 
disease-relevant and predictive preclinical models available to validate these targets, as 
summarised in reviews such as Lassmann and Bradl (2017), with many being able to only 
recapitulate one aspect of the multi-faceted pathophysiology of MS, usually the 
inflammatory phase. The complex nature of the disease also means it is unlikely that a single 
drug against a single target would be effective, with drug combinations being much more 
likely to be effective. Therefore, a “target-agnostic” phenotypic drug discovery approach 
(Zheng, Thorne and McKew, 2013) has been taken, representing an alternative to the 
conventional target hypothesis-driven drug discovery to allow for empirical discovery of 
novel targets and drug combinations if physiological- and disease-relevant screening assays 
can be developed. 
In performing these disease-relevant screening assays, the majority of current published 
high-throughput phenotypic drug screens (where high-throughput is the adoption of various 
automation techniques to increase the accuracy and efficiency of the screen (Clemons, 
Tolliday and Wagner, 2009)) to discover remyelination therapies in MS use a two-
dimensional flat culture system to screen libraries of small molecules or US Food and Drug 
Administration (FDA)-approved drugs. The goal of these screens is to detect compounds that 
increase the number of differentiated but non-myelinating OLs from OPCs (Figure 1.19). 
Deshmukh et al. (2013) used primary rat optic-nerve-derived progenitor cells and identified 
Benztropine, an antagonist of muscarinic receptors, as the most effective compound 
(Deshmukh et al., 2013b). Najm et al. (2015) used mouse epiblast-derived OPCs to identify 
Miconazole and Clobetasol. Although there are no obvious signalling pathways responsible, 
Miconazole activates mitogen-activated protein kinase, and Clobetasol activated the 
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glucocorticoid receptor and is also a potent immunosuppressant (Najm et al., 2015). Lariosa-
Willingham et al. (2016a, 2016c) conducted two different two-dimensional drug screens 
using acutely dissociated and immunopanned purified rat OPCs in “normal” media and in 
media containing tumour necrosis factor α and IFNɣ to mimic the inflammatory condition of 
MS lesions to detect differentiation and cytokine protection hits, respectively, including 
Benztropine and Clemastine identified in other drug screens (Lariosa-Willingham et al., 2016a, 
2016c). Eleuteri et al. (2017) performed a systematic and staged screening of compounds on 
mouse OPCs, starting from stimulation of cellular metabolic activity followed by proliferation 
and differentiation effects (Eleuteri et al., 2017). 
 
 
Figure 1.19 A summary of the current high-throughput drug screens for discovery of a 
remyelination therapy 
The majority of current drug screens use a two-dimensional flat culture platform that is able to 
detect differentiation from OPC to a differentiated but non-myelinating OL. 
The BIMA screen is able to detect one stage further along the OL development by being able to 
detect those extending axon-contacting processes through the use of micropillars. 





1.9.1 Need for shift in focus in drug discovery from differentiation to myelination 
 
These current efforts in drug discovery are screens developed based on the 
assumption that simply increasing differentiation will result in increased 
remyelination.  The biological evidence as reviewed throughout this chapter, 
however, provides strong support towards myelination failure likely being a 
major block in MS, and that its regulation is controlled independently of 
differentiation. There is therefore a clinical need for remyelinating compounds 
in progressive MS that directly enhance myelination, and the current screens 
available poorly model this stage in oligodendrocyte development. Hence, we 
need methods that are able to measure myelination directly. Although Lariosa-
Willingham et al. (2016b) developed a co-culture system of embryonic rat 
cortical cells and rat OPCs, axonal myelination systems are difficult to scale up 
due to these systems being difficult to culture, being impacted by axonal survival 
and density in addition to the OPCs. One screen was able to take screening for 
remyelination compounds one step further towards myelination beyond simply 
detecting markers of differentiation, and allow the process of membrane 
wrapping to be recapitulated and quantified in a high-throughput-compatible 
format. Mei et al. (2014) developed a ‘binary indicant for myelination using 
micropillar arrays’ (BIMA) screen in which cones, or pillars, of micrometre 
dimensions were inserted into the bottom of a 96-well plate. Differentiation 
could then be detected through the expression of OL markers, and myelination 
through the wrapping of the OL membrane around the base of the micropillar 
(Figure 1.19) (Mei et al., 2014b). The drug detected using the BIMA screen, 
Clemastine, was able to meet its primary efficacy endpoint in reducing the 
latency of visual evoked responses and improving the conduction velocities in 
the optic pathway ( Green et al., 2017). The screen has subsequently been used 
to detect the kappa-opioid receptor (Mei et al., 2016) and selective estrogen 
receptor modulators (Rankin et al., 2019) in enhancing remyelination. Although 
the screen is ingenious in its simplicity, the extension of membrane around the 
base of a cone does not quite recapitulate the complexity of the myelin sheath 
formation, therefore leaving room for further development of more 
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physiologically- and disease-relevant cell-based high-throughput drug screen 
that detects myelin sheath formation as its endpoint. 
The overall aim of my project (Figure 1.20) is to develop a high-throughput drug 
screening platform for oligodendrocyte myelination using the PLA microfibre 
culture system developed by Bechler et al. (2015) as a system to recapitulate the 
complexity and 3D nature of the myelin sheaths in vitro. In order to achieve this, 
I have investigated whether there was a difference in response to the published 
pro-differentiation drugs in the 2D flat culture systems and the 3D microfibre 
system. Next, I used bioengineering to scale up the poly-L-lactic (PLA) microfibre 
system into a 96-well plate, which I then verified as compatible for high-
throughput drug screening purposes using the latest advances in liquid-handling 
robots and image-based high content screening. Last, I explored Coherent anti-
Stokes Raman Spectroscopy (CARS) and Stimulated Raman Scattering (SRS) 
microscopy as label-free techniques of imaging myelin in ex vivo slices as a 
potential method of validating the hits from the drug screen in the future. 
 
 
Figure 1.20 Project Overview of the High-Content Screening for Remyelination Treatment in 
MS 
The main high-throughput drug screening phase of my thesis can be divided into 4 main challenges: 
Challenge #1: The development of a high-throughput myelination drug assay using bioengineering 




Challenge #3: The quantification of the myelin sheath formation per compound in an automated 
fashion (done by Dr. Marie E. Bechler, in collaboration with Dr. Beth A Cimini and Professor Anne 
E. Carpenter of the Broad Institute) 
Challenge #4: Exploration of label-free imaging techniques as potential methods of validating the 
hits from the high-throughput assay 









2.1.1 Mixed Glial Culture Dissection Media 
The mixed glial culture dissection media was prepared by adding 1% Penicillin/Streptomycin 
(Pen/Strep; Invitrogen 15140-122) to Minimal Essential Medium (MEM), HEPES, no 
glutamine (Life Technologies 32360-026) at a final concentration of 100U/ml of Penicillin and 
100μg/ml of Streptomycin. 
 
2.1.2 Mixed Glial Culture Media 
The mixed glial culture media was prepared by adding 1% Pen/Strep, and 10% Foetal Calf 
Serum (FCS; Life Technologies 10270106, Batch 42G4850K) to Dulbecco’s Modified Eagle 
Medium (DMEM; Life Technologies 41966-029). 
 
2.1.3 Immunopanned O4+ OPCs Proliferation Media 
The proliferation media for immunopanned O4+ OPCs was prepared by adding 1% 100x SATO 
stock, 1% GlutaMAX supplement (Life Technologies 35050061), 1% Sodium Pyruvate (Gibco 
11360-039), 1% Pen/Strep, 1% insulin-transferrin-sodium selenite (ITS; Sigma-Aldrich I3146), 
0.1% NAC stock, 0.1% Trace Elements B (Corning 25-022-Cl), and 0.1% d-Biotin stock. 
Forskolin (final concentration at 4.2μg/ml; Sigma-Aldrich F6886), CNTF (final concentration 
10ng/ml; PeproTech 450-13-20), PDGF (final concentration 10ng/ml; Peprotech 100-13A), 
and NT-3 (final concentration 1ng/ml; Peprotech 450-03) were added to the media just 
before use. 
100x SATO stock was prepared by adding 1.61mg/ml Putrescine (Sigma-Aldrich P5780), 
6μg/ml Progesterone (Sigma-Aldrich P8783), and 10mg/ml Bovine Serum Albumin fraction V 
(Sigma-Aldrich A-4919) to DMEM. 
NAC stock was prepared by dissolving N-acetyl L-cysteine (Sigma-Aldrich A8199 and A9165) 
in Neurobasal® medium (Life Technologies 21103-049) at 5mg/ml. 
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D-biotin stock was prepared by dissolving d-Biotin (Sigma B4639) in water at 10μg/ml. 
 
2.1.4 Myelination Media 
Myelination media was prepared by mixing 1:1 ratio of Neurobasal® medium and DMEM, 
and the addition of 0.5% GlutaMAX supplement, 1% Pen/Strep, 1% ITS, 1% myelination media 
SATO stock, 2% B27 (Gibco 17504-044) or B19 stock, 0.1% NAC, and 0.1% d-Biotin. 
The 100x SATO stock for myelination media was modified to contain 40μg/ml of L-Thyroxine 
(T4; Sigma T-1775) and 40μg/ml Tri-iodothyroxine (T3) (Sigma T-6397). 
B19 stock (based on NS21 (Chen et al., 2008)) was prepared by adding to Neurobasal media 
containing 2.5mg/ml Bovine Serum Albumin (BSA; Sigma-Aldrich A4161): L-Carnitine (final 
concentration 2μg/ml; Sigma-Aldrich C7518), Ethanolamine (final concentration 1μg/ml; 
Sigma-Aldrich E9508), D(+)-galactose (final concentration 15μg/ml; Sigma-Aldrich G5388 and 
G0625), Putrescine (final concentration 16.1μg/ml), Sodium Selenite (0.01435μg/ml; Sigma-
Aldrich S9133), Corticosterone (0.02μg/ml; Sigma-Aldrich C2505), Linoleic Acid (1μg/ml; 
Sigma-Aldrich L1012), Linolenic Acid (1μg/ml; Sigma-Aldrich L2376), Lipoic Acid (0.047μg/ml; 
Sigma-Aldrich T1395), Progesterone (0.0063μg/ml), Retinol Acetate (0.1μg/ml; Sigma-Aldrich 
R7882), Retinol, all trans (vit. A) (0.1μg/ml; Sigma-Aldrich 95144), D,L-alpha-Tocopherol (vit. 
E) (1μg/ml; Sigma-Aldrich 95240), D,L-alpha-Tocopherol acetate (1μg/ml; Sigma-Aldrich 
T3001), Catalase (2.5μg/ml; Sigma-Aldrich C40), Glutathione (reduced) (1μg/ml; Sigma-
Aldrich G6013), Insulin (4μg/ml; Sigma-Aldrich I6634), Superoxide Dismutase (2.5μg/ml; 
Sigma-Aldrich S5395), and Transferrin (5μg/ml; Sigma-Aldrich T5391). 
 
2.1.5 Live Adult Slices Dissection Media 
The dissection media to slice live adult mouse brains on the vibratome was prepared by 
adding 2% B27 (Life Technologies 17504001), 2mM L-glutamine (Invitrogen 25030-024), and 
1% Pen/Strep to Hibernate-A medium (Thermo Fisher A12475-01). 
 
2.1.6 Live Adult Slices Serum-Free Culture Media 
Live adult slices were cultured in Neurobasal-A medium containing 2% B27, 2mM L-glutamine, 




2.2 Rat Oligodendrocytes Precursor Cell Isolations 
 
2.2.1 Mixed Glial Culture 
OPCs were purified from mixed glial cultures as previously described (Bechler, Byrne and 
ffrench-Constant, 2015; McCarthy and de Vellis, 1980). Briefly, the brains of postnatal day 0 
to 2 (P0-2) Sprague Dawley rats were dissected, and their cortices with the meninges 
removed collected in mixed glial culture dissection media. The cortices were minced with 
fine scissors and digested in filter sterilised mixed glial culture dissection media with 1.2U/ml 
papain (Lorne Laboratories LS003127), 0.1mg/ml L-cysteine (Sigma-Aldrich C7477), and 
0.40mg/ml DNase 1 type IV (Sigma D5025) for 1 hour at 37°C. Digestion was halted by the 
addition of mixed glial culture media, and centrifugation at 1000rpm for 5 minutes. The pellet 
was re-suspended in mixed glial culture media and triturated gently with a 21G needle before 
being added at a density of 1.5 brain per T75 flask (Scientific Laboratory Supplies Ltd. 353110), 
pre-coated in 2.5μg/ml of poly-D-Lysine (PDL; Sigma P6407) overnight at 37°C. Cells were 
cultured at 37°C in 7.5% CO2, with media changes (mixed glial culture media) every 2 to 3 
days. 
After 10 to 12 days, OPCs were purified using mechanical separation on an orbital shaker at 
250rpm and 37°C. The flasks were initially agitated for 1 hour to remove microglia, and then 
shaken for a further 16 to 18 hours in fresh mixed glial culture media to collect OPCs, while 
leaving the astrocytes still attached. The OPC-containing media were added to 10cm 
untreated plastic petri dishes for 30 minutes at 7.5% CO2 and 37°C to remove additional 
microglia. The remaining cells were collected, centrifuged at 1000rpm for 5 minutes, re-
suspended in myelination media, gently triturated with a 21G needle, and counted with a 
haemocytometer to dilute at the appropriate density for the experiment. 
 
2.2.2 Purification of OPCs by Immunopanning 
OPCs were isolated by immunopanning and collecting the O4+ cells in the protocol previously 
described for collecting ITGB5+ astrocytes (Foo et al., 2011; Foo, 2013). The brains of P7 rat 
pups were dissected, and their cortices with the meninges removed collected in dPBS with 
calcium, magnesium, glucose, and pyruvate (dPBS; Thermo Fisher 14287072). The brains 
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were manually diced with a scalpel, and then enzymatically digested in enzyme solution (10% 
Earle’s Balanced Salt Solution (EBSS) 10x (Sigma-Aldrich E7510), 0.46% D(+)-Glucose (Sigma-
Aldrich G8644), 26mM NaHCO3, 0.5mM EDTA dissolved in sterile Milli-Q water, with 
4.55U/ml papain and 0.2mg/ml L-cysteine) with 31.25U/ml of 0.4% DNase (Worthington 
LS002007, dissolved in EBSS (Sigma-Aldrich E6267)) on a 37°C heat block with 5% CO2/95% 
O2 bubbled over the top of the brains to prevent hypoxia for 40 minutes. After the digestion, 
the digested cortices were washed four times in inhibitor solution (10% EBSS 10x, 0.46% D(+)-
Glucose, and 26mM NAHCO3 dissolved in sterile Milli-Q water) containing 6.7% v/v of 10x 
low ovomucoid stock (low ovo; 15mg/ml Bovine Serum Albumin (BSA; Sigma A4161) and 
15mg/ml Trypsin inhibitor (Worthington LS003086) at pH 7.4) and 55.6U/ml 0.4% DNase, 
dissociated in further low ovo-containing inhibitor solution and the single cell solution 
collected in low ovo-containing inhibitor solution. Inhibitor solution containing 16.7% v/v of 
10x high ovomucoid stock (high ovo; 30mg/ml BSA and 30mg/ml Trypsin inhibitor at pH 7.4) 
and 20.8U/ml 0.4% DNase was layered under the single cell suspension, and the solution 
spun down for 5 minutes at 1350rpm (with acceleration and deceleration set to 6) to 
completely inhibit the papain digestion. The collected pellet was re-suspended in 0.02% 
BSA/DNase (10% 0.2% BSA/DNase (10% v/v of 4% BSA stock (40mg/ml BSA in dPBS), and 
5U/ml DNase in dPBS) in dPBS, with an additional 12.5U/ml DNase), filtered through a 20μM 
cell strainer (Pluriselect 43-50020-03), and allowed to recover at 37°C and 7.5% CO2 for 45 
minutes. 
The immunopanning dishes were prepared by coating with secondary antibodies in 50mM 
Tris-HCl (pH 9.5) overnight at 4°C, and coating with primary antibody in 0.2% BSA/Dnase for 
at least two hours at room temperature on polystyrene petri dishes (Greiner Bio-One 
633181). The single cell solution was transferred onto the “secondary only” dish (secondary 
antibody goat anti-mouse IgG + IgM (H+L) (Jackson Immuno 115-005-044), no primary) for 
10 minutes, “BSL-1” dish (no secondary, Unconjugated Griffonia (Banderiraea) Simplicifolia 
Lectin 1 (GSL 1, BSL 1) (Vector Laboratories L1100) dissolved in dPBS, overnight) for 10 
minutes, and “CD45” dish (secondary antibody goat anti-rat igG (H+L) (Jackson Immuno 112-
005-167), and primary antibody rat anti-mouse CD45 (BD biosciences 550539) for 10 minutes 
to remove microglia, macrophages, and endothelial cells. The cells were then transferred 
onto the “O1” dish (goat anti-mouse IgG + IgM, O1 (R&D systems MAB1327)) for 30 minutes, 
and then “O4” dish (goat anti-mouse IgM μ-chain specific (Jackson Immuno 115-005-020), 
O4 (R&D systems MAB1326) for 30 minutes for OPCs. 
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The adhered cells were collected from the “O4” dish with 25U/ml trypsin (Sigma-Aldrich 
T9935, stock prepared in EBSS (Sigma-Aldrich E6267)) in EBSS equilibrated at 7.5% CO2 for 3 
minutes, the reaction stopped with 30% FCS (Life Technologies 10270106, Batch 42G2083RK) 
in dPBS equilibrated at 7.5% CO2, and the dislodged cells collected. The O4 positive cells were 
spun down with 125U/ml DNase at 1350rpm for 12 minutes, re-suspended and plated in 
immunopanned O4+ OPCs proliferation media onto TC-treated dishes for 2-3 days to rest, 
before being lifted using 10% trypsin-EDTA (0.5%) (Thermo Fisher 15400054) in EBSS and 30% 
FCS. The collected cells were centrifuged at 1350rpm for 12 minutes with 125U/ml DNase, 
re-suspended in myelination media, gently triturated with a P200 tip, and counted with a 
haemocytometer to dilute at the appropriate density for the experiment. 
 
2.3 Optimised 96-well Microfibre Plate Construction 
 
These protocols were optimised as described in ‘CHAPTER IV. CONSTRUCTION OF A HIGH-
THROUGHPUT-COMPATIBLE 96-WELL MICROFIBRE PLATE’. 
 
2.3.1 Electrospinning 
The electrospinning set-up (IME device) is shown in Figure 2.1. 10% PLA (Corbion Purac 
Purasorb® PL 18) in 1,1,1,3,3,3-Hexafluoro-2-propanol (HFIP) (Manchester Organics G26383) 
(w/w) was mixed thoroughly on a rolling mixer overnight and loaded into a syringe. The 
syringe was attached to a solution tubing, with an 18G tip connected to the other end. The 
18G tip was inserted and secured into the moving needle, and set 18cm away from the 
rotating collector (working distance). The rotating collector was covered in a sheet of 
aluminium foil with 2 sheets of 10cm by 14cm release paper (Stix2) attached for the 
collection of the microfibre. The control panel was used to set the pump (flow rate) to 
1.3ml/hr, the rotating collector to spin at 2000rpm for fibre alignment, the movement of the 
needle to cover 160mm at 50mm/s, and the voltage of the positive end (needle) to 19-24kV 
(usually 20-22kV) and negative end (rotating mandrel) to -1kV in order to achieve a stable 





Figure 2.1 Electrospinning set-up 
The photograph is of the electrospinner used for the final optimised electrospinning protocol. Note 
the rotating mandrel allowing for aligned fibre collection and the moving needle to allow for even 
distribution of fibres. 
 
Scanning electron microscopy (SEM) to verify the diameter of the electrospun microfibres 
was performed by mounting the microfibres onto SEM aluminium stubs with carbon adhesive, 
sputter coating them with 20 nm gold/palladium by Dr. Stephen Mitchell (EM Facility 
Manager), and imaging on the Hitachi S-4700 Scanning Electron Microscope. The images 
were quantified manually on ImageJ, and plotted using GraphPad Prism. The density of the 
fibres was measured by taking brightfield images on the Leica SP8 confocal microscope with 
the MatrixScreener (section ‘2.5.3 96-well Microfibre Culture Plates’) of the transferred 
fibres onto the base of the 96-well plates (as described below in section ‘2.3.2 Plate 
Construction’), drawing a straight line perpendicular to the alignment of the parallel fibres 
and measuring the distance between individual microfibres on ImageJ. The graph was plotted 
using GraphPad Prism. 
 
2.3.2 Plate Construction 
The final plate construction has been summarised in Figure 2.2. A bottomless 96-well plate 
was prepared by laser cutting holes at the base of the individual 96-wells on a PerkinElmer 
CellCarrier-96 Black plates (CellCarrier, PerkinElmer 6005558) or PerkinElmer CellCarrier-96 
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Ultra microplates (CellCarrier-Ultra, PerkinElmer 6055302) and then sandpapered to smooth 
the surface, or using a bottomless ViewPlate-96 Black (ViewPlate, PerkinElmer 6005430). A 
sheet of electrospun microfibres was lifted from the release paper onto the laser cut double-
sided tape (Stix2), laser cut PCR plate seal (Life Technologies AB0558), and cyclic olefin 
copolymer (COC), and attached to the base of the bottomless 96-well plate with a sheet of 
laser cut double-sided tape. The layers were then compressed together with a metal block. 
Laser cutting was performed by Dr. Anthony Buchoux (Stokes Lab, Scottish Microelectronics 
Centre). 
 
Figure 2.2 Optimised plate construction set-up 
The figure shows the optimised layers for the construction of the 96-well microfibre plate that is cell- 
and imaging-compatible and water-tight. 
 
2.4 Rat OPCs Cultures and Immunostaining 
 
2.4.1 96-well Flat Culture Plates 
CellCarrier plates were prepared by coating in 2.5μg/ml PDL in Milli-Q water overnight. The 
OPCs isolated from mixed glia culture were diluted to 160,000 cells/ml and plated at 50μl per 
well (for a final density of 8,000 OPCs/well) onto pre-dispensed 45μl myelination media per 
well using the MultidropTM Combi Reagent Dispenser (Thermo Fisher 5840300) with the 
MultidropTM ‘small tube plastic tip dispensing cassette’ (Thermo Fisher 24073290) or Steinle 
‘standard tube dispensing cassette’ (Steinle ST-0010). 
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The ‘compound plate’ was prepared by adding the drug at its stock concentration, and doing 
1 in 3 serial dilutions into the solvent (Dimethyl sulfoxide (DMSO, Sigma-Aldrich D8418) or 
0.03M sodium bicarbonate (NaHCO3)). The ‘media plate’ was prepared by doing 1 in 50 
dilutions of the ‘compound plate’ into myelination media. The compounds were then added 
to the ‘cell plate’ (i.e. the CellCarrier plates containing the plated OPCs) 4 hours post-plating 
(to prevent interference with cell adherence) by adding 5μl of the ‘media plate’ per well for 
a final volume of 100μl per well and 1 in 1000 dilution from the ‘compound plate’ at a final 
concentration of 0.1% DMSO per well. Vehicle control (0.1% DMSO) was added to control 
wells. If the cells were cultured for more than 3 days, the ‘media plate’ was prepared again 
from the ‘compound plate’ stored at 4°C, and media change with drug addition performed 
by removing 50μl, adding 45μl myelination media, and 5μl of the ‘media plate’ added. This 
was all performed using the Thermo Fisher E1-ClipTip electronic multichannel pipette and 
compatible 125μl ClipTip pipette tips (Thermo Electron LED GmbH PIP0362). 
The cells were fixed at the appropriate time-point by adding 100μl 8% formaldehyde 
(prepared from 37% formaldehyde solution (Sigma-Aldrich 252549) in PBS) with the 
MultidropTM, for a final concentration of 4% formaldehyde per well, for 10 minutes. The 
BioTek LS 405 microplate washer was used to aspirate (height: 3.811mm to leave 
approximately 50μl of solution per well) and dispense PBS (dispense rate: 2, volume: 
100μl/well, x-axis offset to dispense onto the side of the wells, dispensing height: 14.610mm) 
for 3 cycles to remove the formaldehyde and leave 50μl, 50μl of 0.2% tritonX-100 (0.1% final 
concentration) dispensed with the MultidropTM for cell permeabilisation, washed for 1 cycle 
with the BioTek LS 405, and primary antibody rat anti-MBP antibody, clone 12 (MBP, AbD 
Serotec MCA4095) added with the MultidropTM for a final concentration of 1 in 250 in PBS 
for incubation at 4°C overnight. The plates were washed for 1 cycle with the BioTek LS 405, 
and incubated for 1 hour at room temperature in Alexa Fluor 488 Goat Anti-Rat IgG (H+L) 
antibody (anti-rat488, Life Technologies A-11006) added with the MultidropTM at a final 
concentration of 1 in 1000. After 1 cycle of the BioTek LS 405, the cells were incubated in a 
final concentration of 5μg/ml Hoechst (Thermo Fisher 62249) added with the MultidropTM 
for 10 minutes, remaining antibodies and dyes removed with 3 cycles of the BioTek LS 405, 
and sealed with adhesive PCR plate seals (Life Technologies AB0558) for imaging. The number 
of BioTek LS 405 cycles tolerated by the cells without being damaged was optimised by 
testing the “optimal” number of washes (i.e. 3 cycles in between each step) and “minimum” 
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number of washes (i.e. 1 cycle except after the formaldehyde fixing and at the end of the 
protocol). 
Cell viability assays were performed using the Caspase-Glo 3/7 Assay (Caspase Assay, 
Promega G8091) and CellTiter-Glo Luminiescent Cell Viability Assay (ATP Assay, Promega 
G7571). The cultured cells were removed from the incubator and equilibrated at room 
temperature for 30 minutes. As per standard protocol, 50μl of media/well was removed and 
50μl of the respective assay solution added using the MultidropTM. The Caspase Assay plate 
was shaken at 300rpm for 30 seconds and incubated at room temperature for 30 minutes. 
The ATP Assay plate was shaken at 300rpm for 2 minutes and incubated at room temperature 
for 10 minutes. 25μl per well was transferred into a white 96-well microplate (Greiner 655075) 
in triplicates, and luminescence recorded on the Promega GloMax Explorer. The 
luminescence measurement of no cells was subtracted from each measurement as 
background signal, and each measurement normalised to the DMSO control using Microsoft 
Excel. The resulting data was plotted using GraphPad Prism. 
 
2.4.2 12-well Microfibre Scaffolds 
12-well scaffolds with aligned 2μm PLA microfibres were purchased from the Electrospinning 
Company (TECL006). The fibres were used as previously described by Bechler, Byrne and 
ffrench-Constant (2015). Briefly, the scaffolds were soaked in 70% ethanol for 15 minutes to 
sterilise and increase the hydrophilicity of the hydrophobic microfibres. They were then 
rinsed in sterile Milli-Q water and coated in 2.5μg/ml PDL in Milli-Q water overnight. Before 
plating, the scaffolds were rinsed with sterile Milli-Q water, and soaked in myelination media 
for at least 10 minutes to remove any remaining water before changing to 2ml of fresh 
myelination media per scaffold. The OPCs isolated from the mixed glia culture were diluted 
at 150,000 cells/ml and plated at 34,500 cells per scaffold in a dropwise fashion to prevent 
clumping. 
The drugs were diluted at 1μM and 0.1μM from the 10mM stock concentration into 
myelination media, including the DMSO control, and the concentration at which the cells 
looked healthier visually after staining used for future repeats. The media changes with drug 
addition were performed every 2 to 3 days, with the first drug addition being 3 days post-
plating to target myelination rather than differentiation. 
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At day 14, the scaffolds were rinsed in PBS, fixed for 15 minutes in 4% formaldehyde, and 
permeabilised in 0.1% triton-100 for 15 minutes. The scaffolds were incubated in 1 in 250 
MBP in PBS overnight at 4°C, 1 in 1000 anti-rat488 in PBS for 1 hour at room temperature, 
and 5μg/ml Hoechst in PBS for 5 minutes. The scaffolds were mounted by placing a drop of 
Fluoromount-G® (Fluoromount, SouthernBiotech 0100-01) onto a cut colour frosted blue 
microscope slide (VWR 631-1555), removing excess PBS carefully from the sides of the 
scaffold, placing the scaffold on the Fluoromount drop with additional Fluoromount on top 
of the fibres, sandwiching the fibres onto the microscope slide with a 13mm borosilicate glass 
coverslip (VWR 631-0149), and leaving to dry for at least 24 hours at room temperature. Once 
set, the scaffold was carefully removed, leaving the fibres sandwiched between the 
microscope slide and coverslip for imaging. 
 
2.4.3 96-well Microfibre Culture Plates 
Similar to the 12-well scaffolds, the constructed 96-well microfibre plates were prepared by 
sterilising and increasing the hydrophilicity of the PLA microfibres in 70% ethanol for at least 
15 minutes, being careful of bubbles forming under the fibres, rinsed in Milli-Q sterile water, 
and coated in 2.5μg/ml PDL in Milli-Q water overnight. The fibres were rinsed, soaked in 
myelination media for at least 10 minutes, 100μl of fresh myelination media placed in each 
well, and the plate placed at 7.5% CO2 until ready for plating. The O4+ immunopanned OPCs 
collected from immunopanning were diluted to the appropriate density, i.e. 50,000 cells/ml 
for 100μl plating for 5,000 cells/well. 
The experiments with added growth factors (performed at Roche) in the myelination media 
were prepared by adding 10ng/ml Cilliary neurotropic factor (CNTF, Peprotech 450-13) and 
1ng/ml Neurotrophin 3 (NT3, Peprotech 450-03). 
An additional fibrin-coated PLA microfibres experiment was performed at Roche (Basel, 
Switzerland) using the protocol from Bacakova et al., (2016). After PDL-coating, the fibres 
were coated in 10μg/ml fibrinogen (EMD Millipore 341576, Lot 3105287) for 1 hour, followed 
by 2.5U/ml thrombin (EMD Millipore 605195) for 15 minutes, 200μg/ml fibrinogen and 
0.5U/ml antithrombin III (Sigma A2221) for 1 hour, all dissolved in and rinsed with 50mM 
Tris-HCl buffer, before soaking in myelination media for plating. 
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The drugs were added 3 days after plating, and media changes made every 2 to 3 days 
afterwards, by diluting the drugs to 2 times the final concentration in myelination media, and 
doing half media changes. The cells were fixed 14 days after plating at the Scottish Centre for 
Regenerative Medicine (SCRM), and 17 days after plating at Roche. Fixation was performed 
by removing 100μl and adding 100μl of 8% PFA for 10 to 15 minutes, rinsing in PBS, 
permeabilising in final concentration of 0.1% triton-100 for 10 to 15 minutes, and incubating 
in MBP at 1 in 250 dilution final concentration overnight at 4°C. The cells were then incubated 
in anti-rat488 or goat anti-rat IgG (H+L) Secondary Antibody, Alexa Fluor® 647 conjugate 
(anti-rat647, Invitrogen A21247) for 1 hour at room temperature, and, when appropriate, 
stained with HCS CellMaskTM Green Stain (CellMask_cytoplasm, Life Technologies H32714) at 
1 in 20,000 final concentration for 30 minutes at room temperature. The cells were incubated 
in 5μg/ml Hoechst in PBS for 10 to 30 minutes, and sealed for imaging. 
The plates prepared at Roche were filled with PBS, sealed with a PCR plate adhesive seal and 
parafilm, covered in aluminium foil, and shipped back to Edinburgh in an ice box. This 
resulted in the loss of cells due to the movement of the fibres as the PBS could not be filled 
all the way to the top without losing the ability to adhere the seals. 
 
2.4.4 Compounds 
The compounds used were as follows: 
Drug Company Catalogue # Dissolved in Comments 
Benztropine Stratech 
Scientific Ltd. 








S1847-SEL DMSO Identified in 
differentiation 
drug screen (Mei 





S3163-SEL DMSO Identified in 
differentiation 
drug screen 













S2536-SEL DMSO Identified in 
differentiation 
drug screen 
(Najm et al., 
2015) 
FR 236924 Tocris Biotechne 3091 DMSO Identified to 
increase myelin 
sheath number 





BQ-3020 Tocris Biotechne 1189 0.03M NaHCO3 Identified to 
increase myelin 
sheath number 
by Dr. Matthew 








Tocris Biotechne 1276 DMSO Decreased 
myelin sheath 





U0126 Tocris Biotechne 1144 DMSO Decreased 
myelin sheath 





Compound R Roche  DMSO  
 
 
2.5 Rat OPCs Cultures Imaging and Analysis 
 
2.5.1 96-well Flat Culture Plates 
The 96-well flat culture plates were imaged on the PerkinElmer Operetta High-Content 
Imaging System (Operetta) and Harmony software using the 20x long WD (NA 0.45) lens. The 
MBP was detected using the Alexa 488 settings at 200ms exposure, and the Hoechst detected 
using the DAPI settings at 20ms exposure. 31 non-overlapping fields were selected for 
imaging per well, and imaged at 1 time-point and 1 plane. The imaging of only 1 plane was 
determined based on optimal imaging quality and speed, as the minimum recommended 
distance between planes of the objective used was 3.6μm, with no additional imaging details 
being obtained by increasing the number of planes imaged. 
Image analysis was performed using the PerkinElmer Columbus platform. All images were 
adjusted using the automatic flatfield correction generated to compensate for unequal 
illumination across the fields-of-view. Quantification was conducted by segmenting and 
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selecting the nuclei filtered by morphology (area and roundness) and intensity, and then the 
MBP+ cytoplasm of the selected nuclei filtered by morphology (area) and intensity 
(Supplementary Data 2.1: Columbus 96-well Flat Culture Analysis Pipeline Example). Wells 
containing cells that were only incubated in secondary antibody were used to determine 
background noise of the secondary antibody, and therefore used to determine the minimum 
intensity for a true signal per plate. 
The analysed data was exported into Microsoft Excel, each condition at each concentration 
normalised to the DMSO control, and plotted using the GraphPad Prism software. 
 
2.5.2 12-well Microfibre Scaffolds 
The 12-well microfibre coverslips were imaged by randomly selecting 4 to 24 fields of view 
per condition, depending on the quality of the cells - with all coverslips except 1 having at 
least 8 fields of view, on the Leica TCS SP8 confocal microscope with 5 detectors system using 
the 40x oil (NA 1.25) lens, with a z-step of 0.37μm. The same settings (laser power, gain, etc.) 
were used between coverslips in a single repeat of the experiment. 
The images were blinded and analysed using ImageJ (Schindelin et al., 2012), with a complete 
myelin sheath being defined as a complete and continuous MBP+ signal surrounding the 
microfibre as assessed through the 0.37μm z-series (Figure 2.3). The length and number of 







Figure 2.3 Quantification of myelination on the microfibre cultures 
A. An example of a MBP+ rat OL cell cultured in vitro on the 12-well microfibre scaffold for 14 
days. The orthogonal views demonstrate myelin sheath formation by complete MBP signal 
detected around the individual microfibre. 
B. Lengths of the myelin sheaths (highlighted with blue outlines overlaying the green MBP) were 
quantified by tracing and measuring complete tube formation through the 0.37μm z-series. 
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The measurements were recorded and unblinded in Microsoft Excel, and plotted and 
analysed in GraphPad Prism. Statistical tests were performed by determining the mean per 
condition per biological replicate, and performing the 1way ANOVA with Kruskal-Wallis and 
Dunn’s Multiple Comparison Tests for statistical significance. 
 
2.5.3 96-well Microfibre Culture Plates 
The 96-well microfibre plates were imaged on the Leica SP8 confocal using the 
MatrixScreener extension and the 25x water (NA0.95) lens at 1.6x zoom. The images were 
obtained by imaging the central 8 by 4 wells, with the outer wells being inaccessible due to 
the skirt of the plate, at 290μm FOV with a 10μm overlap, and capture range of 500μm with 
a 0.5μm z-step size, with the settings (image format and resolution, gain, laser power, etc.) 
kept consistent across all plates. The transmission was used to detect the focal plane of the 
microfibres per each plate, and the focus map used to optimise the optimal z-galvo plane to 









Figure 2.4 An example of a focus map of the range of focal plane of the microfibres in a 96-
well microfibre plate as detected by the SP8 MatrixScreener 
The figure shows an example focus map generated by the SP8 MatrixScreener to detect the range of 
focal planes at which it has detected the microfibres. This is used to aid the autofocusing of the 
subsequent imaging in locating the z-plane of the microfibre in each well to capture the cells. The 
colours represent the position of the fibres either above (red) or below (blue) the manually set 
approximate mid-point, showing the range of the position of the fibres in this plate to be about 225μm, 
which was fairly consistent across all plates imaged by the MatrixScreener. 
 
The images, saved as individual .tiff files, were stitched and stacked together per well using 
a script written by Dr. Bertrand Vernay (former Head of Imaging at SCRM) (Supplementary 
Data 2.2: Leica SP8 MatrixScreener Imaging Stitching Script), and the myelin sheath 
formation analysed as per 12-well microfibre scaffold images on ImageJ (Schindelin et al., 






2.6 Mouse Brain Slices for CARS/SRS 
 
2.6.1 Animals 
The organs from wild-type control animals (C57BL/6NCrl) were obtained at the appropriate 
ages by either increasing CO2 concentration and removal of brain into live adult slices 
dissection media or 4% PFA, or by overdosing on Domitor/Vetalar followed by perfusion 
fixation and removal of the brain into 4% PFA. The culls were carried out by Dr. Steffen Mayerl, 
Dr. Lida Zoupi, and Dr. Marie Bechler. 
The LPC injection was performed by Amanda Boyd and Dr. Sarah Jaekel by injecting 2μl of 
lysophosphatidyl choline (LPC) into the corpus callosum of C57BL/6NCrl adult male mice, and 
collecting their brains after 8 days when the lesion should still be clearly visible. The D2O 
animals were obtained by giving 30% deuterium oxide (D2O, Sigma-Aldrich 1518882) in 
normal drinking water once they had been weaned, after P21, for 2 weeks before organ 
harvesting by perfusion fixation by Dr. Steffen Mayerl. 
 
2.6.2 Vibratome 
The slices were obtained on the Leica VT1000M vibratome. The brains were set in 2 to 4% 
agarose, attached to the vibratome stage and placed in either live adult slices dissection 
media or PBS. The slices were obtained at the required thickness (mostly 300μm, 500μm for 
the live slices imaged in 3D printed ring, and 50μm for the D2O experiments), with the blade 
moving at speed 1 to 2 at frequency 7 to 8. Fixed slices were immediately transferred into 
PBS for storage until imaging, and live slices were transferred onto Millicell Insert 30mm 
Organotypic PTFE 0.4μm (MERK Millipore PICM0RG50) in a 6-well plate with 1ml of live adult 
slices serum-free culture media underneath and placed at 5% CO2. 
 
2.6.3 Immunostaining 
The slices were stained by fixing in 4% PFA for 1 hour, placing in block (3% heat inactivated 
horse serum (Life Technologies 26050-088), 2% BSA, 0.5% saponin (vs. tritonX-100 - to 
preserve lipid integrity, Sigma-Aldrich 84510) at room temperature on a rocker for 1 to 2 
hours, and placing in primary antibody (MBP, Caspr (Abcam ab34151), Olig2 (Millipore 
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AB9610)) in block on a rocker at 4°C for two overnights. After washing with block, the slices 
were placed in secondary antibody (anti-rat488 for MBP, and Alexa Fluor 568 Goat Anti-
Rabbit IgG (H+L) Antibody (anti-rabbit568, Life Technologies A11011) for Caspr and Olig2) in 
block on a rocker at 4°C overnight. The slices were stored in PBS until imaging. 
 
2.6.4 Imaging 
Coherent anti-Stokes Raman Scattering (CARS) and Stimulated Raman Scattering (SRS) 
microscopy was performed under the technical support of Dr. Martin Lee (Brunton Lab, 
IGMM) as described in Lee et al. (2015) and Tipping et al. (2017), respectively. Images were 
taken using a custom-built multi-modal microscope setup with an Olympus FV1000MPE 
microscope as the foundation, which is also capable of two-photon fluorescence and Second 
Harmonic Generation (SHG) imaging. Briefly, the tunable pump laser (720-990nm, 7ps, 80 
MHz repetition rate) and a temporally and spatially overlapped Stokes laser (1064nm, 5-6ps, 
80 MHz repetition rate) was created using a picoEmerald (APE, Berlin, Gemany) laser, fed 
into the FV1000 MPE using a series of mirrors and lens based beam expanders. A 25x 
Olympus XLPL25XWMP (NA 1.05) objective lens focused the light onto the sample for imaging. 
The backscattered emission signal was detected using a short-pass 690nm dichroic mirror 
and IR cut filter (Olympus). The various emissions were demodulated onto one of four 
available PMTs in the following fashion: SHG signals were filtered using the following series 
of filters: FF552-Di02, FF483/639-Di01 and FF01-400/40. GFP two-photon fluorescence 
signals were filtered using filters: FF552-Di02, FF483/639-Di01 and FF510/84. RFP two-
photon fluorescence signals were filtered using: FF552-Di02, and FF440/520-Di01 and 
HQ610/75m (Chroma). CARS signals were filtered using: FF552-Di02, and FF440/520-Di01 
and ET687/95m (Chroma). All filters from Semrock unless noted separately.  For SRS Imaging 
the Stokes beam was modulated with a 20MHz Electro-optical Modulator (EoM) built into 
the picoEmerald. Forward scattered light was collected with a 20× Olympus XLUMPLFLN 
objective (NA 1.00) and focused onto a photodiode connected to a lock-in amplifier (APE, 
Berlin). Stokes light was removed by filtering with an ET890/220m filter (Chroma). The signal 
from the lock-in amplifier was passed to the analogue unit of the FV1000MPE system. CARS 
signals were generated at 2845cm-1 and 2915cm-1 by tuning the pump beam to 816.8nm and 
812.2nm, respectively.  SRS signals were generated at 2855cm-1 and 2940cm-1 by tuning the 
pump beam to 816nm and 810.5nm, respectively. SHG and fluorescence images were 
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collected simultaneously with CARS/SRS images using the same laser frequencies. Deuterium 
bonds were detected with the pump tuned to 866.6 or 863.0nm (2141cm-1 or 2189cm-1) and 
off resonance images taken at 870nm or 860nm (2096cm-1 and 2229cm-1), or using the sweep 
function to collect multiple frequencies sequentially. All images were taken at 512 x 512, 
1024 x 1024, or 2048 x 2048 pixels by the Olympus FV10-ASW software. CARS images were 
taken with a pixel dwell of between 4-10µs, and SRS images with a 20µs pixel dwell and 20µs 
time constant on the lock-in amplifier. Laser power on the sample varied from 20mW-50mW 
for the pump laser and 30-70mW for the Stokes laser. 
Image processing was performed in ImageJ (Schindelin et al., 2012) to subtract off resonant 
signals from the deuterium images using the subtract operation on the image calculator 
function.  Flat-field correction done on tilescan images using a script written by Dr. Bertrand 
Vernay (Supplementary Data 2.3: CARS Flat-Field Correction Script for Tile Scan Images). 
Image analysis to measure myelin sheath length was performed using the ‘Simple Neurite 
Tracer’ plugin on ImageJ (Longair, Baker and Armstrong, 2011). 
Live slices were transported sealed with parafilm and placed in a Styrofoam box with “ice” 
packs warmed to 37°C, and imaged in warmed live adult slices serum-free culture media or 
Hibernate-A media in a WPI FluoroDish Cell Culture Dish (imaging dish, WPI FD35-100) with 
an 18mm coverslip (Marienfeld 0117580) balanced on top to prevent the slice from floating, 
or inside a 3D-printed 500μm-thick ring (printed as per requested design by Dr. Anthony 
Buchoux) to balance the coverslip without compressing the slice. Fixed slices were 
transported sealed with parafilm and placed in a Styrofoam box with ice packs, and imaged 
in PBS in the imaging dish with a glass coverslip and small weight on top to reduce tissue 
movement while imaging. 
 
2.6.5 Raman 
Raman spectrum for the D2O samples were obtained by placing the brain slice onto a calcium 
fluoride (CaF2) slide (Crystran Limited CAFP76-26-1U) with a drop of PBS, and sandwiching 
with a CaF2 0.2mm coverslip (Crystran Limited CAFP13-0.2R). The slice was placed into the 
inViaTM confocal Raman microscope (Renishaw), and the accompanying WiRE software used 
to take the Raman measurements with the 532nm laser and 2400 lines/mm grating. 
Measurements were taken between 2500cm-1 to 3300cm-1 to detect the CH2 bond at 2845cm-
1, and 1700cm-1 to 2600cm-1 to detect the DH2 bond at 2141cm-1, with an exposure time of 1 
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second, laser power set to 100%, step size of 10μm for the map, and with a 20x objective. 
The collected Raman spectra were corrected for white light cosmic rays and baseline, and 




CHAPTER III. 2-DIMENSIONAL VS. 3-DIMENSIONAL CULTURES OF 




As discussed in the ‘CHAPTER I. LITERATURE REVIEW’, no disease-modifying treatments are 
currently available to target the non-inflammatory neurodegenerative phase of MS. Several 
lines of evidence suggest that promoting remyelination is neuroprotective and promotes 
functional recovery. Key exemplar experiments are: i) Smith et al. (1979) who recorded the 
restoration of impulse conduction in LPC-induced demyelinated axons of cats once 
remyelination initiated, ii) Irvine and Blakemore (2008) who reported improved axonal 
survival following cuprizone-induced global demyelination and irradiation to prevent 
endogenous remyelination when embryo-derived neural progenitors were transplanted to 
restore remyelination, and iii) Duncan et al. (2009) who showed restoration of function in 
cats with a dietary manipulated model of demyelination following endogenous remyelination.  
As I also reviewed in the Introduction, quantification of OPCs and OLs in MS brain samples 
suggest that there is a failure of remyelination due to a block in OL development, rather than 
a lack of OPC recruitment, in the majority of lesions (Chang et al., 2000; Lucchinetti et al., 
1999; Wolswijk, 1998). Based on these findings, several studies have been published where 
OPCs from various sources have been screened using libraries of FDA-approved drugs to 
detect the increase in MBP+ differentiated cells as their primary output in order to discover 
new treatments that promote remyelination in treating MS (Deshmukh et al., 2013; Lariosa-
Willingham et al., 2016a, 2016c; Mei et al., 2014; Najm et al., 2015). 
However, there is evidence suggesting that the OLs present in these 70% of MS lesions are 
premyelinating immature OLs (Chang et al., 2000; Jäkel et al., 2019; Lucchinetti et al., 1999) 
rather than OPCs. In addition, studies on oligodendrocyte biology show that differentiation 
and myelination may occur as two independent processes in OPC differentiation and OL 
maturation (Colello et al., 1995) with separate critical windows (Czopka, ffrench-Constant 
and Lyons, 2013; Hill et al., 2014; Watkins et al., 2008) and different neuronal signalling (Biase, 
Nishiyama and Bergles, 2010; Wake et al., 2015). Collectively, these different studies show 
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that differentiation and myelination occurs as a two-step process, which indicates pro-
differentiation compounds may not necessarily also enhance remyelination.  
In order to validate this argument, in this chapter, I: (1) conducted a dose-response 
experiment using compounds identified as pro-differentiation in previously published 
screens or pro-myelination in our lab (Yuen et al., 2013; Swire et al., 2019) to verify that an 
increase in differentiation could be detected with the former in a 2D flat culture system, and 
also to determine whether the latter compounds would have been identified as hits in a 2D 
differentiation assay, and (2) screened the pro-differentiation compounds in a 3D microfibre 




3.2.1 Concentration-response curves for oligodendrocyte differentiation, cell death, 
and cell activity using published compounds in the 2D flat culture system 
 
In order to test whether compounds that have previously been published in the 
differentiation (Deshmukh et al., 2013; Lariosa-Willingham et al., 2016a, 2016c; Najm et al., 
2015), ensheathment (micropillar assay (Mei et al., 2014)), and axonal myelination screens 
(Lariosa-Willingham et al., 2016b) also increase differentiation on our OPCs isolated from 
mixed glia cultures, I first performed a concentration-response drug screen on 2D flat 
cultures (as reviewed in the Introduction) using a 96-well plate system. I also included 2 
molecules that have been identified to increase the number of myelin sheaths produced per 
oligodendrocyte by Dr. Matthew Swire in our lab (Swire et al., 2019), the small molecule PKC 
activator, FR236924, and the endothelin receptor agonist peptide, BQ-3020 (Yuen et al., 
2013), to test whether compounds identified in a 3D myelination assay would be identified 
as positive hits in a 2D differentiation assay. The three responses recorded were: (1) the 
changes in differentiation through the number of MBP+ cells, and the effect on cell viability 
through (2) a caspase activity reporter (cell death), and (3) ATP (cell activity) assays. 
In order to be able to carry out the 2D concentration-response differentiation assay, two 
main challenges had to be overcome: (1) the consistency of the plating density, and (2) the 
120 
 
accuracy and timing of the compound addition. For the first challenge of achieving consistent 
cell density throughout the 60 wells of the 96-well plate, with the outer wells filled with PBS 
to prevent the edge effect from evaporation, the use of a single channel manual pipette 
created a large time delay between when the cells were added to the first well to when the 
final well was plated. This created issues on two levels. Firstly, this allowed time for the cells 
to settle during the plating process, especially if more than one plate was being used, leading 
to decreasing cell density over the course of the cells being plated. The consistent re-
suspension of the cells in the media during the plating resolved this issue to a certain degree, 
but also increased the time required for the cell plating overall. Secondly, the time in which 
the cells were outside of the incubator (i.e. at room temperature and CO2 level) was lengthy 
using this plating technique, and increased with more plates required for the drug screen. 
This additionally created inconsistencies in the timing of the drug addition, mentioned again 
below, with the time difference between when the cells were plated and when the 
compounds were added to each well due to the maximum pipetting efficiency with such a 
set-up. The use of the manual or automated multi-channel pipette improved these aspects, 
but still was limited by the maximum speed at which pipetting could be performed, especially 
when two to three plates to test all the compounds at the required drug concentrations with 
three replicates for a minimum of six to nine 96-well plates were required for the full 
concentration-response screen. Therefore, I optimised a protocol in which these cells were 
plated using the automated multi-well plate liquid handling ThermoScientific MultidropTM 
instrument, with media pre-dispensed onto the plates and the plating speed set to low to 
decrease hydraulic stress on the cells, which decreased the time required to plate a single 
96-well plate from over a minute to a couple of seconds each, and also eliminated the settling 
of the cells in the conical tube during the plating, therefore increasing the intra- and inter-
plate consistency of cell density and the throughput of the plating. I was also able to optimise 
the staining and assay solution dispensing protocol by performing these steps using the 
MultidropTM and BioTek LS 405 multiplate washer rather than by manual pipetting, thereby 
increasing the intra- and inter-plate consistency and the throughput of the assay screening 
pipeline, from hours to minutes, at later stages of the protocol as well. 
The compounds were added 4 hours after plating, to allow the cells to adhere without 
potential influence from the compound upon cell adhesion yet still early enough to affect 
differentiation, and fixed 3 days later, when the percentage of MBP+ cells from total nuclei 
were high enough to be able to detect differences from control (assay window range) but 
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without reaching saturation (Supplementary Figure 3.1 A). The second challenge, the 
accuracy and timing of compound addition, was addressed by optimising the protocol in 
compound preparation and addition. The manual preparation of individual compounds and 
their respective multiple concentrations increased the chances of human error and pipetting 
inaccuracies, including in the final volume of the compound and solvent present within each 
well (i.e. 0.1% DMSO standard within the field). Other sources of technical inaccuracies could 
also be identified, including the time required to add the compounds from the first to final 
well of each experiment, which, combined with the length of time required for cell plating as 
previously discussed, could vary the length of time cells were exposed to the compound 
drastically across the experiment. I therefore optimised the final compound addition 
protocol, involving a discussion with screening experts in the Edinburgh Phenotypic 
Screening Centre for advice on the industry standard technique. In this protocol, a 
‘compound plate’ of the various compounds dissolved and diluted in their respective solvents 
(i.e. 100% DMSO and 1000x final compound concentration) was prepared first using a 
standard 96-well plate arranged in a plate map that allowed the use of an automated 
handheld multichannel pipette to perform the serial dilution systematically across the plate. 
This ‘compound plate’ could be prepared up to a week in advance, but was usually prepared 
fresh on the day. Towards the end of the four hours between cell plating and compound 
addition, a ‘media plate’ was prepared, in which the ‘compound plate’ was dissolved in the 
myelination media at 1 in 50 dilution (i.e. 2% DMSO and 20x concentration). This ‘compound 
plate’ was then added to the ‘cell plate’, i.e. the plates in which the cells had been plated 
four hours previously, with 5μl being added to a final 100μl volume per well for the final 1x 
compound concentration (0.1% DMSO). This streamlined protocol therefore addressed the 
technical and timing challenges of compound addition in a multi-compound concentration-
response screen, and was used as the standard protocol in the results discussed below. 
Using the optimised MultidropTM protocol discussed, the intra-plate reliability of plating 
across a 96-well plate was first calculated by plating 9,000 cells per well across a 96-well plate 
using the MultidropTM under control media-only conditions (Figure 3.1 A-C). The 
segmentation and selection criteria for counting Hoechst+ cells is summarised in Figure 3.1 
D. The coefficient of variation (CV), the measurement of variability frequently used in assay 
development (Reed, Lynn and Meade, 2002; Clemons, Tolliday and Wagner, 2009), with an 
intra-plate CV value of <20% being the acceptable threshold. For the number of nuclei in this 
test plate, the CV was calculated to be 8.25% by Columbus, showing good consistency in cell 
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plating density across the plate using the MultidropTM. The CV values for the DMSO and 
NaHCO3 controls were also calculated for 6 of the experimental plates (3 different biological 
replicates) from Figure 3.2 for both Hoechst (plating density) and MBP (differentiation; 
segmentation and selection criteria summarised in Figure 3.1 E). As summarised in Figure 3.1 
F, the intra-plate and inter-plate CV were consistently under 10% for both control conditions, 
and for both Hoechst and MBP measurements, showing good reproducibility within and 





Figure 3.1 Test plate using the MultidropTM to plate 9,000 cells/well shows consistent plating 
density and oligodendrocyte differentiation 
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A. Representative composite image from 1 out of the 93 fields-of-view imaged and analysed per 
well across the 96-well plate taken with the 20x objective on the Operetta system. 
B. Representative composite image of a single well (E4) from the 96-well plate in A. 
C. Representative single FOV from a single well (H6) taken on the Operetta using the 20x 
objective. 
D. Segmentation and selection of Hoechst+ nuclei by Columbus from B. 
The selection criteria was: roundness > 0.8, 35 < area < 150, and mean intensity < 3000. 
E. Segmentation and selection of MBP+ Hoechst+ cytoplasm by Columbus from B. 
The selection criteria was: morphology > 350, 295 < mean intensity < 1600. 
F. The table summarises the coefficient of variation (CV) values for the DMSO and NaHCO3 
controls for 6 of the plates in the experiment in Figure 3.2 for the Hoechst and MBP counts, 
segmented and selected on Columbus as per C. and D. n = 6 
The CV for both variables were consistently below 10% within and between plates, showing 
consistency for both plating density and oligodendrocyte differentiation using the 
MultidropTM plating and Operetta imaging set-up in order to be able to determine changes 
based on compound addition. 
 
Once CV calculations confirmed that differences in differentiation were due to changes in 
compounds and conditions rather than technical variability under the current experimental 
paradigm, concentration-response curves were performed for each of the compounds. 
Statistically significant increases in differentiation were detected at 0.37μM for Benztropine 
and Clemastine (Figure 3.2 A and B). Interestingly, there was also a decrease in caspase level 
at the corresponding concentration (Figure 3.3 A), from 0.12μM to 1.11μM. A preliminary 
experiment (n = 1) to count the number of caspase-positive Hoechst-positive cells in a live 
cell culture assay, which needs to be further optimised to improve staining quality, did not 
detect this decrease (Supplementary Figure 3.1 B). No statistically significant increases were 
detected for ATP levels in any of the conditions tested (Figure 3.3 B). However, adjacent 3D 
PLA microfibre culture system experiments and observations from the lab noticed a 
significant batch-to-batch variability in the cell viability and quality based on the batch of B21 
prepared at the time of these experiments. As these assays were performed with media from 
2 different batches of B21, I re-plotted and re-analysed the data to check whether any 





Figure 3.2 Differentiation quantification for a concentration-response curve on the 2D flat 
culture system shows increased oligodendrocyte differentiation with Benztropine and 
Clemastine at 0.37μM 
A. Representative images taken on the Operetta of the DMSO control (left) and 0.37μM 
Clemastine (right). A statistically significant increase in MBP+ cells was detected in the 
0.37μM Clemastine condition when compared to the DMSO control, as represented by the 
increased number of MBP+ cells in the images. 
B. Differentiation response quantified by the number of MBP+ Hoechst+ cells as a ratio to the 
DMSO or sodium bicarbonate (BQ-3020 only) control shows significantly increased 
differentiated oligodendrocytes at 0.37μM for Benztropine and Clemastine. 
Each biological replicate was performed in duplicates or triplicates, and their average taken 
for statistical analysis. The 96-well flat culture plates were imaged on the Operetta, analysed 
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using a pipeline on Columbus, and plotted and analysed on GraphPad Prism. The dashed line 
depicts the DMSO and sodium bicarbonate control. n = 4-8 
All statistics was performed on GraphPad Prism using the two-way ANOVA with post-hoc 






Figure 3.3 Cell viability quantification for a concentration-response curve on the 2D flat 




A. Decreased caspase levels were detected at 0.12μM to 1.11μM for Benztropine and 
Clemastine. 
Cell viability response for caspase was quantified using the Promega Caspase-Glo® 3/7 Assay 
and luminescence measured on the Promega GloMax Explorer using the standard 
programme. The measured luminescent signal was divided by the average DMSO or sodium 
bicarbonate (BQ-3020 only) control measurements for the plate and recorded as a 
percentage. The data was plotted and analysed on GraphPad Prism. The dashed line depicts 
the DMSO and sodium bicarbonate control. n = 3-5 
B. ATP levels were not significantly different for any of the compounds at all concentrations 
tested. 
Cell viability response for ATP was quantified using the Promega CellTiter-Glo® Luminescent 
Assay and luminescence measured on the Promega GloMax Explorer using the standard 
programme for the assay. The measured luminescent value was divided by the average DMSO 
or sodium bicarbonate (BQ-3020 only) control measurements for the plate and recorded as 
a percentage. The data was plotted and analysed on GraphPad Prism. The dashed line depicts 
the DMSO and sodium bicarbonate control. n = 3-7 
All statistics was performed on GraphPad Prism using the two-way ANOVA with post-hoc 
Bonferroni test in comparison to the appropriate control. * = p < 0.05, ** = p < 0.01, *** = p 
< 0.001 
 
As can be seen in the re-plotted and re-analysed data (Figure 3.4 ), there was a clear 
difference in the readout for all 3 responses between the two different B21 batches, with 
‘Media Batch #2’ seeming to eliminate the statistically significant increase in the 
differentiation effect for both Benztropine and Clemastine (Figure 3.4), and increase caspase 
levels (Figure 3.5) and decrease ATP levels (Figure 3.6) in comparison to ‘Media Batch #1’. In 
adjacent experiments, ‘Media Batch #1’ produced oligodendrocytes with better myelin 
sheath formation on the 3D PLA microfibre culture system (Figure 3.7 A), with a higher 
percentage of cells cultured in ‘Media Batch #2’ not producing myelin sheaths and appearing 
blebby (Figure 3.7 B). It may therefore be possible to conclude that the results from ‘Media 
Batch #1’ better reflect the effect of the compounds, and that ‘Media Batch #2’ may not have 
been conducive to supporting the development and survival of the oligodendrocytes in vitro. 
The preliminary live caspase count (Supplementary Figure 3.1 B) was performed in ‘Media 
Batch #2’. Based on this assumption, Benztropine showed statistically significant increases in 
differentiation at 1.11μM (p < 0.05) and 0.37μM (p < 0.01) and Clemastine at 1.11μM (p < 
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0.01) (Figure 3.4), with significant decrease in caspase levels at 1.11μM and 0.37μM for both 
compounds (p < 0.05) (Figure 3.5). Statistically significant increase for ATP was not observed 
at the corresponding concentrations, but was observed at 0.12μM and 0.04μM for 
Benztropine (p < 0.05) and at 0.12μM for Clemastine (p < 0.05) (Figure 3.6). Collectively, it 
could be concluded that out of the published compounds tested on the 2D flat culture system 
using our mixed glia-purified OPCs, Benztropine and Clemastine showed a statistically 
significant effect in increasing differentiation and decreasing cell death (caspase) at certain 
concentrations. Importantly, the pro-myelination molecules FR236924 identified in a 3D 
myelination assay (Swire et al., 2019) did not show any statistically significant effects in any 





Figure 3.4 Differentiation concentration-response curve from Figure 3.2 divided by the batch 
of B21 used in the myelination media show a loss of increased differentiation response in 
‘Media Batch #2’ 
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The data from Figure 3.2 was re-plotted to divide the biological replicates conducted in the 
myelination media prepared with the two different B21 batches due to the batch-to-batch variability 
in the cell culture quality between different B21 preparations. 
The (A) first batch of B21 (n = 4) and the (B) second batch (n = 4) for the differentiation response show 
a loss of the significantly increased differentiation response for Benztropine and Clemastine at 
multiple concentrations in ‘Media Batch #2’ compared to ‘Media Batch #1’. 
All statistics was performed on GraphPad Prism using the two-way ANOVA with post-hoc Bonferroni 





Figure 3.5 Cell death concentration-response curve from Figure 3.3 divided by the batch of 
B21 used in the myelination media show increased caspase levels in ‘Media Batch #2’ 
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The data from Figure 3.3 was re-plotted to divide the biological replicates conducted in the 
myelination media prepared with the two different B21 batches due to the batch-to-batch variability 
in the cell culture quality between different B21 preparations. 
The (A) first batch of B21 (n = 2) and the (B) second batch (n = 3) for the caspase levels show the 
absence of the significantly decreased caspase levels with Benztropine and Clemastine in ‘Media Batch 
#2’ compared to ‘Media Batch #1’. 
All statistics was performed on GraphPad Prism using the two-way ANOVA with post-hoc Bonferroni 





Figure 3.6 Cell activity concentration-response curve from Figure 3.3 divided by the batch of 
B21 used in the myelination media show decreased ATP levels in ‘Media Batch #2’ 
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The data from Figure 3.3 was re-plotted to divide the biological replicates conducted in the 
myelination media prepared with the two different B21 batches due to the batch-to-batch variability 
in the cell culture quality between different B21 preparations. 
The (A) first batch of B21 (n = 4) and the (B) second batch (n = 3) for ATP levels show the absence of 
the significantly increased ATP levels with Benztropine and Clemastine in ‘Media Batch #2’ compared 
to ‘Media Batch #1’. 
All statistics was performed on GraphPad Prism using the two-way ANOVA with post-hoc Bonferroni 
test in comparison to the appropriate control. * = p < 0.05, ** = p < 0.01, *** = p < 0.001. 
 
 
Figure 3.7 Comparison images of oligodendrocytes cultured on microfibres in 12-well 
scaffolds in ‘Media Batch #1’ versus ‘Media Batch #2’ show poor cell quality in ‘Media Batch 
#2’ 
A. Representative image of oligodendrocytes cultured on microfibres in the DMSO control 
condition in ‘Media Batch #1’ imaged on the Leica SP8 (40x objective) show MBP+ 
oligodendrocytes producing myelin sheaths, as confirmed by z-stack imaging. 
B. Representative image of oligodendrocytes cultured on microfibres in ‘Media Batch #2’ show 
MBP+ oligodendrocytes that are not producing myelin sheaths and appear to be producing 
blebs of broken up MBP+ membranes, highlighting poor cell quality in this batch of B21. 




3.2.2 Testing of the compounds identified in published drug screens on their effect on 
myelin sheath formation on 3D PLA microfibre culture system 
 
In order to test whether these published drugs increased myelin sheath length and number, 
they were tested on OPCs purified from mixed glia cultures plated on 12-well PLA microfibre 
scaffolds. The drugs were first added 3 days after plating onto the fibres to test their effect 
on myelin sheath formation rather than differentiation with fresh drugs being added every 2 
to 3 days until fixation on day 14. In the initial cultures, each of the drugs were tested at two 
different concentration, 1μM, as 1.11μM increased differentiation for Benztropine and 
Clemastine in the 2D flat culture system (‘Media Batch #1’), and 0.1μM, a ten-fold lower 
concentration. The concentration at which the cells looked more viable when checked by 
confocal microscopy was used for all further repeats of the experiment (Figure 3.8 A). During 
this period, our lab experienced significant issues with myelination on the microfibre culture 
system to which we narrowed down the issue to the B27 in the myelination media. Although 
I was able to obtain myelin sheath formation to a certain degree for this experiment, it was 
to a much lower quality and quantity than previously described (Bechler, Byrne and ffrench-
Constant, 2015), and especially impacted the number of myelin sheaths that each 
oligodendrocyte was able to produce from an average of 6 sheaths per cell, and up to 15, to 
an average of 3 sheaths per cell in the impacted myelination media. 
Figure 3.8 B represents the range of myelin sheath lengths observed across all quantified 
myelin sheaths in the control and compound treated conditions. The average per biological 
replicate was plotted, as shown in Figure 3.8 C, and a one-way ANOVA with the post-hoc 
Dunn’s Multiple Comparison test performed to check for significant changes in myelin sheath 
length compared to the DMSO control. None of the compounds at the tested concentrations 
appeared to significantly increase or decrease myelin sheath length on our PLA microfibre 
culture system. Potentially more physiologically and pharmacologically relevant for MS 
treatment, due to myelin sheath length being a key factor in saltatory conduction and nerve 
signalling coordination and therefore significant pharmacological changes in this property 
potentially hindering its physiological function, the number of myelin sheaths produced per 
MBP+ cell was also quantified. Figure 3.9 A represents the range of myelin sheath numbers 
observed across all quantified cells in the control and compound treated conditions. The 
average per biological replicate, as shown in Figure 3.8 B, was used to perform a one-way 
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ANOVA with the Dunn’s Multiple Comparison test. This detected no significant changes in 
myelin sheath number in any of the drug conditions as compared to the DMSO control. As 
mentioned, due to the number of myelin sheaths produced per cell being impacted by the 
poor quality of the B27 in the myelination media, especially highlighted by the average 
number of myelin sheath in the media control in Figure 3.8 C, the data was re-calculated to 
control for the average number of myelin sheaths produced by the DMSO control in the same 
biological batch of cells to test whether the low inter-experimental consistency was masking 
any effect. However, even when taking into account the differences in the average number 
of myelin sheaths produced between different replicates, there was no significant changes 





Figure 3.8 Myelin sheath length quantification on the 3D PLA microfibre culture system show 
no significant changes in any of the compounds identified from published screens 
A. Representative images of myelin sheath-forming oligodendrocytes from each of the drug 
conditions taken with the 40x objective on the Leica SP8 confocal for quantification. Each of 
the compounds at the concentration tested show robust myelin sheath formation as 
determined by visualising an overview of each coverslip, and taking z-stack images of at least 
15 cells per condition per biological replicate. 
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B. Myelin sheath length measurements was quantified by manual measurements on Fiji using 
simultaneous z-stack and maximum projected images, recorded on Excel, and plotted and 
analysed on GraphPad Prism 5. The box-and-whisker plot show the range of measurements 
obtained as represented by the maximum and minimum at the ‘whiskers’, and the 75th, 50th, 
and 25th quartiles with the lines on the ‘box’ from top to bottom. n =7 
C. The average myelin sheath length per biological replicate was calculated from the data in A 
to test for statistical significance. No significant changes in any of the tested conditions were 
shown compared to media and DMSO controls. 
The statistical test performed was the one-way ANOVA with post-hoc Dunn’s Multiple 







Figure 3.9 Myelin sheath number quantification on the 3D PLA microfibre culture system 
show no significant changes in any of the compounds identified from published screens 
A. The number of myelin sheath per MBP+ cell as shown on a box-and-whisker plot. Sheaths 
were only counted when MBP+ cells were distinctly separate, and excluded when the cell 
bodies were clumped in close proximity, making it difficult to distinguish the cell body from 
which the sheath originated. n = 7 
B. The average number of myelin sheath per biological replicate as calculated from the data in 
A to test for statistical significance. None of the compounds tested showed statistically 
significant changes in the number of myelin sheaths produced compared to media and DMSO 
controls. 
Statistical analysis was performed using the one-way ANOVA with post-hoc Dunn’s Multiple 
Comparison test for analysis. 
C. The average number of myelin sheath was normalised for the DMSO control per biological 
replicate from data in C. Even after taking the potential variability between replicates into 
account, no significant changes were shown in the number of myelin sheaths in all of the 
conditions tested. 
Statistical analysis on this data was performed using the one-way ANOVA with post-hoc 




In this chapter I asked the question whether, given that differentiation and myelination 
occurs as a two-step process, pro-differentiation compounds may not necessarily also 
enhance remyelination. To do this, I utilised compounds and peptides that have been 
previously published in differentiation (Deshmukh et al., 2013; Lariosa-Willingham et al., 
2016a, 2016c; Najm et al., 2015), ensheathment using wrapping around the base of 
micropillars (BIMA) (Mei et al., 2014), and axonal myelination (Lariosa-Willingham et al., 
2016b) screens, as well as compounds identified to increase myelin sheath number by Swire 
et al. (2019) and Yuen et al. (2013), and tested these in a 2D versus 3D culture system using 
OPCs isolated from mixed glia cultures. My results provide preliminary support for the 




This conclusion is based on three results. First, accounting for the difference in results based 
on the batch of B21 used, and assuming ‘Media Batch #1’ to better reflect the OPC 
differentiation and the effects of the drugs in a more supportive environment based on the 
caspase and ATP assays and parallel 3D myelination experiments, and taking into 
consideration that the number of biological repeats for experiments solely performed on 
‘Media Batch #1’ is quite low, especially for the caspase levels (n = 2), early results show a 
statistically significant increase in differentiation could be detected at 1.11µM and 0.37µM 
for Benztropine and at 1.11µM for Clemastine, with decreased caspase levels at 1.11µM and 
0.37µM for both compounds and increased ATP levels at 0.12µM and 0.04µM for 
Benztropine and 0.12µM for Clemastine. The Clemastine was of particular interest as its 
positive Phase I clinical trial results have been published (Green et al., 2017), and is currently 
in Phase II clinical trials. 
Second, FR236924, one of the compounds identified to increase myelin sheath number by 
Dr. Matthew Swire, did not show pro-differentiation and cell survival results in the three 
metrics examined based on results of its testing in ‘Media Batch #1’. It would therefore 
potentially not have been picked up in a pro-differentiation-based screen despite its pro-
myelination property. Another myelination-promoting compound, the EDNRB agonist BQ-
3020, was only included in the experiments using ‘Media Batch #2’ so, although it didn’t show 
any positive effects, it would need to be re-tested in a different batch of media to confirm 
whether it was a pro-myelination but not a pro-differentiation compound, or whether it was 
potentially both but had its effect masked by the problematic media. Previous experiments 
conducted in our lab by Tracy Yuen using BQ-3020, however, showed that this compound 
does not increase the number of differentiated OPCs, and therefore suggests that it is likely 
a pro-myelination but not a pro-differentiation compound. Although this compound would 
ideally need to be re-tested in my experimental paradigm for direct comparison, this suggests 
that both these pro-myelination compounds would not likely have been identified in pro-
differentiation assays. 
Third, when tested on the 3D microfibre culture system, none of the published pro-
differentiation compounds increased either myelin sheath length or number. Interestingly, 
γ-secretase inhibitor DAPT, a compound used as the positive control in an axonal myelination 
assay (Lariosa-Willingham et al., 2016b), did not show increased myelin sheath formation in 
our microfibre oligodendrocyte myelination assay. This compound had previously been 
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reported to enhance differentiation and ensheathment in a myelinating CNS co-culture 
system of retinal ganglion cells (RGCs) from the optic nerve and OPCs, with the inhibition of 
the γ-secretase-activated Notch1 signalling enhancing differentiation, and the inhibition of 
γ-secretase enhancing ensheathment through a Notch1-independent mechanism (Watkins 
et al., 2008). This highlights one of the limitations of a single cell type-specific assay, in which 
a compound may potentially work through a mechanism that requires the interaction 
between multiple cell types, and therefore not increase differentiation in 2D OL flat culture 
or increase myelination in 3D OL microfibre culture. Another reason as to why DAPT may not 
have increased myelination in the microfibre culture system was that it increased the number 
of OLs that were able to differentiate and ensheath axons in a system with poor OPC 
differentiation or high degree of trans-differentiation into astrocytes by the OPCs (Watkins 
et al., 2008). Therefore, the increase in myelination through γ-secretase inhibition by DAPT 
may have been a characteristic of the co-culture system to improve its application in studying 
axonal myelination in vitro. 
Collectively, although further biological replicates performed in media with a more 
supportive B21 batch would strengthen the evidence, these data support the conclusion that 
pro-differentiation screens do not necessarily pick up pro-myelination compounds, and that 
pro-differentiation compounds may not also be pro-myelination. This highlights the 
biological validity of developing a drug screening platform aimed at detecting myelination as 
its primary output. The low yield of RGCs, the difficulties of culturing neuronal-OPC co-
cultures in vitro, and the reproducibility of the assay limits the current method of assessing 
myelination in vitro using co-cultures in its potential application for high-throughput screens.  
How can one solve these problems with existing assays in detecting pro-myelinogenic drugs? 
Lariosa-Willingham et al. (2016b) targeted some of the limitations of low neuronal cells yield 
by using embryonic rat cortical brain cells in developing their co-culture based myelination 
assay, which resulted in cultures with approximately 23% neurons, 47% astrocytes, 22% 
OPCs/OLs, and 9% other unidentified cell types, with no exogenous OPCs added. However, 
the batch-to-batch variability of the cell composition may pose an issue in the reproducibility 
and consistency of the assay. A different approach, the 3D OL microfibre system has been 
shown to be able to detect increases in myelin sheath formation through OL mechanisms, 
such as endothelin receptor type B in OL lineage cells through the endothelin receptor 
agonist peptide BQ-3020 (Yuen et al., 2013), and small molecule PKC activator FR236924, 
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which were both verified to increase the number of myelin sheath number per OL on the 
microfibre system (Swire et al., 2019). Therefore, the development of a high-throughput-
compatible 96-well microfibre plate in screening for pro-myelination compounds in a 
neuron-free myelination assay takes a step forward in addressing: (1) the difference between 
pro-differentiation and pro-myelination compounds as tested through the 2D versus 3D 
culture systems in this chapter, (2) being able to detect compounds that are pro-myelination 
through OL mechanisms, and (3) the ability to increase the throughput of a myelination assay 




CHAPTER IV. CONSTRUCTION OF A HIGH-THROUGHPUT-
COMPATIBLE 96-WELL MICROFIBRE PLATE 
 
4.1 Introduction  
 
To create a phenotypic screening platform suitable for the assessment of myelin sheath 
formation, the challenges are: i) to manufacture a material that can provide an artificial axon 
for the OL to form myelin sheaths around, and ii) to insert it into a multi-well plate as a floor 
suspended above an optically-transparent base so creating a format that is suitable for 
screening. As previously discussed, OLs cultured in the presence of artificial axons will wrap 
membranes around them, with materials used successfully including glass (Bullock and Rome, 
1990) although coating is required for ensheathment (Howe, 2006), paraformaldehyde-fixed 
axons (Rosenberg et al., 2008), and electrospun polystyrene and PLA fibres (Bechler, Byrne 
and ffrench-Constant, 2015; Lee et al., 2012, 2013). The ability of myelin sheath formation 
on electrospun fibres is of particular interest due to, as described in the next section, the 
ability to use electrospinning to produce customised electrospun fibres of consistent 
diameter (of approximately 2μm) and density by controlling various parameters, that can 
then potentially be incorporated into a multiwell plate format suitable for high-throughput 
drug screening applications. As discussed in this chapter, I therefore started by developing 
this technology working with the guidance and expertise of colleagues at the Schools of 
Chemistry and Engineering, with the goals being: (1) to manufacture fibres permissive for 




In 1887, C. V. Boys described “the old, but now apparently little-known experiment of 
electrical spinning”, whereby he observed that if a small insulated dish filled with a viscous 
material, including melted rosin, beeswax, and shellac, was connected to an electrical source, 
the material would be shot out as threads at the edge of the dish along “lines of force” (Boys, 
1887). Patents for slightly different variations of the technique have been filed since 1934, 
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and the term “electrospinning” was introduced in literature more recently in 1994 (Huang et 
al., 2003). 
In the electrospinning process, a strong electrostatic field, ranging in the several tens of kV, 
is applied to a capillary tube/spinneret (i.e. a needle tip) that is connected to a syringe 
containing a viscous solution of a polymer dissolved in a solvent (Figure 4.1 A). The 
electrostatic force causes the polymer solution at the end of the needle tip to deform into a 
Taylor cone (Figure 4.1 B). As the voltage is increased, the electrostatic force overcomes the 
surface tension, resulting in a charged jet of polymer solution being ejected from the tip of 
the Taylor cone, at which point the solvent begins to evaporate to leave behind a deposition 
of thin polymer fibres that travels in an unstable and whipping manner. As the jet is charged, 
a counter electrode is used to control its trajectory and act as the grounded collecting plate, 
typically in the form of a metal screen, plate, or rotating mandrel. The rotating collector is 
particularly useful for the collection of aligned, mostly parallel electrospun fibres (Figure 4.1 







Figure 4.1 The electrospinning set-up 
A. Schematic diagram of the set-up of a horizontal electrospinning apparatus: the polymer 
solution is contained within the syringe and extruded through the spinneret, where the high 
voltage is applied, for the fibres to be accumulated at the collector. 
(Figure from Bhardwaj and Kundu, 2010) 
B. Photograph of the conical shaped solution at the tip of the needle/capillary tube called the 
Taylor cone. The formation of the Taylor cone indicates that a stable flow of the polymer 
solution has been achieved at the tip of the needle, which is obtained by balancing the 
concentration of the polymer solution with the diameter of the spinneret, the voltage 
applied, the working distance to the collector, and the charge at the collector. 
(Figure from Meesters et al., 1992) 
C. Photograph of the horizontal electrospinning set-up at the School of Engineering, The 
University of Edinburgh. The syringe contains the polymer solution, which is placed in the 
pump to control the flow rate. The solution travels through the solution tubing to the needle, 
which is placed in a moving head to allow even distribution of the fibres across a wider surface 
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area, and allows the high voltage to be applied. The solution travels across the working 
distance to the collector, which in this set-up is a rotating mandrel which allows the fibres to 
be collected in a parallel alignment by pulling the fibres across it as it spins. The control panel 
allows the speed of the pump, the voltage at the needle and the mandrel, the rate and 
distance travelled of the moving needle, and the rotation speed of the mandrel to be 
adjusted. 
 
The properties of the electrospun fibres are dictated by several factors including: (1) solution 
parameters, (2) processing parameters, and (3) ambient parameters. A few key solution 
parameters include the molecular weight of the polymer, which influences electrical and 
rheological properties, and concentration, important for viscosity and surface tension of the 
solution and therefore having a strong influence on the shape and thickness of the fibres. 
The optimisation of a suitable solvent to be used in the complete dissolving of the polymer 
into solution in the preparation of the polymer solution is the essential first step in the 
optimisation of the electrospinning process as it not only dissolves the polymer, but also 
carries the polymer molecules towards the collector. Important solvent properties include: 
(a) its volatility in the formation of the polymer structures due to its influence on the phase 
separation process, (b) boiling point due to the use of high voltages, and (c) vapour pressure 
in determining the rate of its evaporation. Processing parameters include: (a) the voltage in 
overcoming the threshold to initiate electrospinning, (b) flow rate of the polymer from the 
syringe into the needle tip to control the material transfer rate and jet velocity while allowing 
the solvent to evaporate in controlling fibre diameter, (c) working distance from the tip to 
collector in regulating fibre diameter and morphology, and (d) the type of collector in the 
alignment and transfer of the collected fibres. In addition, ambient parameters including 
humidity and temperature could be of importance in manipulating fibre morphology due to 
their effect on polymer solution viscosity and solvent evaporation (Huang et al., 2003; 







4.2.1 Optimisation of the polymer solution for electrospinning and myelination 
 
The first step in the construction of 96-well plate suitable for screening applications is the 
generation of microfibres of appropriate diameter (2μm).  As described above, solvent and 
polymer choices (together creating the polymer solution) are the key variables, and so I 
started by optimising these. 
Based on the expertise of the early electrospinning collaborators (Dr. Hua Dong, Bradley Lab 
at the School of Chemistry), initial experiments used 8% polyurethane (PU, Sigma-Aldrich 
81367) as the polymer dissolved in 1 demethylformamide (DMF, Rathburn PTS6020): 1 
tetrahydrofuran (THF, Thermo Fisher T/0701/17) (w/w/w) ratio or 8% PU in 1 DMF: 1 
dichloromethane (DCM, Thermo Fisher D/1852/17) (w/w/w). Both ratios were initially tested 
as the polymer for electrospinning at the School of Chemistry, the University of Edinburgh. A 
vertical electrospinner set-up (Spraybase) with a stationary syringe and needle tip over a 
metal plate was used, with a 18G needle tip as the spinneret, voltage was set to between 
6.43 and 6.76kV, and the working distance set to between 16 and 19cm. Temperature and 
humidity was also monitored. As shown in Figure 4.2 A, the fibres were of uneven diameter 
and morphology, with differences in diameter of 1μm to over 5μm. Additionally, OPCs 
cultured on these PU fibres differentiated, as they expressed the marker MBP, but did not 
seem to ensheath the fibres even after 10 days (Figure 4.2 B), in contrast to the myelin sheath 
formation being seen in commercially obtained electrospun microfibre cultures by at least 7 
days by Bechler, Byrne and ffrench-Constant (2015). The OLs that had differentiated on these 
PU fibres seemed to more closely resemble OPCs cultured on flat coverslips rather than on 
fibres.  
As OL myelin ensheathment had previously been shown on commercially obtained fibres 
made of PLA fibres by Bechler, Byrne and ffrench-Constant (2015), I next tested PLA as the 
polymer in this electrospinning device. 10% PLA (Sigma-Aldrich 81273) was dissolved in 3 
DMF to 7 DCM (w/w/w) ratio, with an 18G needle tip, working distance set to 15cm, voltage 
to 9.09kV, and a pump to control the flow rate of the jet added, set to 0.6ml/hr. DCM was 
used due to its property as a good solvent, but due to its low boiling point, DMF was added 
to increase the boiling point of the solution and keep the polymer in solution when not being 
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warmed. The SEM image (Figure 4.2 C) showed smoother, more tube-like fibres in 
morphology, and OLs cultured on these fibres for 10 days showed structures that looked like 
myelin sheath formation (Figure 4.2 D). However, when the diameter of the fibres was 
measured across two different batches, the diameter was too low (based on previous work 
published by Bechler, Byrne and ffrench-Constant (2015) using fibres of 2μm diameter) with 
the majority of the fibres being between 1 to 1.5μm, and slight variations in diameter 
between the two batches (Figure 4.2 E). To increase the diameter of the fibres, different 
concentrations of the PLA (10% vs. 12% vs. 15%) and in different ratios of DMF to DCM (w/w) 
(2:8, 4:6, 6:4). However, in all these tested concentrations and ratios, the solution turned too 
viscous to electrospin with (15% PLA), only produced a small amount of solution compared 
to the amount of material (10% and 12% PLA, 2 DCM: 8 DMF), or turned white and solid as 





Figure 4.2 Polyurethane and poly-L-lactic acid dissolved in DCM and DMF does not produce 
microfibres of even appearance and equal diameter 
a) Representative SEM image of electrospun 8% PU microfibres. The values of the individual 
fibres are labelled on the image, and range from just above 1μm to over 5μm, with the 
appearance of clumping and uneven morphology. 
b) Representative confocal image of an OL cultured on the 8% PU fibres for 10 days, showing 
differentiation but not sheath formation. 
c) Representative SEM image of electrospun 10% PLA microfibres dissolved in DCM and DMF, 
showing variable appearance between and within each microfibre, and not showing 
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consistently smooth and round tubular topography. The ‘n’ number represents the number 
of individual fibres measured for each batch. 
d) Representative confocal image (Leica SP8, 40x objective) of an OL cultured on the 10% PLA 
(DCM:DMF) microfibre for 10 days, showing both differentiation and myelin sheath formation 
as determined by MBP staining and z-stack imaging. The myelin sheaths are randomly 
orientated using electrospun fibres produced using this set-up. 
e) Histogram of the fibre diameter measured for the 10% PLA in DCM: DMF fibres across two 
independent batches. Variation in the distribution of the fibre diameter between the two 
batches can be seen, as well as uneven distribution within a batch. 
 
In order to overcome the difficulty of producing a solution at a high enough polymer 
concentration to achieve the desired diameter, the speciality organic solvent 1,1,1,3,3,3-
hexafluoro-2-propanol (HFIP, Sigma-Aldrich 105228) was used as the solvent in further 
experiments. HFIP, although costly, is reported to be able to dissolve a wide range of 
polymers, including those difficult to dissolve in ordinary organic solvents (Zhang et al., 2007). 
On the Spraybase electrospinner, (1) 10% PLA in HFIP (w/w) at 15cm working distance, 18G 
needle tip, 6.14kV voltage, and 0.5ml/hr pump rate showed thin fibres of between 0.5 to 
1.1μm, (2) 12% PLA in HFIP (w/w) at 20cm working distance, 18G needle tip, 8.49kV, and 
0.6ml/hr pump rate only increased the diameter to slightly higher at around 1.5μm, and (3) 
13% PLA (w/w) with otherwise same parameters increasing it to around 1.7μm. Given this 
modest increase, and the additional difficulties in collecting wide areas of evenly distributed 
fibres with a stationary needle, discussed further in the next section, along with the strong 
influence of the temperature and humidity fluctuations (due to the location of the machine 
in the School of Chemistry building in a room with large windows) on the ability to form a 
stable Taylor cone for electrospinning, I decided at this point to switch electrospinning 
machines.  The IME electrospinner with a moving head and rotating mandrel collector (Figure 
4.1 C, located in a non-windowed room at the School of Engineering), was chosen as the most 
appropriate electrospinning machine for our purposes. 
10% PLA (Corbion Purac Purasorb® PL 18) in HFIP (Manchester Organics G26383) (w/w) 
solution was loaded into a pump set to speed 1.3ml/hr (optimised from an initial trial of 
1.2ml/hr), with an 18G needle tip inserted into the moving head set 18cm from the rotating 
mandrel. The moving head was set to move 16cm, slightly larger than the length of a standard 
96-well plate, and travel at 50mm/s, as previously used on this machine (as advised by Dr. 
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Maaria Ginai, Callanan Lab at the School of Engineering). The rotating mandrel was covered 
in aluminium foil to allow the fibres to be removed, with 2 sheets of 10 by 14cm release 
sheets later added (as discussed in the next section), and set to 2000rpm to collect aligned 
fibres. The voltage to form a stable Taylor cone was between 19 to 23kV, and the counter 
electrode (i.e. the rotating collector) set to -1kV. Each batch of electrospinning was 
performed for 20 minutes to keep a consistent density. As shown in Figure 4.3 A, the 
electrospun fibres using these conditions produced mostly aligned, smooth, tube-like 
microfibres, which OLs would ensheath to myelinate (Figure 4.3 B). In addition, across 10 
different batches, the fibres electrospun using this set-up and these parameters consistently 
produced microfibres with an average of around 2.1μm (Figure 4.3 C), with a coefficient of 
variation (CV) ranging from 11.1 to 15.25 (average of 13). I was therefore able to optimise 
the electrospinning parameters required to produce consistent sheets of electrospun 





Figure 4.3 Poly-L-lactic acid dissolved in hexafluoroisopropanol is required to form a 
uniformly dissolved polymer solution for electrospinning, and to produce microfibres 
consistently of 2μm in diameter which the OLs will ensheath 
a) Representative SEM image of electrospun 10% PLA microfibres dissolved in HFIP, showing 
smooth and round topography with consistent appearance between and within each 
microfibre. 
b) Representative confocal image (Leica SP8, 40x objective) of an OL cultured on the 10% PLA in 
HFIP microfibres for 14 days. As shown by the MBP staining, the oligodendrocyte is able to 
extend multiple processes and form myelin sheaths around the electrospun PLA microfibres. 
c) Histogram of the fibre diameter for the 10% PLA in HFIP fibres across 10 different batches 
showing peak microfibre diameter of approximately 2.1μm consistently across all 10 batches. 
The ‘n’ number represents the number of individual fibres measured for the batch. 
 
4.2.2 Electrospun microfibres collection and transfer optimisation 
 
Having established the protocol required to electrospin fibres suitable for myelination, I next 
addressed the question of transferring aligned electrospun fibres to form the base of each 
well in the final 96-well plate platform. This required that the method of collection was also 
optimised. Initially, electrospun fibres were collected on coverslips laid on the metal plate of 
the Spraybase electrospinner. However, due to the diversion of electrical charge from the 
glass, the fibres were electrically repelled from landing on the coverslips. To address this, the 
use of glue (3M VetbondTM), 1% agarose, and acid treating the coverslips in 1M HCl at 50°C 
for 4 hours was further explored. However, the glue and agarose was difficult to apply along 
the edge of the coverslips in a controlled manner, with the glue running along the fibres even 
when it visually appeared to have dried, and neither of them helping noticeably with the fibre 
collection due to not aiding with the electrical charge of the coverslips. Pre-treating the 
coverslips with acid to increase their charge also did not seem to make a significant difference 
to the collection of the fibres. 
As an alternative strategy to increase the quantity and alignment of fibres collected, two 
other methods were explored next. In one method, a metal rod was bent in half, with the 
electrospun fibres being collected in between the two ends. In the second, pieces of 
aluminium foil were cut in a zig-zag manner and wrapped around a 12-well plate, with 
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scaffolds placed upside down to collect the fibres onto (Figure 4.4 A). In both methods, the 
goal was to re-direct the electrical charge in between the pieces of metal, and therefore 
control the direction in which the fibres were collected. Both were able to align the fibres in 
a mostly parallel manner, with an example being shown from the second method in Figure 
4.4 A (inset figure), and the latter method producing better results in terms of fibre alignment 
and distribution. However, these methods were only able to align fibres in a fairly narrow 
area, i.e. approximately the width of one column of a 12-well plate, and therefore not 
appropriate for collecting aligned fibres across the bottom of an entire 96-well plate. 
To increase the area of aligned fibres that could be collected, I therefore next designed and 
constructed a rotating plate collector (Figure 4.4 B) in collaboration with Dr. Hua Dong and 
the School of Chemistry Workshop. The collector consisted of a metal holder for a bottomless 
96-well plate, connected to a rod that would rotate the plate through an attached motor, so 
that the fibres were stretched across the plate in the direction of the rotation as they were 
produced and landed on the plate. As shown in Figure 4.4 C, although the fibres were mostly 
collected in one direction, they were unevenly distributed, observable even by eye, with a 
higher density directly below the stationary needle tip and towards the edges close to the 
metal plate holder. This highlighted that for a wide area of evenly distributed fibres to be 
collected, a stationary needle set-up was not ideal. 
To overcome this limitation imposed by a stationary needle, I therefore explored the use of 
an IME Electrospinner with a rotating mandrel, to collect aligned fibres, and a moving needle, 
for even distribution (set-up shown in Figure 4.1 C). The rotating mandrel was covered in a 
piece of aluminium foil to allow easy removal of the fibres, with the fibres being attracted to 
the foil to keep them in place until their use. The rotating mandrel and moving needle was 
able to collect fibres of even distribution and aligned orientation (Figure 4.3 A, Figure 4.4 D - 
F).  
Having solved the problem of creating fibre sheets of appropriate alignment and diameter, 
the final step required for their use is releasing them from the surface onto which they were 
sprayed. In initial attempts to transfer the sheet of electrospun fibres to the base of a 96-well 
plate, transfer of fibres directly spun onto the aluminium foil by sheets of adhesives (i.e. 
double-sided tape and/or PCR plate adhesive, as optimised in the next section) was 
problematic due to the tight adhesion of the tape onto the foil, which proved difficult to 
remove without disturbing the fibres. When the aluminium foil was soaked in water to lift 
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the fibres off, the orientation and distribution of the fibres was also disturbed. Therefore, I 
cut sheets of release paper to 10 by 14cm, slightly larger than the standard 96-well plate size 
of approximately 12.8 by 8.5 cm, to attach to the aluminium foil on the rotating mandrel 
(Figure 4.4 D). The release paper was chosen as it is extremely thin and therefore did not 
seem to disturb the electrical charge significantly (Figure 4.4 E), and also had a slightly waxy 
side to allow easy transfer of the fibres with the tape. When fibres were collected and 
transferred using this release paper method onto the base of bottomless 96-well plates, and 
their density quantified across 6 different constructed plates, the distribution of fibres stayed 
fairly consistent as controlled by both the length of the electrospinning and the transfer 
method, with the average distance between fibres across the 6 plates being at around 
4.85μm (Figure 4.4 F). By making use of a combination of a moving needle and rotating 
collector set-up and release paper, I was therefore able to optimise the collection and 







Figure 4.4 A moving needle and rotating collector is required to form sheets of evenly 
distributed electrospun microfibres, with release paper to allow the sheets to be lifted 
A. Top (left) and side (right) view of the aluminium foil wrapped around a 12-well plate with 
scaffolds for “aligned” fibre collection. The inset image in B. is a representative SEM image of 
the PLA microfibres dissolved in HFIP solvent collected using this method, showing smooth 
and even topography in the fibre appearance. 
B. Photograph of the rotating plate collector with a metal holder for the 96-well plate, which is 
attached to a motor to spin the plate as the fibres are produced. 
C. Photograph of the electrospun fibres collected using the rotating plate collector. A higher 
density of fibres can be seen at the centre of the plate, which is located just below the needle 
in this vertical electrospinner set-up, and towards the edges, due to the charge of the metal 
plate holder. 
D. Photograph of the electrospun fibres collected on a rotating mandrel with 2 sheets of release 
paper attached (with autoclave tape) for easy transfer of the sheets of fibres. 
E. Close-up photograph of the aligned fibres collected on the rotating mandrel from the area 
highlighted with the black box in C. The white vertically aligned PLA fibres can be seen against 
the silver aluminium foil in the region in between the release paper attached with autoclave 
tape. 
F. Histogram of the density of fibres after being transferred from the sheet (as shown in D.) into 
a 96-well plate format to show consistent fibre density between independently constructed 
plates. The distance in between the fibres in a well was measured by taking brightfield images 
on the Leica Confocal SP8 MatrixScreener, stitching and stacking the images, drawing a line 
perpendicular to the direction of the fibres randomly across a well, and measuring the 
distance between fibres along the line using ImageJ. The measurements were taken from 2 
wells from different parts of the plate, and the ‘n’ denotes the number of measurements 
taken per plate. 
 
4.2.3 Optimisation of the bottomless 96-well plate and adhesive 
 
In order to construct the plate, I needed to find a consistent source of bottomless 96-well 
plates over which I could lay the fibres before adding an imaging-compatible lower surface 
to the plate to act as a base to each well within which the fibres form a suspended floor. The 
suspended floor is created by the use of a spacer, ensuring the fibres were elevated from the 
base of the plate and therefore would be accessible for myelin sheaths to form around them. 
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The basic design is shown in Figure 4.5 A; the sheet of fibres is stuck to the base of a 
bottomless 96-well plate, with the optically transparent floor then glued on with a spacer 
(into which holes have been cut to align with those in the plate) separating fibre sheet and 
base so as to create the suspended floor of fibres.  
Contacts with various companies did not reveal any suitable suppliers of the bottomless 96-
well plates, with only one company, Greiner, having some left-over stock from a discontinued 
product. Therefore, several alternative options were explored. Firstly, using the AutoCAD 
software and with the help of the Bradley Lab, I attempted to 3D print a portion of a 96-well 
plate (2 x 4 wells) as an initial test. However, the machine struggled to print this design 
without the layers of the 3D-printed material lifting off from the collecting surface, and 
therefore was excluded as a viable option. Next, I purchased sheets of acrylic (Sheet Plastics) 
and polypropylene (Cut Plastic Sheeting), the former material for cost and the latter as it is 
commonly used in the production of lab equipment including plates, for laser cutting. In 
collaboration with Dr. Anthony Buchoux (Stokes Lab at the Scottish Microelectronics Centre), 
I was able to successfully laser cut 96-well plates out of these materials (Figure 4.5 B). 
However, due to the thickness of the plastics required to construct plates with enough height, 
the length of time it took for each plate to be cut and the distortion of the material due to 
the laser needing to re-trace each cut multiple times was problematic. In addition, due to the 
settings only allowing cuts to be made all the way through the material, these plates could 
not be cut with the standard skirt that is present around the base of all commercial 96-well 
plates, making them less compatible with components of the high-throughput pipeline such 
as liquid-handling machines and robotic arms for placing the plates into high content imaging 
systems. Therefore, the final design of the bottomless 96-well plates was created around 
commercial 96-well plates (PerkinElmer CellCarrier) with the base of each well cut out using 
the laser cutter, and then the base smoothed out by manual sandpapering to get rid of the 
slight ridges left behind by the high heat of the laser cutter. The PerkinElmer CellCarrier-Ultra 
plates also offer an alternative as the skirt of the plate is shorter, and therefore give the 
option of more wells being accessible for imaging on various imaging systems. 
In order to create a 96-well plate with the layer of electrospun microfibres inserted under 
the plate and separated from the base by a spacer layer, I needed to ensure that I had a 
method of adhering the layers together that would be watertight to allow different drugs at 
different concentrations to be tested in each well. I therefore tested multiple alternative 
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medical adhesives for compatibility with cell culturing, including 3M’s VetBondTM, a medical 
adhesive paste (Factor II, Inc. A-100), a spreadable secure silicone adhesive (Factor II, Inc. B-
460), and a medical adhesive spray (Factor II, Inc. 7730) (Figure 4.5 C). However, none were 
suitable. The VetBondTM, medical adhesive paste and silicone adhesive were difficult to apply 
as a thin even layer, and the medical adhesive spray was difficult to control. In addition, the 
VetBondTM, silicone adhesive, and the medical adhesive spray, due to the consistency of the 
adhesive, would run along the fibre even if the microfibre layer was applied after giving 
plenty of time to allow the adhesive to dry and become tacky. 
In order to overcome this issue of consistent adhesive application, I next tested double-sided 
tape, along with PCR plate adhesives, to act as both a spacer and the glue to hold the plate 
together. I first cultured OPCs isolated from the mixed glia culture method on 18-mm glass 
coverslips (VWR 631-1580) with or without a piece of double-sided tape and PCR plate 
adhesive adhered to the side of the well in a 12-well plate. By widefield microscope, I was 
able to check that the OPCs did not appear to be growing away from the adhesives nor were 
there any obvious differences in the cell density in the well with the tapes. This seemed to 
suggest that these adhesives were safe for use in close proximity with our OPCs. Next, I 
needed to be able to cut the tape to fit on the base of a bottomless 96-well plate without 
making the wells inaccessible. By layering a sheet of double-sided tape and a PCR plate 
adhesive, which would be the thicker sheet of adhesive required for the plate construction, 
I tested a biopsy punch, a single hole-punch, and a 96-well punch created by the School of 
Engineering Workshop. The biopsy punch and 96-well punch (Figure 4.5 D (left) and E) proved 
difficult to punch holes through the adhesive layers, with the edges of the holes being rough 
and uneven, and the sheets of adhesive getting stuck on the 96-well punch and tearing while 
being removed. The single hole-punch (Figure 4.5 D (right)) efficiently punched holes. To 
confirm that this provided a means of creating a watertight seal onto the bottomless plate, I 
used different food colouring dyes in adjacent wells. When the tape was cut into pieces (as 
shown in Figure 4.5 D), there was leaking of the food colouring horizontally along the cuts 
made in the tape (Figure 4.5 F) but not in the rest of the plate, confirming the adhesive was 
able to seal the plate with the microfibres in a watertight manner.  
Although this proved the adhesive worked, it also showed the hole punch method was not 
satisfactory as the glue would easily clog up the hole-punch. Moreover, due to the design of 
single hole-punches, only the very outer-most two rows and columns were accessible.  In the 
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final construction method, therefore, the adhesive layers were laser cut (Figure 4.5 G), which 





Figure 4.5 Laser cut sheets of adhesives produce the most controlled and evenly distributed 
adhesives to attach the microfibres to the base of a (laser cut) bottomless 96-well plate 
A. A schematic of the basic layers required for the construction of a 96-well microfibre plate. 
The sheet of electrospun microfibres need to be layered under a bottomless 96-well plate so 
that the oligodendrocytes can be plated and the compounds added through the individual 
wells of the plate onto the fibres. The fibre also needs to be suspended by a spacer above a 
base compatible with imaging so that the oligodendrocytes are able to access all sides of the 
fibres to form complete myelin sheaths, and be imaged through an inverted microscope. 
B. Laser-cut 96-well plate from a sheet of polypropylene. The large sheet of polypropylene took 
several times of laser cutting over the same lines to cut all the way through the material, and 
the high heat from the laser left the surface uneven that required a lot of time in 
sandpapering to smooth out. 
C. 4 types of medical adhesives tested for the adhesion of the fibres to the base of a bottomless 
96-well plate, as labelled in the photograph. All the adhesives were difficult to apply evenly 
and precisely. The glue from the VetBond, silicone adhesive, and medical adhesive spray 
additionally ran along the fibres even when they had been given time to dry and become 
tacky before the fibres were added. 
D. Double-sided tape and PCR plate adhesive (spacer) layers with holes punched with either a 
single hole-punch or with a biopsy punch (left), or just with a single hole-punch. The adhesive 
layers were cut into pieces due to the design of the single hole-punch only allowing the outer 
two rows or columns of holes to be accessed. The biopsy punch could not easily penetrate 
both layers of adhesives, even when placed on a firm surface with a slight give to allow for 
the punch to cut through to the other side whilst the adhesives layers stayed flat. Both the 
hole-punch and biopsy punch had to be cleaned regularly to remove the adhesives from the 
tape and plate adhesive sticking to the metal cutter. 
E. Hole-punched double-sided tape and PCR plate adhesive layers with a 96-well hole-punch 
constructed by the School of Engineering Workshop. Due to the thickness of both layers of 
the adhesives combined, it was difficult for the 96-well hole-punch to cut through 
consistently and evenly, and the tape was easily ripped when being removed from the hole-
punch. 
F. Photograph of a laser-cut 96-well polypropylene plate with double-sided tape, sheet of 
microfibres, double-sided tape and PCR plate adhesive, and COC film layers. The white lines 
dividing the plate are the locations of the cuts along the adhesive layers for hole-punching 
using the single hole-punch. Leaking of the food colouring horizontally along the left dividing 
line and complete leaking of the liquid out of the plate after 1 night along the right dividing 
line could be observed, although the rest of the plate appeared to be watertight. This 
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confirmed that it was not the adhesive that was the issue but rather the cuts required for the 
hole-punch to access the inner areas of the tape. 
G. Laser-cut double-sided tape and PCR plate adhesive layers, produced with the help of Dr. 
Anthony Buchoux. As shown, the cuts are even, smooth, and consistent along the holes 
corresponding to each well of a 96-well plate, and the flexibility offered by the laser cutter 
means that the sheet of adhesives can easily be cut to size to fit the base of a bottomless 96-
well plate. 
 
4.2.3 Final construction of the high content-compatible 96-well microfibre plate with 
suspended PLA microfibres 
 
Thus far, I was able to find a consistent source of bottomless 96-well plates, optimise the 
production of the electrospun microfibres, and test for the current best option in adhering 
the layers together (summarised in Figure 4.6 A). Lastly, I needed to be able to seal the base 
of the plate with a thin sheet of material that would be compatible with imaging. Cyclic olefin 
copolymer (COC) was tested due to its transparency, high heat-deflection temperature (for 
culturing in 37°C incubators for long periods), and low moisture absorption and strong water-
vapour barrier qualities (Lamonte and McNally, 2001). TekniFilms CSF1416 and TOPAS 
8007X4 COC films were initially tested by preparing them as PDL-coated “coverslips” and 
culturing OPCs isolated by the mixed glia culture method, and staining for MBP and Hoechst 
for confocal microscopy. As shown in Figure 4.6 A, OPCs could be cultured and would 
differentiate in close proximity with COC, and it was possible to take confocal images through 
this material. Therefore, TOPAS COC 8007 X-04, which is approximately 140μm in thickness 
and was the closest to the standard 170μm commercial 96-well plate bases, and was the only 
readily available product in the quantity and format required for consistent plate 
construction, was used for further testing. 
96-well microfibre plates were constructed fully as shown in Figure 4.6 B, including the COC 
film base. In order to ensure that the layers were firmly adhered, metal blocks were placed 
on the base of the plate to compress the layers together for at least 2 days. The metal blocks 
were found to be the best weights due to their similar shape and size to the base of the plate.  
By contrast, irregular non-rectangular shapes compressed the layers unequally as confirmed 
by the Leica SP8 MatrixScreener, even when placed on lighter rectangular shapes to 
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distribute their weight. 96-well microfibre plates constructed using this optimised technique 
had food colouring placed in alternate wells for testing for cross-well contamination of 
individual wells to ensure they were watertight. No obvious leaking could be observed 
immediately. In order to verify whether changes in temperature would affect this, the plates 
were placed in the 37°C incubator for 2 weeks, the length of time required for the OL 
myelination culture, and placed for several days at room temperature and in the 4°C fridge, 
as required for staining and storage. The plate did not show any signs of leakage following 
these tests, as shown in Figure 4.6 C, and therefore it was concluded that they could be used 
for drug screening, where distinct drugs or drug combinations added to the individual wells 




Figure 4.6 Final high-throughput-compatible 96-well microfibre plate design optimisation 
165 
 
A. Confocal image of OPCs isolated by the mixed glia culture method, cultured on COC film, and 
stained and imaged as per the 12-well scaffold method to confirm that the COC film is 
imaging-compatible. 
B. Schematic of the final 96-well microfibre plate construction components. The bottomless 96-
well plate was produced by laser cutting the bases of each of the individual 96-well plates 
and the edges smoothed using sandpaper. A single layer of double-sided tape was used to 
adhere the sheet of electrospun microfibres underneath. A laser cut PCR plate seal was used 
to suspend the fibres, and another layer of double-sided tape used to make both sides of the 
spacer layer adherent. The plate was finally sealed with COC film which, as shown in A, is 
imaging-compatible. The COC film used was 140μm in thickness, which was the most similar 
in thickness to the 170μm thickness of standard 96-well plates out of the commercially 
available films that could be obtained. 
C. Water-tight test performed with food colouring mixed into alternative wells using the 
construction method in B. As shown in the photograph, there is no mixing and leaking of the 
food colouring into adjacent wells, highlighting that this construction method allows the 
construction of a 96-well plate with a suspended layer of electrospun microfibres that is 





The key technological and bioengineering advancement of my PhD project is the production 
of the 96-well microfibre plates with suspended electrospun microfibres (Figure 1.20 
Challenge and Solution #1). To achieve this,  I designed and optimised: i) the concentration 
of poly-L-lactic acid (PLA) dissolved in hexafluoroisopropanol (HFIP) for fibre diameter; ii) 
electrospinning using a moving needle with a rotating collector for equal distribution, with 
release paper enabling easy transfer; iii) bottomless 96-well plates produced by laser cutting 
and sandpapering; iv) the adhesives to attach the sheet of electrospun fibres made 
compatible with the plate  by laser cutting; and v) an optically-compatible cyclic olefin 
copolymer (COC) film providing the imaging-compatible base. 
The basis of electrospinning fibres and inserting them into a 96-well plate format in itself is 
not novel – for example, the Electrospinning Company, from which I acquired the 12-well 
scaffolds for my experiments, also produce a product called ’96-well plate fixed scaffolds 
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(TECL-005)’. However in their product, the electrospun fibres are in close contact with the 
base of the plate. Although the production of plates without a spacer to suspend the fibres 
completely from the base of the plate may be technically easier and less expensive to 
produce due to fewer components being required in making watertight plates, for the study 
of myelin sheath formation, work from our own lab and others has found that such plates 
are unsuitable for quantitative myelination assays for two reasons.  First, as observed by Dr. 
Marie Bechler in using the Electrospinning Company product, and by Ong et al. (2018) in their 
set-up of electrospun PCL fibres suspended by PCL films on glass coverslips (Figure 4.7), 
oligodendrocytes cultured on electrospun fibres that are in close proximity to flat surfaces 
will detect both the 3D fibres to ensheath and the 2D surfaces to extend membranes across, 
or a combination of both by the same cell. When developing a myelination assay where the 
measurement of complete myelin sheath is the quantifiable output, the degree to which the 
electrospun fibre is in contact with the fibres versus the underlying surface, and therefore 
the likeliness of membrane extension versus sheath formation, introduces an uncontrollable 
factor that reduces the precision and reproducibility of the assay.  
 
 
Figure 4.7 Confocal images from oligodendrocytes cultured on PCL fibres suspended by PCL 
films on glass coverslips 
When oligodendrocytes are cultured on fibres that are in contact with a flat surface, they produce cells 
that form flat membranes (left), complete myelin sheaths (middle), and a combination of both flat 
membranes and myelin sheaths (right) as they detect both the 3D fibres and the 2D coverslip. 




Second, the inter-plate consistency of the plate construction technique is very poor with the 
commercially available plates. As shown in Figure 4.8 A and B, the consistency of the working 
distance required to image the myelin sheaths on the microfibres on the purchased plates 
varied vastly between and within plates, with certain wells not being within the available 
working distance (as shown in Figure 4.8 B) or needing to divide up the plate into multiple 
sections to scan individually to be able to capture all the wells. On the other hand, the fibres 
and myelin sheaths in all the plates that I constructed using the final described construction 
method (Figure 4.6 B) were well within the 500μm imaging range provided by the Leica SP8 
MatrixScreener (Figure 4.8 C and D), showing improved intra- and inter-plate variability, even 
when the number of fields-of-view being imaged was increased (Figure 4.8 D). The 
significance of this reduced variability is its importance in high content imaging compatibility, 
with an increase in the range of z-steps that the microscope has to image to capture the cells 
reducing the potential for image automation and increasing the time required to scan a single 
experiment, if the microscope can image the plate at all. As also mentioned in the next 
chapter, this was highlighted when a plate from The Electrospinning Company and a plate 
that I constructed were prepared by Dr. Marie Bechler and myself, respectively, and imaged 
on the Yokogawa CV7000 at the Phenotypic Screening Centre in Dundee. The plate from The 
Electrospinning Company could not be registered on the microscope, and therefore no 
images could be obtained, whereas the 20x long working distance objective could be used to 
register and image the plate that I had prepared, with the potential for the use of higher 
objectives with further exploration and technical assistance from the engineers. The 
increased reproducibility and decreased variability of the construction technique for 96-well 
plates with suspended microfibres that I developed therefore shows more promise for its 





Figure 4.8 Autofocus maps obtained using the Leica SP8 MatrixScreener show better 
consistency between plates in the variation of the height of the fibres from the base of the 
plate using my construction method 
The figure shows representative autofocus maps obtained using the Leica SP8 MatrixScreener from 
two plates prepared by The Electrospinning Company (A and B, images provided by Dr. Marie Bechler) 
and by myself using the construction technique as described in this chapter (C and D). 
The autofocus maps were taken by setting an arbitrary mid-point for the range at which the 
microfibres are distanced from the base of the plate, and the MatrixScreener image-based 
autofocusing function used to detect how far the fibres at each set autofocus point were located above 
or below this mid-point. The colours represent the distance (±, in μm) at which the fibres were 
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detected to be most in focus from the arbitrary mid-point as shown in the calibration bar. The 
calibration bar in each image therefore indicates the total distance range for the fibres within the plate 
that could be imaged. 
The small squares indicate each field-of-view included in the MatrixScreener scan, and the larger 
squares these make up represent each well. The blank squares in B (top left corner) are wells which 
were outside of the 500μm range for the autofocus map and subsequent imaging, and therefore could 
not be included in the scan. 
 
These results showing the difficulties of working with commercially available products 
emphasize the importance of the technique described in this chapter of my PhD to reliably 
produce 96-well microfibre plates in which the electrospun microfibres are suspended from 
the base of the plate but are also within working distance range of imaging by high content 
imaging platforms. Such a plate also offers much greater future potential in increasing the 
flexibility of the experiments by adjusting the electrospinning and fibre preparation method 
(i.e. different diameters, materials, or coating). It will therefore provide a useful advance in 
allowing for the execution of high-throughput experiments for studying oligodendrocytes in 




CHAPTER V. VERIFICATION OF THE HIGH-THROUGHPUT 96-WELL 
MICROFIBRE PLATE PLATFORM 
 
5.1 Introduction  
 
The goal of the plate I have designed and constructed (described in the previous chapter) is 
to enable phenotype-based screens that identify compounds that directly promote 
myelination. This chapter describes initial work towards that aim in which I have: (5.2.1) 
tested whether the 96-well microfibre plate that I constructed was compatible for use in a 
high-throughput pipeline and with high content imaging platforms, (5.2.2) optimised the OPC 
isolation method and cell density required for individual oligodendrocytes and their 
respective myelin sheaths to be identifiable in the high-throughput format, (5.2.3) calculated 
the reproducibility of the assay using the coefficient of variation values, and (5.2.4) quantified 
the sheath length and number in the 96-well microfibre plates using compounds previously 
identified in the differentiation assays in Chapter 3 and a compound currently under 
investigation at Roche. Preliminary results of an experiment to increase the sensitivity of the 
assay using fibrin-coating of the fibres is also discussed at the end (5.2.5). To introduce this 
work I will review three relevant aspects of phenotype base screens: (5.1.1) the logic behind 
them, (5.1.2) aspects of assay design, and (5.1.3) the challenges introduced by 3-D screens 
such as the one I have designed. 
 
5.1.1 Phenotypic-based screens 
 
Although phenotypic-based screening strategies laid the groundwork for modern drug 
discovery in the 20th century, the past 30 years has seen the molecular target-based screening 
strategies becoming the traditional method due to the advances in pharmacology, molecular 
biology, synthetic and medicinal chemistry, laboratory screening automation, and 
understanding of disease at the genetic level. As summarised in Figure 5.1, the molecular 
target-based screening approach identifies a disease-relevant target, and then the 
development of an assay that searches for hits against the target in order to conduct a high-
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throughput screen. On the other hand, phenotypic screening approach focuses on the cell- 
or organism-based characteristic of the disease to identify compounds that ameliorate the 
disease phenotype, without prior knowledge of the drug target (Clemons, Tolliday and 
Wagner, 2009; Zheng, Thorne and McKew, 2013). 
 
 
Figure 5.1 Comparisons of various drug discovery pipelines 
Screening approaches can be divided into two main types: screening approaches, as shown in (a) 
molecular target and (b) phenotypic, and drug repurposing screens, as shown in (c) and (d). 
The molecular target-based screening approach identifies the target molecule for the disease selected, 
and develop a screen specific for this molecule to identify a lead compound to optimise (i.e. improve 
the potency by working with medicinal chemists by studying and adjusting the molecular structure of 
the lead compound) and move forward towards in vivo validation and clinical trials. The phenotypic 
screening approach develops a screen to identify the phenotype that indicates a positive outcome for 
the disease selected in order to identify a hit, with the hit compound subsequently needing to undergo 




The use of repurposing screens is to reduce the time and money required in this drug discovery process 
by using compounds that already have known profiles for other diseases, such as the molecular 
pathways it targets, and its safety and efficacy profile, allowing the money- and time-intensive process 
to be reduced. 
(Figure from Zheng, Thorne and McKew, 2013) 
 
The increasing rate of failure of compounds identified as hits making it through clinical trials 
(Pammolli, Magazzini and Riccaboni, 2011; Scannell et al., 2012), the limit in the number of 
novel validated druggable targets, and the recent advances in cell-based assay screening 
technologies such as high-throughput imaging, iPSC technology, CRISPR gene editing, and 
more relevant 3D in vitro models, has resulted in renewed interest in phenotypic-based 
screens over the past decade (Clemons, Tolliday and Wagner, 2009; Zheng, Thorne and 
McKew, 2013). The phenotypic screen is generally more biologically and clinically relevant, 
but also more complex to develop and comparatively lower in throughput compared to the 
cell-free target-based screens. However this may be offset by the lower attrition rate in later 
stages of the drug discovery pipeline, although more data is still needed to provide evidence 
for this, and improved upon by the development of robotic platforms for automation, 
miniaturisation, and throughput. Although the retrospective identification of the mechanism 
of action and target may be complicated and lengthy, drugs shown to be safe and efficacious 
may still be approved for clinical use, and lead identification with repurposed drugs can speed 
up and reduce the cost of bringing a compound to market, with the validation of the target 
by a phenotypic screen also possibly leading to the identification of further drug targets 
(Figure 5.1) (Clemons, Tolliday and Wagner, 2009; Zheng, Thorne and McKew, 2013). 
 
5.1.2 Assay development 
 
The construction of a high-throughput cell-based phenotypic assay requires the balance of 
biological-relevance with the ability to adopt automation, including the readout and data 
analysis of the assay. High content screening is the technique by which multiple 
measurements are obtained per well, providing more dynamic and mechanistic information 
than uniform single well measurements, and can include the use of an image-based 
automated microscope system. The development of an assay itself requires optimisation of 
173 
 
the throughput, sensitivity of the signal and readout, variability, degree of miniaturisation 
appropriate, and adaptation to the available screening platforms, and expand to cell density, 
optimal concentration of tested compounds, sensitivity to the compound solvent (which is 
usually DMSO), and length of culturing with the compounds among other factors with cell-
based assays (Buchser et al., 2004; Clemons, Tolliday and Wagner, 2009; Bray, Carpenter and 
Broad Institute of MIT and Harvard Imaging Platform, 2012). 
Liquid-handling robots can improve the precision, throughput, and the ability to miniaturise 
the assay. However, this requires careful testing of the volume of dispensing, speed of 
dispensing and aspirating, and height and position of the tips, to prevent damage to the cells, 
especially if repeated use is required. Reproducibility between wells of the same plate (intra-
plate), between different plates (inter-plate), and between different biological replicates and 
batches require testing and optimisation using a DMSO-control and a compound shown to 
produce positive activity when one is available, as well as quality control to eliminate data 
that are due to non-compound-related variables, such as cell density or imaging artefacts. As 
discussed further below, the Z’ factor is one of the most widely accepted measures of the 
quality of the assay, allowing for the determination of whether the assay can determine 
positive activity from background control, with a large number of replicates being required 
for this calculation. Various techniques for data normalisation also exist to account for inter- 
and intra-plate variability based on errors, such as changes in compound concentrations due 
to evaporation, anomalies from external factors such as robotic failures or pipette 
malfunction, and variations in incubation times and temperature differences of the 
incubators, or other sources of systematic errors, which are often identifiable as repeated 
artefacts (Clemons, Tolliday and Wagner, 2009; Bray, Carpenter and Broad Institute of MIT 
and Harvard Imaging Platform, 2012). 
 
5.1.3 3D cellular models for drug discovery 
 
In addition to the complexities of a cell-based phenotypic assay, there are additional 
considerations for a 3D cellular model, such as our in vitro myelination system. As 
summarised in the SWOT analysis by Carragher et al. (2018), 3D models provide the promise 
of being able to provide a more physiologically-relevant model of the disease-relevant cells, 
and may provide new and richer data that is more innovative and intelligent in its design. 
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However, the complexity of such models also brings about complications, such as the 
expense and additional difficulties of validating such multifaceted and heterogeneous 
models, as well as the difficulties of imaging, screening, and analysing such large and rich 
data sets which pushes the limits of the imaging platforms currently available and the balance 
between image quality and working distance with long acquisition times, and the 
computational demands of storing and analysing the extensive data when few 3D-compatible 
image analysis software packages are available (Horvath et al., 2016; Carragher et al., 2018). 
Despite the caution required in not yet overestimating the translation of the physiologically 
more relevant 3D models to increased clinical relevance when the data is not yet available to 
support this (Carragher et al., 2018), the development of more complex 3D cellular models 
along with the expanding ability to increase the throughput of their readouts with the 
development of more high-throughput and high content-compatible robots and software 





5.2.1 Testing of the compatibility of the 96-well microfibre plate with high-throughput 
liquid handling machines and high content imaging platforms 
 
In order to be able to use the 96-well microfibre plates for high-throughput drug screening, I 
needed to verify that the plates could be incorporated into a high-throughput pipeline, 
including the use of liquid handling machines and high content imaging platforms, which 
allows for the reduction of human error, increase in reproducibility and reduction in 
variability (i.e. CV), as well as decrease in timescale of sample processing. Firstly, I used the 
ImageJ Cell Counter plugin to quantify the number of Hoechst+ cells in DMSO control when 
OPCs isolated from mixed glia cultures were plated onto a 96-well microfibre plate using a 
MultidropTM (Figure 5.2 A). When imaged using the Leica SP8 MatrixScreener and the cell 
numbers counted from the maximum projected image, the coefficient of variation was 7.8% 
(individual values: 207, 205, 181, 219 cells) (n = 1), showing both that the MultidropTM could 
be used to plate cells in the 96-well microfibre plates, and that, at least based on preliminary 
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results, there is a high degree of intra-plate plating density consistency even accounting for 
some of the cells that may have fallen through in between the fibres if the distance is larger 
than 10μm. 
In addition, in order the process the plates for imaging, the MultidropTM and the BioTek LS 
405 microplate washer can be used to dispense liquids (fixative and antibody solutions) and 
rinse with PBS in between the steps, respectively. The microplate washer, due to the 
repeated aspiration directly from the centre of the well, as opposed to the dispensing which 
is performed towards the side of the well, could result in cells and fibres being detached. I 
therefore took a 96-well microfibre plate with immunopanned OLs cultured for 14 days, fixed 
and stained it by manual pipetting, and imaged the plate on the Operetta before using the 
BioTek LS 405 microplate washer (Figure 5.2 B). I then calculated the minimum number of 
aspiration-dispensing cycles required to be able to use the BioTek LS 405 as 10x, estimated 
the aspiration distance from the bottom of the well as 6.987mm using a standard 96-well 
plate to leave approximately 125 to 130μl of liquid in each well of a 96-well microfibre plate 
after aspiration, and re-imaged the same wells on the Operetta after the 10x cycles (Figure 
5.2 C). I repeated this experiment with a further 3x cycles on the microplate washer to 
account for the potential maximum number of cycles before imaging the plate again (Figure 
5.2 D). As shown in Figure 5.2 B-D, in this preliminary test, there does not appear to be any 
cell loss after 10x or 13x cycles on the microplate washer, verifying that the 96-well 






Figure 5.2 The 3D 96-well microfibre plates are compatible with high-throughput liquid-
handling robots 
A. Maximum projected confocal image of the Hoechst nuclei staining of OPCs isolated from 
mixed glia cultures plated on the 96-well microfibre plates with the Multidrop taken with the 
SP8 MatrixScreener. The number of nuclei in the 4x DMSO control wells (individual values: 
207, 205, 181, 219 cells) were counted using the Cell Counter plugin on Fiji to calculate the 
coefficient of variation (CV = 7.8%) in a single plate. n = 1 
B. Representative Operetta non-confocal image of a single well of a 96-well microfibre plate 
with OPCs isolated from immunopanning and plated at 5,000 OPCs per well. n = 1 
C. Well from (B) after 10x cycles of aspiration and dispensing with the BioTek LS 405 microplate 
washer, the minimum number of cycles required for fixation and staining. 
D. Well from (C) after a further 3x cycles with the BioTek LS 405 microplate washer, to include 
additional cycles to improve fixation and staining. 
 
Although we are able to automate the imaging of the 3D 96-well microfibre system using the 
Leica SP8 MatrixScreener, as the SP8 is not a high content imaging system, it is inherently 
slow and incompatible with a high-throughput pipeline. In addition, due to the objectives 
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available and the stage set-up of the microscope at SCRM, only the 25x water objective has 
the working distance to be able to image the suspended microfibres compared to the 40x oil 
objective used when imaging the coverslips of the 12-well microfibre scaffold, and only the 
central 32 wells can be accessed due to the distance from the skirt to the base of the plate, 
excluding two-thirds of the wells. As discussed below, the Operetta and Opera do not provide 
the resolution to distinguish between membrane extension and ensheathment, and 
therefore is incompatible with our myelination assay. Therefore, I also explored the 
Yokogawa CV7000 and the Opera Phenix high content imaging systems in Dundee (National 
Phenotypic Screening Centre) and Glasgow (Dr. Lynn McGarry, Beatson Institute for Cancer 
Research), respectively. The Yokogawa CV7000 was able to register my custom-made plate 
and detect the fibres using the 20x long working distance, but was not able to using the 60x 
objective based on initial tests. Interestingly, a  commercial custom-ordered 96-well plate (by 
Dr. Marie Bechler) with suspended microfibres by The Electrospinning Company could not be 
registered on any of the objectives tested on the Yokogawa CV7000, suggesting that my 
plates were more compatible for high content imaging platforms than what could be 
purchased commercially. The Opera Phenix could access the central 60 wells with a plate 
constructed using the standard PerkinElmer CellCarrier plate, and all 96 wells using the 
CellCarrier Ultra plates with the shorter skirt, as exemplified with the brightfield transmission 
images of the fibres across an entire plate taken on the Opera Phenix in Figure 5.3 A. 
Additionally, using the 63x objective, it was possible to image individual oligodendrocytes 
and their respective myelin sheath at 0.5μm z-step sizes (Figure 5.3 B), therefore confirming 






Figure 5.3 The 3D 96-well microfibre plates with suspended microfibres is compatible with 
the PerkinElmer Opera Phenix as a high content imaging platform 
A. Brightfield images of the fibres in focus in a 96-well microfibre plate constructed using the 
PerkinElmer CellCarrier Ultra plates as taken on the Opera Phenix. As shown, all wells are 
accessible and can be imaged using the CellCarrier Ultra plates versus the standard CellCarrier 
plates, where the outer wells cannot be accessed. 
B. Confocal image of a single cell taken using the 63x objective at 0.5μm z-step on the Opera 
Phenix on a 96-well microfibre plate constructed using the PerkinElmer CellCarrier Ultra 
plate. This highlights that individual myelin sheaths can be visualised for quantification using 
this high content-compatible imaging platform. 
 
5.2.2 Optimising the OPC isolation method and cell density required for individual 
oligodendrocytes and their respective myelin sheaths to be identifiable in the high-
throughput format  
 
On the 96-well microfibre plates constructed and verified to be water-tight in Chapter 4, 
OPCs isolated using the mechanical isolation technique from mixed cultures were plated at 
8,000 cells per well in myelination media. An initial drug screening experiment was 
performed using compounds identified in the published differentiation drug screens that had 
also been tested in 2D 96-well flat culture and 3D 12-well scaffolds in Chapter 3 to test 
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whether there was a difference between 2D pro-differentiation and 3D pro-remyelination 
assays, and whether the results obtained in the 3D 12-well scaffolds could be recapitulated 
in the 96-well plate format. The experiment was adjusted to include the small molecule PKC 
activator, FR236924, and the endothelin receptor agonist peptide, BQ-3020 (Swire et al., 
2019; Yuen et al., 2013), to test whether the plate could detect compounds that have been 
confirmed to enhance myelin sheath formation. However, for the reasons listed below, these 
experiments did not yield myelin sheath-producing oligodendrocytes to quantify. 
As shown with an example image in Figure 5.4, several wells in different plates showed an 
abundance of the appearance of CellMask cytoplasm-positive cells that were morphologically 
distinct from oligodendrocytes and not MBP-positive, appearing to be closer to astrocytes by 
morphology. Due to a combination of the contaminating cells and the myelination media 
issue, as discussed further in Chapter 3 and below, only one repeat of the four initial repeats 
of the experiment yielded oligodendrocytes with myelin sheaths in a majority of its wells (18 
out of 32 wells), and could therefore be quantified (Figure 5.1 B and C). It was therefore not 











Figure 5.4 There is an abundance of contaminating cells when OPCs isolated using the 




A. Example images show the presence of cytoplasmic staining (CellMask_cytoplasm) that is not 
MBP+ and is morphologically distinct from oligodendrocytes, suggesting the presence (left) 
and abundance (right) of a second type of contaminating cells in the culture. 
B. Myelin sheath length measurements quantified by manual measurements on Fiji, recorded 
on Excel, and plotted and analysed on GraphPad Prism 5. No measurements could be 
obtained from the 0.05μM Clemastine condition (performed in triplicate) from the 3 wells 
imaged and analysed. n = 1 
C. Number of myelin sheath per MBP+ cell. Sheaths were only counted when MBP+ cells were 
distinctly separate, and excluded when cell bodies were clumped in close proximity. n = 1 
 
The presence of contaminating cells would create complications in performing a drug screen 
due to the inability to determine whether the effect of certain compounds was on the 
oligodendrocytes or indirectly through the contaminating cells, and due to the variability of 
the oligodendrocyte to contaminating cell ratio in different biological replicates. It was 
difficult to determine whether there was a high percentage of contaminating astrocytes from 
the isolation technique when plating, promotion of proliferation of the contaminating 
astrocytes, or whether the 96-well plate format was more conducive to the trans-
differentiation of OPCs into astrocytes (Raff, Miller and Noble, 1983). Should the cause be 
the first two possibilities, increasing the purity of the OPCs in the isolation technique should 
decrease the appearance of these contaminating cells, such as through immunopanning. 
Next, therefore, and as part of a 4-month industry research internship I undertook at Roche 
in Basel, Switzerland as part of my PhD training and an ongoing industry-academic 
collaboration based on the 96-well microfibre plates that I had constructed, I used the 
immunopanning technique developed by Foo et al. (2011).  Under her guidance I isolated 
O4+ OPCs to use for drug screening on the 96-well microfibre plates to compare them to 
those obtained by mechanical isolation of the mixed glia cultures as used at SCRM in 
Edinburgh, UK. The 3 compounds tested, in addition to the DMSO control, were Clemastine, 
due to its identification in the BIMA screen (Mei et al., 2014) and positive Phase 1 trial results 
(Green et al., 2017), DAPT, which was used as a positive control for Lariosa-Willingham et al. 
(2016)’s axonal co-culture screen of myelination rather than differentiation, and Compound 
R, a compound undergoing early research studies at Roche. 
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I initially dissected and isolated O4+ OPCs and plated them into my 96-well microfibre plates 
at a density of 8-10,000 cells/well. However, very few cells were present in each well, 
suggesting either poor survival and/or low plating density. Therefore, reasoning that the 
vigorous immunopanning protocol might compromise viability, I plated the O4+ OPCs onto 
normal tissue culture-treated dishes for 2-3 days in a ‘recovery phase’ prior to lifting them 
up and re-plating on my fibres, as well as plating these cells at multiple densities. Plating at 
higher than 10,000 cells/well (Figure 5.5 A-C) resulted in the density being too high, and 
therefore unable to distinguish individual oligodendrocytes and their respective myelin 
sheaths. 8,000 cells/well (Figure 5.5 D) allowed individual oligodendrocytes and their myelin 
sheaths to form in culture and be detected, although a few clusters of cells could still be 
identified. Therefore, the optimal plating condition was determined to be the plating density 
of 6-8,000 cells/well after the O4+ OPCs had undergone a ‘recovery phase’. 
 
 
Figure 5.5 Immunopanned OPCs can be plated and cultured in 96-well microfibre plates, and 
result in lower contamination compared to OPCs isolated from mixed glia cultures 
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Representative Operetta images when cells are plated at 40,000 (A), 20,000 (B), 10,000 (C), and 8,000 
(D) cells per well on the 96-well microfibre plates, with a majority of the Hoechst+ cells also being 
MBP+. As can be seen, the nuclei density at 40,000 cells per well is too high for process extension. The 
20,000 and 10,000 cells per well conditions showed improvement, but was still too dense to identify 
individual oligodendrocytes and their respective myelin sheaths. At 8,000 cells per well, individual 
oligodendrocytes and their myelin sheaths could be identified. As a few clusters of cells could still be 
seen, the optimal density was determined to be approximately 6-8,000 cells per well. 
 
5.2.3 Assessing reproducibility: Intra- and inter-plate coefficient of variation and Z’ 
calculations for the Roche 96-well microfibre drug screening platform 
 
The coefficient of variation (CV) is defined as the standard deviation (SD) of a set of data 
divided by its mean. It is used to calculate the magnitude of difference that can be attributed 
to assay variability, i.e. by chance, rather than true difference due to experimental conditions, 
and can therefore be used as a measure of assay precision and reproducibility (Reed, Lynn 
and Meade, 2002). To determine the CV of the 96-well microfibre drug screening platform, 
the average value of myelin sheath length (Table 5.1) and myelin sheath number (Table 5.2) 
per well in each plate was calculated, and used to obtain the intra-plate CV for each DMSO 
control concentration. The inter-plate CV per DMSO concentration across the 3 plates was 
calculated by taking the average of the CV of the respective DMSO concentration in each of 
the 3 plates.  
A CV of less than 20% is generally the acceptable standard for more complex assays such as 
the 96-well microfibre drug screen, which, according to Reed et al. (2002)’s formula, a CV of 
20% would approximate to about 1.3% random twofold changes. When interpreting the CV 
for myelin sheath length (Table 5.1Table 5.1 Coefficient of variation calculations for myelin 
sheath length from the Roche 96-well drug screen experiment), there was variable results in 
intra-plate CV per DMSO concentration, with CV ranging from less than 2% to just under 30%. 
The inter-plate CV per DMSO concentration was within 20% for 0.1% and 0.01% DMSO, but 





Table 5.1 Coefficient of variation calculations for myelin sheath length from the Roche 96-
well drug screen experiment 
 
The CV of the myelin sheath number (Table 5.2) showed more random variability, with intra-
plate CV reaching almost 50% in 0.001% DMSO in plate 2, and inter-plate CV being over 20% 
in the 0.01% and 0.001% DMSO condition. These CV calculations highlight the variability of 
both the myelin sheath length and myelin sheath number potentially by random chance in 
the 96-well microfibre plates. Although some of this will be down to technical issues from 
the transport and the lack of cells to quantify in some wells as discussed below, the use of 
liquid handling machines to decrease human error in areas such as plating density could be 
used to improve the assay precision. 
 
 
Table 5.2 Coefficient of variation calculations for myelin sheath number from the Roche 96-
well drug screen experiment 
 
Plate 1 Plate 2 Plate 3 Plate 1 Plate 2 Plate 3 Plate 1 Plate 2 Plate 3
MEAN by well 31.11 28.49 13.98 30.76 17.73 22.86 24.02 15.44 21.83
31.86 23.85 15.69 25.69 29.21 17.47 24.14 23.33 12.45
29.07 27.45 27.34 28.74 17.57
SD 0.52 3.28 1.21 2.58 6.19 4.94 2.69 5.58 4.70
MEAN 31.49 26.17 14.83 28.51 24.80 22.56 25.63 19.38 17.28
Intra-plate CV 1.67% 12.54% 8.14% 9.05% 24.94% 21.92% 10.49% 28.79% 27.19%
Inter-plate CV
Per well
DMSO control (0.1%) DMSO control (0.01%) DMSO control (0.001%)
DMSO control (0.1%) DMSO control (0.01%) DMSO control (0.001%)
7.45% 18.64% 22.16%
Plate 1 Plate 2 Plate 3 Plate 1 Plate 2 Plate 3 Plate 1 Plate 2 Plate 3
MEAN by well 1.67 2.33 3.00 3.00 2.10 1.43 1.89 1.50 2.50
1.57 1.83 2.50 1.57 2.00 3.20 2.43 3.00 1.60
1.67 2.40 4.00 1.84 2.33
SD 0.07 0.35 0.35 0.80 0.21 1.32 0.33 1.06 0.48
MEAN 1.62 2.08 2.75 2.08 2.17 2.88 2.06 2.25 2.14
Intra-plate CV 4.16% 16.97% 12.86% 38.41% 9.61% 45.75% 15.91% 47.14% 22.33%
Inter-plate CV
Per well
DMSO control (0.1%) DMSO control (0.01%) DMSO control (0.001%)




Further experiments were conducted to include compounds, in addition to the 
differentiation and co-culture myelination compounds used in Chapter 3 that have been 
shown to have positive and negative effects on myelin sheath formation on the fibre culture 
system by Dr. Matthew Swire to test the sensitivity of the 96-well microfibre platform (Swire 
et al., 2019). The aim was to calculate the Z’-factor, defined as 1 - 
3(𝜎𝑝+ 𝜎𝑛)
|𝜇𝑝− 𝜇𝑛|
, where μ is the 
mean and σ is the standard deviation of the positive (p) and negative (n) controls, and is 
widely used in high content screening assays as a measure of assay performance in assessing 
its ability to pick up hits whilst reducing false positives and negatives (Bray, Carpenter and 
Broad Institute of MIT and Harvard Imaging Platform, 2012; Zhang, Chung and Oldenburg, 
1999). For positive effect, the small molecule PKCε activator FR236924 and endothelin 
receptor agonist peptide BQ-3020 were included as both were shown to increase sheath 
number (Swire et al., 2019). For negative effect, MAP kinase inhibitor U0126 shown to 
decrease sheath length and number and epidermal growth factor receptor kinase inhibitor 
AG 1478 which decreased sheath number were included. However, as also discussed in 
Chapter 3, due to media issues which we narrowed this down to be most likely a result from 
the batch-to-batch variability of the commercial B27 and home-made B21, I was unable to 
get myelin sheath formation after 15 sets of experiments were performed, including in the 
media and DMSO controls, using different batches of commercial B27 and home-made B21, 
using media with lower T3/T4 concentration to reduce stress to the cells and as our lab 
protocol adds 10x concentration of T3 in comparison to similar media in addition to adding 
T4, as well as using media components shipped from Roche. Thus, a Z’ factor could not yet 
be determined at the time of completing this thesis. 
 
5.2.4 Determining the changes in myelin sheath formation using Clemastine, DAPT, 
and Compound R on immunopanned OPCs on 96-well microfibre plates 
 
Once the plating condition had been optimised and the miniature drug screen test performed, 
an automated high content screening technique with the appropriate imaging resolution was 
explored. Neither the Opera (Figure 5.6 A) nor the Operetta (Figure 5.6 B), the two high 
content imaging machines available at Roche, offered the z-step size in resolution or the 
autofocusing capabilities required for automated imaging of these highly complex myelin 
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sheath structures, with the Opera also not being high content-compatible with these plates.  
Their Leica SP8 confocal system also didn’t have the appropriate MatrixScreener plugin, 
which is an extension that allows screens to be set up on the confocal system by allowing 
parameters such as the autofocusing range, and wells and fields-of-view selected for imaging 
to be set up and run automatically (Eberle et al., 2017). These investigations highlight the 
limitations of commercial high content and commercial imaging platforms with regards to 
imaging bespoke 3D cell assay plate formats. Along with the timeline of the experiments 
performed at Roche and the end of the internship, it was therefore determined that the only 
feasible method of imaging these microfibre plates would be to ship them back to SCRM and 
image them using the Leica SP8 MatrixScreener. However, as shown in Figure 5.6, comparing 
the representative images of a single well taken at Roche on the Opera and Operetta 
compared to on the MatrixScreener post-shipment, with an average well being shown in 
Figure 5.6 C with other wells having slightly more cells and others having significantly fewer, 
there appeared to be a loss of cells during the transportation process despite filling each of 
the wells with as much PBS as possible to reduce the amount of air, sealing tight with a plate 
adhesive, parafilming the edge of the plates, and shipping them in thick Styrofoam boxes 





Figure 5.6 96-well microfibre plates transported from Roche (Basel, Switzerland) to SCRM 
(Edinburgh, UK) show the loss of cells in the wells during the transit process 
Representative immunofluorescence microscopy images of single wells in the 96-well microfibre 
plates with 8,000 cells per well plated at Roche in Basel, Switzerland taken on the (A) Opera and (B) 
Operetta, and after the plates have been transported to SCRM in Edinburgh, UK on the (C) SP8 
MatrixScreener. 
 
Despite these issues, the plates were imaged on the MatrixScreener, and myelin sheath 
quantification performed using ImageJ (Figure 5.7 A and B), although interpretation of the 
data is limited due to the effect of the transportation on these plates and the number of cells 
available for quantification in each condition in each biological replicate. When sheath length 
was quantified (Figure 5.7 C) and the average per biological replicate taken for statistical 
analysis using the one-way ANOVA with post-hoc Dunn’s Multiple Comparison test (Figure 
5.7 D), none of the compounds and concentrations significantly changed the myelin sheath 
length compared to the DMSO control. Statistical analysis of the myelin sheath number was 
difficult as the transportation issues resulted in as few as 2 or 3 cells being available for 
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quantification in some plates due to the additional criteria of excluding myelin sheaths where 
there were clumps of MBP+ cell bodies, as this makes it difficult to distinguish the originating 
cell body and results in less than 1 sheath per cell if calculated. When the myelin sheath 
number was quantified (Figure 5.8 A), and the average per biological replicate taken for 
statistical analysis with the available data using the one-way ANOVA with post-hoc Dunn’s 
Multiple Comparison test (Figure 5.8 B), no statistically significant changes in myelin sheath 
number could be identified in comparison to the DMSO control. Even taking into account 
variations between biological replicates by controlling for the DMSO in intra-plate 
normalisation (Bray, Carpenter and Broad Institute of MIT and Harvard Imaging Platform, 
2012), there was no statistically significant changes in sheath number for any of the 
compounds and concentrations tested (Figure 5.9 A and B). However, as shown by the wide 
inter- and intra-plate variability determined by CV calculations (Table 5.2) in addition to the 
lack of quantifiable cells in each condition per biological replicate, caution must be taken in 




Figure 5.7 No significant changes in myelin sheath length was seen using three compounds 
tested on immunopanned OPCs at Roche 
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A. Representative maximum projected confocal image of a single well in the 96-well microfibre 
plate with the SP8 MatrixScreener. 
B. Zoomed in image of the cell in (A). The red lines represent complete myelin sheath formation 
as determined by observing the z-stack images, and therefore included in the quantification. 
C. Myelin sheath length measurements quantified by manual measurements on Fiji, recorded 
on Excel, and plotted and analysed on GraphPad Prism 5. 
The box-and-whisker plot show the range of measurements obtained as represented by the 
maximum and minimum at the ‘whiskers’, and the 75th, 50th, and 25th quartiles with the 
lines on the ‘box’ from top to bottom. n = 3 
D. The average myelin sheath length per biological replicate from the data in C was used to 
perform statistical analysis. This showed no significant changes in myelin sheath length for 
any of the compounds in all concentrations tested. 
The statistical test performed was the one-way ANOVA with post-hoc Dunn’s Multiple 







Figure 5.8 No significant changes in myelin sheath number was seen using three compounds 
tested on immunopanned OPCs at Roche 
A. The number of myelin sheath per MBP+ cell. Sheaths were only counted when MBP+ cells 
were distinctly separate to allow each process to be traced back to their respective cell body, 
and excluded when cell bodies were clumped in close proximity. n = 3 
B. The average number of myelin sheath per biological replicate from data in A was used to 
perform statistical analysis. Although the extent to which the results can be interpreted is 
limited due to the restricted number of qualifying cells for quantification, initial results seem 
to suggest no significant changes in myelin sheath numbers using any of the compounds at 
all concentrations tested. 
The statistical test performed was the one-way ANOVA with post-hoc Dunn’s Multiple 





Figure 5.9 No significant changes in DMSO-controlled myelin sheath number was seen using 
three compounds tested on immunopanned OPCs at Roche 
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A. The number of myelin sheath per MBP+ cell was normalised for the DMSO control per 
biological replicate from the data in Figure 5.8. 
B. The average number of myelin sheath normalised for the DMSO control per biological 
replicate from the data in A was used to perform statistical analysis. Once again, although the 
interpretation of the data is limited, the data thus far seems to suggest no significant changes 
in myelin sheath numbers, even taking into account the average number of sheaths in the 
DMSO control per biological replicate. 
The statistical test performed was the one-way ANOVA with post-hoc Dunn’s Multiple 
Comparison test on GraphPad Prism 5. 
 
5.2.5 Effect of coating the fibres with fibrin on myelin sheath formation on the 96-well 
microfibre drug screen 
 
Bechler, Byrne and ffrench-Constant (2015) showed that on these microfibre culture systems, 
the length of the myelin sheath corresponded to the diameter of the fibre on which they 
were cultured. One question about this screening platform was that should myelin sheath 
formation occur at such efficiency that they reached their optimal quantity even in conditions 
with no compounds added, whether this would result in the masking of the effect of 
potentially pro-myelinating compounds and therefore result in increased false negatives. 
Petersen et al. (2017) showed that the coagulation factor fibrinogen inhibits the 
differentiation of OPCs into mature myelinating OLs in primary cultures, OPC/dorsal root 
ganglion co-cultures, and in nanofibre culture system, by activating the bone morphogenetic 
protein (BMP) signalling pathway. Evaluation of post-mortem MS lesions suggested the 
association of fibrinogen and increased BMP signalling occurred at sites of increased blood-
brain barrier permeability, and that the administration of a defibrinogenating agent post-LPC 
demyelination in an in vivo model reduced BMP signalling and increased remyelination, 
highlighting the clinical and therapeutic relevance of this molecule in MS. 
Therefore, using Bacakova et al. (2016)’s protocol for coating electrospun PLA fibres which 
showed stable nanocoating for the 14 days in culture media at 37°C tested, with the rate of 
fibrin coating degradation corresponding to the degree of cell proliferation, I conducted an 
experiment in which immunopanned O4+ OPCs were plated onto 96-well microfibre plates 
with or without fibrin coating to test whether the presence of a MS-relevant inhibitory 
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molecule would increase the sensitivity of the screen. Under the fibrin-coated condition, 
some cells showed a higher degree of myelin sheath formation on the fibrin-coated fibres 
(Figure 5.10 A, 0.05 μM Clemastine) versus other cells where processes and membrane 
extension could be detected but were not ensheathing the fibres (Figure 5.10 B, 0.001% 
DMSO control). Although the same caution in interpretation must be taken as the other 
experiments plated at Roche and transported to SCRM, initial results seem to show that the 
average myelin sheath length comparing the non-fibrin-coated (Figure 5.10 C) and fibrin-
coated (Figure 5.10 D) conditions stayed similar at around 20 to 25μm average across all 
compounds and concentrations. Conversely, when comparing the myelin sheath number, in 
the non-fibrin-coated condition (Figure 5.11 A), the average sheath number across tested 
compounds and concentrations were around 2 sheaths per MBP+ cell, with a slightly higher 
value at 2.75 in 0.1 μM DAPT and above 3 in Compound R (3.67 at 10 μM, 3.80 at 1 μM, and 
3.17 at 0.1 μM), whereas in the fibrin-coated condition (Figure 5.11 B), the average sheath 
number was more variable. Interestingly, despite the potential preliminary slight increase in 
myelin sheath number with Compound R in the non-fibrin-coated condition, this was not 
apparent in the fibrin-coated condition at 1 μM and 0.1 μM concentrations. Whilst no 
significant conclusions can be drawn from this experiment due to the technical issues with 
transportation and the subsequent low number of cells included in the quantification, as well 
as the low number of biological replicates thus far (n = 1), the morphology of the cells as seen 
by confocal microscopy (Figure 5.10 A and B) and the preliminary quantification does suggest 
that fibrin-coating of the microfibres may potentially impact the number of myelin sheaths 
that the OLs are able to form on the microfibre drug screening platform and might be worth 




Figure 5.10 Preliminary results from coating the fibres with fibrin shows no change in the 
average myelin sheath length on the 96-well microfibre drug screen 
A. Example of a confocal image of cells isolated by immunopanning on the fibrin-coated 
microfibres in the 0.05 μM Clemastine condition with myelin sheath formation as verified by 
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the z-stack images. The red lines represent complete myelin sheaths that were included in 
the quantification. 
B. Example of a confocal image of cells on the fibrin-coated microfibres in the 0.001% DMSO 
control condition with myelin processes that did not form myelin sheaths as verified by the 
z-stack images. The red lines represent complete myelin sheaths that were included in the 
quantification. 
C. Myelin sheath length measurements on a 96-well non-fibrin-coated microfibre plate showing 
an average of 20 to 25μm across all conditions and concentrations. The lengths were 
quantified by manual measurements on Fiji, recorded on Excel, and plotted on GraphPad 
Prism 5. n = 1 
D. Myelin sheath length measurements on a 96-well fibrin-coated microfibre plate using the 
same batch of immunopanned OPCs as C showing similar average sheath length across all 
conditions and concentrations. The lengths were quantified using the same method and 







Figure 5.11 Preliminary results from coating the fibres with fibrin shows potential differences 
in the average myelin sheath number for some conditions on the 96-well microfibre drug 
screen 
A. Number of myelin sheath per MBP+ cell on the 96-well non-fibrin-coated microfibre plate, 
showing an average of 2 sheaths per MBP+ cells across the compounds and concentrations 
tested, with 0.1 μM DAPT and Compound R showing potentially slightly higher numbers. 
Sheaths were only counted when MBP+ cells were distinctly separate, and excluded when 
cell bodies were clumped in close proximity. n = 1 
B. Number of myelin sheath per MBP+ cell on the 96-well fibrin-coated microfibre plate using 
the same batch of immunopanned OPCs and quantified using the same criteria and method 
as A. The average myelin sheath number was highly variable across all conditions and 




In this chapter, I showed that the 96-well microfibre plates that I constructed were 
compatible with use with liquid-handling machines, specifically the MultidropTM for plating, 
fixing, and staining and the BioTek LS 405 microplate washer for staining and washing. The 
incorporation of these, in addition to the Integra ViaFlo 96/384 liquid-handling pipette 
machine to increase precision in the media changes with the dissolved compounds, would 
be essential in future experiments to improve reproducibility and the CV values for the assay. 
In addressing the issue of imaging the 3D myelin sheaths with the increased working distance 
of the suspended microfibres and the resolution required to determine complete 
ensheathment (Figure 1.19 Challenge and Solution #2), the Leica SP8 Confocal system, 
Yokogawa CV7000, Operetta, Opera, and Opera Phenix were tested. The Yokogawa CV7000 
was eliminated due to the limitations in the objectives compatible with the 96-well 
microfibre plates, and the practical difficulties of accessing the system for further testing and 
imaging. The Operetta and Opera were excluded due to their incompatibility for 3D imaging. 
The Leica SP8 Confocal system with the MatrixScreener plugin is able to automate the 
imaging, but is not high content. The Opera Phenix appears to be the most promising in terms 
of high content imaging and resolution for 3D myelin sheath detection. 
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Due to transport issues of the plates from Roche in Basel, Switzerland, followed by ongoing 
severe myelination media problems due to the change in the commercial B27 supplement 
(ThermoFisher Scientific) and the batch-to-batch variability of the homemade B21 (Chen et 
al., 2008), I had limited scope in performing compound library screening in the 3D 
myelination assay during the available timeline of my PhD. However, from the experiments 
conducted, with limited scope for data interpretation due to the technical issues discussed, 
none of the three drugs tested, Clemastine, DAPT, or Roche’s Compound R, seemed to show 
statistically significant increases in myelin sheath length and number so far. One potential 
factor with the myelination assay was the possibility that in optimal myelination media, 
myelin sheath formation would be too efficient to detect increases beyond DMSO control. 
This issue was addressed by coating the fibres in fibrin, which has been shown by Petersen 
et al. (2017) to inhibit OPC differentiation into mature myelinating OLs, and may also be a 
clinically and therapeutically relevant inhibitor in MS. Culturing the OPCs on fibrin-coated 
microfibres showed the presence of extensive incomplete myelin sheath formation in some 
conditions. Although statistical analysis was not possible to compare fibrin-coating versus 
non-fibrin-coating results as only one biological replicate was able to be conducted, this 
shows early promise in potentially increasing the sensitivity of the assay in a clinically-
relevant manner in future experiments. 
As stated here and in Chapter 3, the lab had persistent problems with myelination media 
during the course of my PhD, which severely limited the work I could perform. The 
myelination media for the microfibre culture system, as developed by Bechler, Byrne and 
ffrench-Constant (2015), is based on neuronal-OPC co-culture media (such as Watkins et al., 
2008), requiring multiple components as listed in Chapter 2 (Materials and Methods), 
including B27. The commercial B-27TM Supplement (ThermoFisher #17504044) and the 
homemade B21 (based on NS21 (Chen et al., 2008)) were both optimised for use in neuronal 
cultures to support their growth and activity. It is therefore possible that these media 
components do not provide optimal conditions for oligodendrocyte differentiation and 
myelination, and that continued quality control has shifted B27 towards higher neuronal 
survival and activity which may not be as compatible for oligodendrocytes. An alternative 
media for oligodendrocyte myelination on microfibres is a B27-free low serum myelination 
media. However, serum is ill-defined, including undefined growth stimulating factors such as 
hormones (Barnes and Sato, 1980), and therefore increases batch-to-batch variability 
between different lots of serum in both cell growth and drug response. It is therefore 
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imperative to the continued progress of the microfibre culture system and the 96-well 
microfibre drug screening platform that a third ‘B27’ is optimised specifically for 
oligodendrocytes, which may include screening the components of the current homemade 
B21 to determine which are required for oligodendrocytes and remove superfluous, or 
potentially even unfavourable, components included specifically for neurons, and 
determining whether certain sources of media components are preferable for OLs like 
determined for BSA and transferrin for neuronal cultures by Chen et al. (2008). 
Some progress has been made in this goal. Subsequent to initial thesis submission, our lab, 
led by Dr. Marie Bechler, was able to test the various components of B21 and whether their 
removal affected myelin sheath formation in my 96-well microfibre plate. Different B21 
combinations were tested, including the removal of Glutathione, Sato, various combinations 
of Vitamin components, and lipids, as well as the use of an alternative Vitamin E source, and 
switching unbound apo-Transferrin to iron-bound holo-Transferrin, with transferrins 
functioning to mobilise iron. Out of the 24 combinations of B21 in myelination media tested, 
the use of holo-Transferrin appeared to give the best myelin sheath formation, although this 
was still poorer than the serum-free myelination media. This suggests an importance of the 
presence of iron in the myelination media. As reviewed by Todorich et al. (2009), iron is an 
essential trophic factor for vital cell functions in oxygen consumption and ATP production, 
with OLs having been shown to be a major source of iron accumulation and consumption in 
the brain and requiring sufficient iron to be acquired from external sources in a timely 
manner for normal myelination to occur. Infants with iron-deficiency anaemia have been 
shown to have increased latency in indirect markers of myelination, auditory brain stem 
potentials and visual evoked potentials (Algarín et al., 2003), and animal models of disrupted 
iron homeostasis have shown decrease in myelin proteins and lipids levels and loss of myelin 
compaction (Ortiz et al., 2004). With OLs having been shown to be able to produce transferrin, 
and its mRNA level increasing uniquely in the brain post-natally with OL maturation (Bartlett, 
Li and Connor, 1991; Bloch et al., 1985), iron is an essential component for optimal OL 
function, and suggests the reasoning behind why the availability of iron using holo-
Transferrin would improve the in vitro microfibre myelinating culture above apo-Transferrin. 
Using this variation of B21, my constructed 96-well microfibre plate, optimised 
immunopanned O4+ OPCs plating protocol, and compounds I had selected as positive 
(endothelin B receptor agonist BQ-3020 and PKCε agonist FR 236924 (Yuen et al., 2013; Swire 
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et al., 2019)) and potential negative (MAPK/ERK inhibitor UO126) regulators of myelin sheath 
formation, Dr. Marie Bechler prepared a plate on which these compounds and their 
respective controls had been tested, imaging performed by myself, and blind analysis for 
sheath length and number performed by Dr. Peggy Assinck (Figure 5.12). As shown in these 
preliminary results (n = 1), the endothelin B receptor BQ-3020, shown by Dr. Matthew Swire 
to increase myelin sheath number on microfibres in 12-well scaffolds (Swire et al., 2019), 
appears to potentially increase the number of myelin sheaths produced per OL in the 96-well 
microfibre platform. This gives early promise that pro-myelination compounds could be 
detected on these 96-well microfibre plates using the holo-Transferrin variant of B21 
myelination media, with further experiments being required to increase the number of 
biological replicates to confirm these initial findings and to determine a compound that 





Figure 5.12 Preliminary results from selected compounds tested on the 96-well microfibre 
plate using the holo-Transferrin variant of B21 myelination media 
A. Representative confocal images taken using the 25x water objective on the Leica SP8 confocal 
system manually for selected conditions: (1) the media control, (2) the control for BQ-3020 
(0.03M sodium bicarbonate), and (3) BQ-3020, which showed early results of potentially 
increasing myelin sheath number. 
The Cell Mask (for cytoplasmic staining) was included to improve the supervised machine 
learning CellProfiler pipeline as discussed in the ‘Discussion’. 
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B. The average number of myelin sheaths produced per MBP+ Hoechst+ cell per condition. 
Although FR 236924 and UO126 did not seem to increase or decrease myelin sheath number 
in comparison to the control, respectively, preliminary results comparing BQ-3020 to its 
sodium bicarbonate control show a potential increase in myelin sheath number. n = 1 





CHAPTER VI. LABEL-FREE RAMAN-BASED IMAGING OF MYELIN 
 
In the final stage of drug discovery for my PhD project, I explored imaging techniques that 
could be used to validate the compounds that have come up as hits in the 3D high-throughput 
single cell in vitro platform as potentially being pro-myelination in more complex in vivo and 
ex vivo models of myelination, and potentially be applicable for live imaging to track changes 
in in vivo and ex vivo mouse brains before and after treatment. In order to achieve this, I 
investigated the use of a label-free imaging techniques based on Raman spectroscopy, 
Coherent anti-Stokes Raman spectroscopy (CARS) and Stimulated Raman Scattering (SRS) 
microscopy techniques. Although its application in myelin imaging in itself is not novel, as 
mentioned in the studies described below, its use in drug discovery for myelination therapies 
would be a novel application of the technique and provide key benefits such as being label-
free and providing potential to track changes pre- and post-treatment. In this final chapter, I 
explored whether (1) label-free Raman-based imaging techniques could be used to detect 
myelin in live and fixed tissue, (2) quantification of myelin sheaths was feasible, and (3) if it 
could be applied to study the effect of a potential pro-myelination compound in vivo, 
including the investigation of whole brain imaging and deuterium labelling of newly formed 
myelin sheaths. 
 
6.1 Raman Spectroscopy 
 
Raman scattering was described by and named after the Indian physicist Sir Chandrasekhara 
Venkata Raman in 1928, who first observed the phenomena of inelastic scattering of light in 
organic liquids predicted by Adolf Smekal in 1923. Raman became the first Asian and first 
non-white recipient of a Nobel Prize for this discovery, with an award in Physics in 1930 
(Raman, 1928; Singh, 2002). Raman spectroscopy is a technique that measures the shift in 
energy that occurs due to inelastic scattering of light when a photon from the incident light 
produces a scattered photon when it interacts with matter (Figure 6.1). In Rayleigh (elastic) 
scattering, when the photon of light interacts with a molecule, there is a temporary transition 
to an increased virtual energy state followed by relaxation back to ground state as the photon 
is re-emitted in a scattered direction, and therefore no transfer of energy between the 
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photon and the molecule. However, in Raman (inelastic) scattering, which occurs only in 
approximately 1 in 108 photons, during this molecule and photon interaction, energy transfer 
results in the molecule releasing a different amount of energy to the incident photon as it 
equilibrates with its surroundings and relaxes via thermal relaxation. In Stokes scattering, 
energy is transferred to the molecule from the incident photon by nuclear motion, resulting 
in reduced energy and frequency of the scattered photon. In anti-Stokes, energy is 
transferred to the photon, increasing the energy and frequency of the scattered photon. As 
the shift in energy and the measured wavelength of the scattered light is dependent upon 
the chemical composition of the matter, and the intensity of the signal proportional to the 
quantity of the molecules, it can used to “fingerprint” the presence and concentration of 
molecular bonds in the sample (Ember et al., 2017; Rostron, Gaber and Gaber, 2016; 
Tarnowski and Morris, 2001). 
 
 
Figure 6.1 Jablonski-style diagram of energetic transitions in Raman 
Rayleigh scattering is described as elastic as the incident and scattered photon are of equal energy. In 
Stokes scattering, the scattered photon is lower in energy than the incident photon, whilst the reverse 
is true in anti-Stokes scattering where the scattered photon gains energy. 




Raman Spectroscopy has major advantages compared to complementary vibrational 
spectroscopy techniques like IR spectroscopy, particularly when it comes to biological 
samples and imaging. Raman requires minimal sample preparation for good spatial 
resolution (0.5 to 2μm) and spectral resolution (3-4cm-1, depending on the spectrometer). 
Unlike IR spectroscopy which is strongly absorbed by water, the Raman scattering intensity 
of water molecules is very weak and does not overwhelm the generation of more 
characteristic spectral data. Due to the rarity of Raman scattering occurring, the signal is 
inherently weak. Therefore, a number of Raman techniques have been developed to enhance 
the signal generated for various biological questions, including Surface enhanced Raman 
spectroscopy (SERS) that uses metal nanoparticles, usually gold for its biocompatibility, to 
increase the signal-to-noise ratio, or Spatially offset Raman spectroscopy (SORS) which 
detects diffuse Raman scattering to collect measurements from increased depth than can be 
penetrated by light. Of particular interest to my biological problem were Coherent anti-
Stokes Raman spectroscopy (CARS) and stimulated Raman scattering (SRS) (Ember et al., 
2017; Rostron, Gaber and Gaber, 2016; Tarnowski and Morris, 2001). 
 
6.2 Coherent anti-Stokes Raman Spectroscopy and Stimulated Raman 
Scattering Microscopy 
 
CARS and SRS, which overcome the low signal levels of spontaneous Raman and are typically 
used for imaging, are nonlinear optical processes that involve the use of two pulsed lasers 
rather than the conventional single continuous laser for Raman spectroscopy (Figure 6.2 A). 
The initial idea for CARS is attributed to P.D. Maker and R.W. Terhune, but was first 
constructed in 1982 by M.D. Duncan (Begley, Harvey and Byer, 1974; Duncan, Reintjes and 
Manuccia, 1982; Rostron, Gaber and Gaber, 2016). The first publication showing the use of 
CARS in biological samples, in Gram negative bacterium and HeLa cells, was published in 1999 
(Zumbusch, Holtom and Xie, 1999). SRS was initially accidentally discovered by Woodbury 
and Ng in 1962, and the theory behind its process described by Healthwarth (Rostron, Gaber 
and Gaber, 2016). The application of SRS in biological samples, including unstained cells, 
tissues, and drug delivery monitoring was first reported by Freudiger et al. (2008), and 
independently by Ozeki et al. (2009).  
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In CARS (Figure 6.2 A), the pump field (ωp) and Stokes field (ωs) are optically mixed and 
applied to a sample. If the frequency of the two beams (the ‘beat frequency’) is matched to 
the energy gap between the two vibrational energy states of a molecule (the molecular bond 
“fingerprint”), all of the molecules vibrate ‘coherently’ between these two energy states. A 
third beam (ωp) is used to excite the molecule to a ‘virtual’ vibrational energy state which 
emits a Raman-scattered photon (ωaS) as it relaxes back. The ‘coherent’ vibration results in 
constructive interference and therefore an increase in signal intensity in a quadratic manner 
(Ember et al., 2017; Fu et al., 2008; Potma and Xie, 2004; Rostron, Gaber and Gaber, 2016; 
Wang et al., 2005). By targeting the CH2 bonds abundant in lipid, CARS has previously been 
shown to be able to image the myelin fibres in the mouse brain (Figure 6.2 B) (Fu, T. Brandon 
Huff, et al., 2008) and in live spinal tissue of guinea pigs (Wang et al., 2005) in label-free and 
minimally-prepared samples. I therefore wanted to apply CARS to be able to image 
myelination and quantify myelin sheaths in unlabelled fixed and live brain samples, with the 
ability to image myelin sheaths in live samples being particularly interesting as this currently 
requires the use of transgenic animals with membrane-bound GFP labelling under the control 
of myelin-associated proteins such as MBP (i.e. Chong et al., 2012). 
The basic principle of SRS is similar to CARS (Figure 6.2 A); a pump and a stokes beams are 
applied to the sample, and when the frequency difference between the two lasers match the 
molecular vibration frequency of the bond, excitation of the molecule occurs. In SRS, this 
stimulated excitation results in the loss of intensity in the pump beam (stimulated Raman 
loss, SRL) and gain in the Stokes beam (stimulated Raman gain, SRG). To detect SRL/SRG, one 
of the beams in amplitude modulated, and the corresponding modulation in the other beam 
detected by using a lock-in amplifier. A benefit of using SRS over CARS is that SRL and SRG 
cannot occur when Δω does not match the molecular vibration, whereas in CARS, a signal is 
still generated at the anti-Stokes frequency due to off-resonant electronic transitions that 
also add coherently.  This non-resonant signal can interfere and overwhelm the CARS signal, 
especially in situations with low concentrations or weak resonances. Although SRS is not 
entirely free of background (Zhang et al., 2013), it is often more sensitive than CARS, and is 
therefore more appropriate for sparse labelling and imaging (Rostron, Gaber and Gaber, 





Figure 6.2 CARS and SRS Microscopy 
A. Schematic diagram of the energy levels for: (1) spontaneous Raman, where the pump beam 
(ωp) interacting with the sample results in a shifted signal (ωs) due to inelastic scattering; (2) 
SRS, where two lasers at frequencies ωp and ωs are tuned so that the frequency difference 
(Δω = ωp – ωs) is equal to the molecular vibration (Ω) being observed, and (3) CARS, which 
involves a complex four-beam mixing process to probe the anti-Stokes frequency (ωaS) so that 
ωaS = 2ωp - ωs and Δω tuned to the Ω. 
Figure from Tipping et al. (2016). 
B. CARS image of the mouse brain white matter, showing that the presence of myelin sheaths 
can be detected by targeting the CH2 molecular bond using CARS microscopy. 




6.3.1 Verifying the use of Coherent anti-Stokes Raman Spectroscopy (CARS) 
microscopy to detect myelin by targeting the CH2 bond 
 
Initially, we tested whether we would be able to detect myelin sheaths by using the 2845cm-1 
wavelength to detect the CH2 molecular bonds in lipid. Coronal brain sections from 6-week 
WT mice were stained with MBP for myelin and Olig2 for cell bodies (Figure 6.3 A). The 
standard staining protocol for brain sections use the detergent Triton X-100, which contain 
uncharged and hydrophilic head groups, as the permeabilising agent to non-selectively 
dissolve lipids from the cell membranes to make them permeable to antibodies. However, 
the removal of lipid would be incompatible with the sample preparation for CARS due to 
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requiring the lipid molecules to be present for the detection of myelin sheaths. I therefore 
developed an adapted staining protocol using saponin, which selectively removes cholesterol 
to make approximately 100Å holes in the membrane, as the permeabiliser to allow for 
intracellular antibody binding in the cholesterol-rich brain tissue (Jamur and Oliver, 2009). 
When simultaneous CARS signals was detected from the same brain sections in the same 
regions (Figure 6.3 B), the structures detected by MBP and CARS were almost identical, 
highlighting that detection of CH2 bonds by CARS preferentially picks up myelin in the brain. 
In order to test whether this was not due to cross-talk between the immunofluorescence 
channel and CARS or artefacts of the CARS imaging, coronal brain sections from the shiverer 
mutant mice with no compact myelin (Figure 6.3 C) and LPC-injected mice with focal 
demyelinated lesions (Figure 6.3 D and E) were also imaged as negative controls. As can be 
seen, no distinct CARS signals could be detected in the shiverer mutant brain slice (Figure 6.3 
C), and an absence of signal was seen in the location of the LPC-induced lesion (Figure 6.3 D), 
which included structures more similar to lipid droplets from the breaking down of myelin 
rather than sheath-like structures (Figure 6.3 E). 
An advantage of CARS is that as it is label-free, live imaging of brain slices for myelin may be 
possible. To test this, unlabelled live coronal brain sections from 6-week old WT mice were 
imaged by CARS. Imaging a live brain section using the same set-up as with the fixed tissue 
slices proved more difficult than expected due to the weaker integrity of the brain pre-
fixation. This resulted in the slices floating out of range of the working distance of the 
objective when suspended in media to keep them alive and prevent them from drying out, 
and becoming severely compressed and losing their structural integrity progressively over 
the course of an image being taken when a light weight (the same as with the fixed slices or 
lighter) was applied on top to keep them against the base of the imaging dish. There was 
therefore a need for balance in keeping the brain slices submerged in sufficient media to 
keep them alive and prevent drying out with the need to lightly compress the sections in 
order to have the section lay flat against the base of the imaging dish and reduce its 
movement for the duration of the imaging. I therefore came up with the solution to 3D print 
a 500μm-thick ring (with the technical assistance of Dr. Anthony Buchoux) and cut the live 
brain slices at 500μm on the vibratome, so that the coverslip would rest most of its weight 
on the ring rather than directly on the brain slice. Although the softness of the live brain when 
cutting meant that the brain slice was not precisely at 500μm, this set-up was able to reduce 
tissue motion and compression of the brain slice while preventing it from floating above the 
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working distance of the objective. Using this set-up, it was possible to image and detect 
myelin-like structures in the myelin-dense corpus callosum (Figure 6.3 F). 
 
 
Figure 6.3 CARS microscopy is able to detect myelin by targeting the CH2 bond 
A. Immunofluorescence-labelled 6-week WT male mouse fixed coronal brain slices at the corpus 
callosum. MBP labelling was used to detect OLs and myelin, and Olig2 for OL-lineage cell 
bodies. The circular structures appear to be cross-sections of wrapped myelin sheaths, and 
long structures of full internodes. n = 3 
B. The corresponding CARS image for A. Similar structures can be detected in the CARS image 
versus the immunofluorescence image. The differences between A and B are highlighted with 
blue (in A) and red (in B) arrows. 
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C. Shiverer mutant mouse fixed coronal brain slice of the corpus callosum and cerebral cortex 
regions. There appears to be no significant regions of CH2-positive CARS signal in this sample 
with no compact myelin formation. n = 4 
D. Fixed coronal brain slice of the corpus callosum of an LPC-injected mouse. The region along 
the corpus callosum with less intense CARS signal is the location of the demyelinated lesion. 
n = 1 with lesion out of 3 injected 
E. Higher magnification image of the region highlighted with the red box in B showing what 
appears to be lipid droplets but no distinct myelin sheath-like structures. 
F. CARS image of a live coronal brain slice at the corpus callosum. Myelin sheath-like structures 
can be detected even in the absence of immunofluorescence-labelling (no cross-talk) and 
without tissue fixation (feasibility of live imaging). n = 5 
Scale bars as labelled in individual images. 
 
Next, I wanted to test whether different densities of myelination and individual myelin 
sheaths could be detected and measured for sheath length. In order to do this, the corpus 
callosum from WT mice from 4 different time-points (P2, P6, P14, and P21) were imaged 
(Figure 6.4 A). The development of the corpus callosum could be observed using CARS, 
highlighting its ability to detect the increasing density of myelination in the predicted pattern 
(Wahlsten, 1984) at the time-points observed. To test whether individual myelin sheaths 
could be imaged and quantified, the cortical layers of 3-week WT mice were imaged, where 
there are sparser myelin sheaths than the corpus callosum with the highest density closest 
to the corpus callosum in layer VI, and decreasing density towards the upper layer II, and a 
layer of denser myelin sheaths in layer I. The different densities of myelin sheaths in the 
cortical layers of the sections were detectable by CARS (Figure 6.4 B), and individual myelin 
sheaths distinguishable (as shown in layers I-III) and quantifiable with the ‘Simple Neurite 
Tracer’ plugin on ImageJ (Figure 6.5 A). When the sheath length was measured from 2 
different animals from layers III to V, the regions where individual myelin sheaths was 
distinguishable by the plugin, the sheath lengths ranged from 30 to 120μm (Figure 6.5 B), the 
length of internodes in the cerebral cortex as has been previously reported by Chong et al. 
(2012), providing preliminary results that measurements of myelin sheath length can be 





Figure 6.4 Different densities of myelin sheaths, by age and cortical layer, can be detected 
with CARS microscopy 
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A. Tilescan images of fixed WT mouse coronal brain slices from different time-points: P2, P6, 
P14, and P21 (n = 2 per group). Increasing presence of the CH2-positive CARS signal in the 
corpus callosum and bright regions in the cortex can be seen with increasing age, as expected 
for their developmental progress (Wahlsten, 1984). 
B. Tilescan overview (top left) and higher magnification images of the cerebral cortex at various 
layers (layers I to III, layers IV to V, and layer VI) of a 3-week WT male mouse in fixed coronal 
brain slices, showing increasing density of myelin sheaths at the deeper cortical layers closer 
to the corpus callosum. The full length of a myelin sheath as detected by CARS is highlighted 





Figure 6.5 Individual myelin sheaths can be quantified using an ImageJ plugin and appear to 
be the expected range of sheath length for the brain region 
A. Myelin sheath length quantification was performed using the ‘Simple Neurite Tracer’ plugin 
on ImageJ. The image was adjusted by setting the brightness and contrast automatically at 
the brightest z-stack, and zooming to 200% (left). The ‘Simple Neurite Tracer’ plugin was used 
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to manually detect the two ends of a single myelin sheath (dark blue dots joint by yellow line, 
middle). The plugin automatically scanned in between the two dots to identify the path of 
the myelin sheath (light blue, middle) to predict the location and length of the myelin sheath 
(dark blue, right), which was then manually verified and accepted for sheath length 
quantification. n = 1 
B. Quantification of the lengths of myelin sheaths from layers III-V (where individual myelin 
sheaths can be detected) of 2 different 3-week WT male mouse from fixed coronal brain slices 
as described in A (on left). The sheath lengths from both animals ranged from 30 to 120μm, 
the expected internodal range for the cerebral cortex as reported by Chong et al. (2012) (on 
right). 
 
As live imaging and sheath length quantification is feasible using CARS, I next tested whether 
in vivo imaging of myelin sheaths may be possible by removing a whole brain from a 5-week 
male mouse and placing it onto the imaging dish with the cortex facing towards the objective. 
As shown in Figure 6.6 A, individual myelin sheaths can be detected clearly at 85μm, and as 
far as 120μm into the whole brain. However, CARS is limited by how far the light can 
penetrate the sample, with the dark shadows across the top being due to blood vessels 
obstructing the light. Considering that these brains would have become partially drained of 
blood due to its position on the imaging dish during the image acquisition, which would not 
occur if imaging through a cranial window in a whole animal, the depth of penetration in vivo 
would be significantly less with our current set-up. Alternative methods of tracking 
myelination, as discussed below with SRS microscopy and D2O labelling, was therefore 
explored. Additionally, it is possible to image sections of the spinal cord (Figure 6.6 B), 
although the resolution with the lenses available means that meaningful quantifications such 




Figure 6.6 CARS microscopy can image the whole adult mouse brain and the spinal cord 
A. Images from the z-stack of a whole 5-week male mouse brain. The depths at which the images 
were taken are written below, showing a working distance of approximately 120μm at which 
individual myelin sheaths are still visible. The blue triangles highlight the ends of the observed 
myelin sheaths. The dark shadow across the top of the image is most likely due to blood 
vessels obstructing light penetration to the underlying tissue, therefore limiting the working 
distance of imaging, especially in live in vivo animals. n = 1 
B. Composite image from two consecutive z-stacks from a fixed spinal cord slice of a 6-week 
male WT mouse, showing the feasibility of using CARS microscopy to visualise myelin in the 
spinal cord. The composite image was constructed from the z-stack sections where the slice 
was most in focus due to the spinal cord slice not laying completely flat during imaging. n = 2 
C. Higher magnification image from B, showing the circular cross-sections and long internodal 
structures of myelin sheaths. However, the resolution of the images with the objectives 
currently available in our set-up makes it difficult to distinguish the clear outlines of the cross-
sections of myelin sheaths. 
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6.3.2 Early exploration of Stimulated Raman Scattering (SRS) microscopy as an 
alternative method to distinguish newly formed myelin sheaths by labelling with 
deuterium (heavy) water 
 
As an alternative method for detecting myelin sheath changes to live time-point imaging 
would be to label newly formed myelin sheaths that were formed subsequent to the 
initiation of drug administration, and therefore more likely to have formed as a direct result 
of the treatment. The current technique for detecting new oligodendrocytes is through the 
crossing of two transgenic mouse lines: Pdgfra-creERT2 for transcriptional control under 
Pdgfra for OPCs and creERT2 so that they are tamoxifen-inducible and therefore the 
expression controllable, and a reporter line such as Rosa26-YFP for oligodendrocyte 
cytoplasm, showing cell bodies and processes (Rivers et al., 2008), or Rosa26-mGFP for 
membrane-bound labelling that allows myelin sheath tracking (Kang et al., 2010). However, 
the cost of producing and maintaining transgenic animals is high, and also restricts being able 
to track newly formed myelin to species where the production of transgenic animals is 
currently possible, i.e. specific mouse lines. The administration of heavy water (D2O) 
containing deuterium (heavy hydrogen, 2H) has previously been used in drinking water to 
label myelin for analysis of its turnover by mass spectrometry (Ando et al., 2003), and was 
more recently shown to also work with SRS by Shi et al. (2018). In their paper, they were able 
to show that HeLa cells incorporated deuterium, and that molecular bonds containing 
deuterium produced distinct Raman peaks to their hydrogen counterparts (Figure 6.7 A), 
allowing them to be targeted for Raman detection and imaging. 
Shi et al. (2018) were also able to show that animals fed D2O either indirectly through their 
mother’s milk as pups or through direct consumption as adults had deuterium incorporated 
into the brain. This was confirmed using SRS imaging on P11 animals at the internal capsule 
(Figure 6.7 B). Although individual myelin sheaths were not shown in their article, it is 
promising that deuterium is incorporated and is detectable in CH/CD bonds in the brain. As 
an alternative to expensive and complex transgenic and virus labelling, deuterium delivery 
through drinking water may therefore provide a relatively easy method to distinguish newly 
formed myelin sheaths through its incorporation into the CH2 bonds to form CD2 bonds, 
which would then have a different Raman molecular wavelength signature (2845cm-1 for CH2 
bonds versus 2141cm-1 for CD2 bonds). Due to the non-resonant background signals in CARS 
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microscopy, Stimulated Raman Scattering (SRS) microscopy was used for deuterium imaging. 
I wanted to test whether: (1) I could recapitulate the labelling of the brain with deuterium 
administration as D2O water, (2) verify whether the deuterium incorporation and signal was 
real, and (3) further test whether this could be used to detect individual myelin sheaths for 
future experiments in labelling newly formed myelin sheaths in a demyelination and 
remyelination model of MS for drug testing. 
 
 
Figure 6.7 Stimulated Raman Scattering (SRS) microscopy is able to distinguish between CH 
and CD bonds and has been shown to be incorporated into the brain 
A. SRS microscopy images of HeLa cells cultured in 70% D2O medium 5 minutes and 24 hours 
after medium addition, showing the absence and subsequent increase in C-D detection from 
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deuterium incorporation into lipids and proteins, versus non-deuterium-related C-H 
detection. The Raman spectrum shows the shift in Raman peak between C-H (2940cm-1) and 
C-D (2160cm-1), allowing their distinct detection. 
Figure adapted from Shi et al. (2018). 
B. SRS microscopy images from the internal capsule of mouse brains. Pups (P5 and P11) were 
fed on the milk of animals drinking 25% D2O for 6 days, and adult animals were fed 25% D2O 
water for 9 days prior to imaging. CD bonds can be detected in the internal capsule of P11 
animals, showing the incorporation of deuterium labelling in the brain and in the same areas 
as the SRS signals for CH bonds. 
Figure adapted from Shi et al. (2018). 
 
Mice from the same litter that had been weaned, at P23, were divided into two groups: one 
group receiving 70% deuterium water mixed with 30% normal drinking water (D2O group), 
and the other receiving normal drinking water (H2O group). Water drinking was otherwise 
not controlled and restricted, with the water bottles from each group measured daily by the 
SCRM animal facility technician to ensure levels of water drinking was not impacted by the 
presence of deuterium. The mice were kept on this water for 2 weeks to allow sufficient time 
for deuterium incorporation and as it would be a similar length of time used for future 
potential LPC remyelination experiments, after which they were perfused and their organs 
removed. As shown in Figure 6.8, deuterium appears to have incorporated into the D2O mice 
but not the H2O animals in both the corpus callosum and cortex. Although the data is still too 
preliminary to draw any conclusions from yet, interestingly, the signal intensity of the 
deuterium in the corpus callosum was relatively weak compared to the cortex, with the 
corpus callosum reaching myelination maturity earlier than the cortex. In addition, the 
locations of the highest deuterium signals as detected by CD2 bonds correlated to the 
locations of the myelin sheaths detected using CH2, suggesting that they were preferentially 
incorporated into myelin sheaths. This suggests a preliminary proof-of-principle (n = 2 for 
each group with 2 weeks of deuterium water feeding, and additional n = 1 for 1 week of 
heavy water administration (data not shown)) that we are able to recapitulate the deuterium 
labelling of the brain, and that it may be preferentially incorporated into the lipid-rich myelin 
at regions of increased myelination at the time of heavy water administration. This supports 
the potential for further samples to be prepared to verify these concepts, and the 
requirement for examples of deuterium-labelled and non-labelled myelin sheaths in the 
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cortex of deuterium-fed animals to confirm whether deuterium was preferentially labelling 







Figure 6.8 Deuterium signal is only detected by SRS in the brain of the animal fed deuterium 
water 
SRS images for CH2 and CD2 (as labelled) from WT mice fed 70% deuterium water from P23 for 2 weeks 
(top panel) and from animals fed normal water (bottom panel), with the corpus callosum on the left 
and cortex on the right for each condition. n = 2 
The top row are images from detecting the CH2 molecular bond for lipid. The bottom row is the images 
for the CD2 molecular bond based on intensity of the SRS signal with the off-resonant background 
subtracted  The calibration bar for signal intensity is in the figure, with white being the highest intensity, 
and black being no signal. 
Note the weak CD2 signals of the deuterium-fed animals in the corpus callosum, where there would 
be reduced active myelination at the stage when heavy water was administered, and the stronger 
signals in the actively myelinating cortex, with apparently increased CD2 intensity at the locations of 
myelin sheaths as detected with the presence of CH2 bonds. The lack of CD2 signals in the non-deterium 
water-fed animals confirms that the signal detected in the deuterium water-fed animals is likely due 
to the incorporation of 2H. 
Scale bar as shown on image (50μm). 
 
In order to confirm whether the signal we were obtaining from the deuterium samples were 
true, incremental step changes in the wavelength between 850 to 870nm were obtained, 
and the peaks of the signal intensities plotted using ImageJ. As shown in Figure 6.9 A, two 
peaks were identified, with the first peak at approximately 863nm, which lines up with the 
CD3 protein molecular bond, and the second peak at 866nm, at the CD2 lipid bond. In addition, 
Raman spectroscopy was also performed on the corpus callosum of the D2O slices (Figure 6.9 
B and C) on the Renishaw Raman spectrometer/microscope. Measurements were taken 
between 2500cm-1 and 3300cm-1 to detect the CH2 bond at 2845cm-1 (and CH3 at 2930cm-1) 
(Figure 6.9 B) and between 1700cm-1 and 2600cm-1 to detect the CD2 bond at 2141cm-1 (and 
CD3 at 2189cm-1) (Figure 6.9 C). The resulting spectra was corrected on the WiRE software 
with the help of an experienced Raman spectrometrist (Katie Ember, Forbes (SCRM) and 
Campbell (School of Chemistry) Labs). Firstly, the cosmic rays, which are high energy particles 
that produce false peaks, were removed by processing features that had the width of 3 and 
height of 13, or width of 4 and height of 12 (AU). Then, the baseline of measurement was 
adjusted by changing the polynomial order between 3, 5, and 8 and taking the lowest value 
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to remove the baseline without introducing an artefact. Lastly, Principal Component Analysis 
was performed, and the PCA with the closest fit to the expected spectra taken as the 
reference to compare our spectra with. Although the signal intensity was approximately 100-
fold lower, a potential peak at the CD2 bond was also detectable by Raman spectroscopy, 
with the shape and position of the peaks also matching well to Figure 6.9 A. These initial 
measurements (n = 1 for each) further indicated that deuterium appears to be incorporated 
into the brain, further highlighting the potential for future experiments in order to validate 





Figure 6.9 Measurements taken on the SRS microscope and Renishaw Raman spectrometer 
show evidence towards the incorporation of deuterium into the brain 
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A. Measurements taken with the SRS microscope used for Figure 6.8 between 860 to 870nm, 
the expected range at which the deuterium signal should be detected, show increased signal 
at two peaks. The left peak lines up to the CD3 protein molecular bond, and the right peak the 
CD2 lipid molecular bond. n = 1 
B. Raman spectroscopy of 2500cm-1 to 3300cm-1 from the corpus callosum of the deuterium 
water fed mice to detect the CH2 molecular bond located at 2845cm-1. n = 1 
The blue line represents the Principal Component Analysis (PCA), and the red line the cosmic 
ray and baseline-adjusted Raman measurement from the tissue sample. 
The black box highlights the location of the peak for CH2, and a magnified image of this region 
of the spectroscopy graph shown below. 
C. Raman spectroscopy of 1700cm-1 to 2600cm-1 from the same brain slice and region as B to 
detect the CD2 molecular bond located at 2141cm-1. The signal was less intense than that for 
the CH2. n = 1 
The black box highlights the location of the peak for CD2, and a magnified image of this region 
of the spectroscopy graph shown below. 
 
Lastly, to test whether the signals obtained in the brain samples were not an artefact, SRS 
imaging was performed on other organs of the same animals, including the liver (Figure 6.10 
A), fat cells from the lower abdomen (Figure 6.10 B), pancreas (Figure 6.10 C), and kidney 
(Figure 6.10 D). This confirmed that the structures identified by CH2 imaging were also 
observed with CD2, especially prominent in the pancreas and kidney due to their distinct 
morphology. Although some “signals” were detected in the H2O negative controls, repeated 
measurements of the same region confirmed that these non-specific “signals” were due to 
artefact from the tissue moving during and in between imaging as the lasers were being 
switched from D2O to off-resonance, which took a few minutes, and therefore being detected 
as “differences” between the D2O and off-resonance images in the subtraction, as well as 
another potential source being background noise (Zhang et al., 2013). The incorporation of 
the deuterium in the lipid-dense fat cells was particularly interesting to my question due to 
the composition of myelin sheaths being predominantly lipid. These samples therefore added 
confidence, although preliminary (n = 1 for each group) at this point, to the seeming 
incorporation of deuterium by the organs and its specific detection by SRS. SRS combined 
with deuterium labelling, based on these early results, therefore may be a viable option for 
further experiments to confirm its use in newly formed myelin sheath quantification in in vivo 
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demyelination and remyelination in the presence of remyelination-promoting compounds, 
with remyelination being detected by deuterium labelling. 
 
 
Figure 6.10 Deuterium-labelled and non-labelled sections from other organs confirm the 
specific incorporation and signal detection in the deuterium administered animal only 
Deuterium-labelled and non-labelled slices from A. the liver, B. fat, C. the pancreas, and D. kidney (n = 
1-2 per organ per group). Low to mid signal intensities were detected in the liver, pancreas, and kidney, 
whereas high signal intensity was detected in the fat of the deuterium-labelled animals for the CD2 
bond (calibration bars in figure). Low to no signals were detected in the non-labelled slices as expected. 
The low signals in these samples may have appeared due to potential background noise, and due to 
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the slice moving in between the imaging for the deuterium and the off-resonance wavelengths, 





In order to explore an imaging technique to validate hits from high-throughput drug screens 
in more relevant ex-vivo and in vivo models, I explored the use of label-free CARS and SRS to 
validate the hits in an ex vivo and in vivo system (Figure 1.20 Challenge and Solution #4). 
CARS microscopy could be used to detect myelin in fixed and live ex vivo slices by targeting 
the CH2 bonds that are abundant in lipids, and showed preliminary results as being able to 
be used to quantify myelin sheath lengths in fixed slices. The potential for live in vivo imaging 
was explored by imaging through the upper layers of the cortex of a whole mouse brain that 
had been removed from the animal (Figure 6.6), with a prospective use being for time-point 
quantification of myelination changes in the presence of potential pro-myelination 
compounds. In order for longitudinal in vivo live CARS imaging to be performed, invasive 
surgical procedures would need to be performed to implant a cranial window or thin the skull, 
and potentially expose the underlying brain tissue to more meaningful regions, such as the 
corpus callosum for LPC injected models of demyelination, in order to be able to artificially 
achieve the working depth. Not only would this impact animal survivability post-surgery, the 
formation of scar tissue and related blood deposition would complicate subsequent imaging 
and reduce the optical penetration (Fu et al., 2008; Shi et al., 2011), as well as likely impacting 
the biologically relevant regeneration process of the potential pro-remyelination compound 
versus post-surgery healing. In addition to the impact of motion artifacts when imaging the 
brain due to vital functions such as breathing and the beating of the heart that needs to be 
accounted for with in vivo imaging (Shi et al., 2011; Paukert and Bergles, 2012), the working 
depth of CARS for live in vivo imaging, limited by the depth of penetration of light, as well as 
the repeatability of imaging the same regions with post-surgical complications to consider, 
especially if the region of interest is well below the upper cortical layers, would prove to be 
challenging to overcome. 
I therefore started to explore an alternative method by which an animal could undergo 
demyelination, such as by LPC injection to form a demyelinated lesion, and deuterium water 
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given to label newly formed myelin sheaths in the presence or absence of the potential pro-
myelination compounds identified in the high-throughput screen. Although further 
verification is required to confirm the results obtained thus far by increasing the number of 
biological replicates, initial tests seem to suggest that deuterium is incorporated into the 
brain after 2 weeks of drinking 30% deuterium water, that the signal detected by SRS is likely 
specific for deuterium, and that there may potentially be preferentially higher intensity of 
deuterium signal in myelin sheaths in the brain. Although still early in the validation process, 
this highlights the future promise of the use of this technique to potentially specifically label 
and detect newly formed myelin sheaths using deuterium administration. 
 
6.3.1 Implications of the Raman-based imaging and deuterium water labelling 
 
Currently, the ability to detect newly formed myelin sheaths is restricted to the creation of 
double-transgenic mouse lines, such as the Pdgfrα-creERT2 x Rosa-mGFP (Kang et al., 2010). 
One of the considerations of this is the cost. In order to obtain the animals required to 
perform a set of experiments, as estimated with the guidance of Dr. Peggy Assinck from our 
lab, who uses this double-transgenic animal line, and Vince Ranaldi, Senior Research Support 
Manager of the University’s Bioresearch & Veterinary Services, you need to purchase a male 
and female Rosa-mGFP transgenic mouse line and a male and female Pdgfrα-creERT2 mouse 
line. Similar transgenic animals on the Jackson Laboratory website range from £300-800 per 
animal, and costs between £1500-2000 for the breeding pair plus shipping, and a further 
£600 for the quarantine holding and screening, totalling up to £2,500+. A male and female 
need to be obtained from each of these breeding pairs to obtain at least 3 sets of breeding 
pairs for cross-breeding, which would result in approximately 18 pups total, of which 6 would 
likely be double-transgenic and therefore usable in the experiment. Each of these breeding 
pairs and male and female pups would need to be kept in separate cages, and the entire 
breeding process would take approximately 6 months, with each cage costing about £2-3 per 
day, or £7.21 maintenance costs per week excluding estates, throughout this entire process. 
A further cost would be incurred when the successfully breeded double-transgenic animals 
are induced with tamoxifen to label the newly formed myelin, which requires once a day 
injection for 5 days, for approximately £40 for 6 animals. For reference, the maintenance of 
Peggy’s Pdgfrα animals requires 40 to 50 cages per line per week, and cost £1,500 in 
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maintenance alone for 4 weeks. In contrast, my deuterium water labelling experiment was 
performed through a wild-type pregnant female mouse, and the pups separated into two 
different cages to be given either normal or deuterium water once they were weaned with 
no additional breeding time required. A wild-type C57BL/6 female with a litter costs about 
£110 from Envigo, and the SCRM facility charges £15 per wild-type adult mouse, plus the 
£7.21 maintenance per week. Although exact pricing per experimental animal or for a set of 
experiment is difficult to calculate due to the multitude of factors that influence the actual 
costs, the estimated cost of obtaining one litter of double-transgenic animals is in the £1000s, 
whereas it is in the £100s using the deuterium method. Although access to the method is 
restricted by the availability of a CARS/SRS microscope, deuterium-labelling could provide a 
cheaper and non-invasive method for labelling newly formed myelin and other hydrogen-
dependent processes should this pre-requisite be met. 
A potentially more significant implication for the deuterium water labelling of newly formed 
myelin is its potential for application in non-mouse models of myelination. Due to our current 
ability to create transgenic animals being restricted mostly to mice, the double-transgenic 
technique of labelling newly formed myelin sheaths is currently limited to one species in 
mammals. The ability to observe this process in rats would open up the possibility of 
correlating the myelination process with more sophisticated behavioural studies than 
possible in mice. Myelination has also been studied in larger mammals, including in pigs in 
traumatic spinal cord injury (Kim et al., 2018), and in models of MS in guinea pigs, rabbits, 
and non-human primates (’T Hart et al., 2000; Brok et al., 2008). The autoimmune EAE 
models in common marmoset and rhesus monkeys in particular better recapitulate the 
clinical and neuropathological heterogeneity seen in MS patients that are poorly represented 
in the more stereotypical rodent models (Brok et al., 2008). They may therefore provide a 
better insight into the myelination process in a disease model of MS beyond what we can 
currently infer from rodent models by studying them using the minimally-invasive deuterium 
labelling technique. In addition, as potentially both a limitation and benefit, as the deuterium 
labelling is non-specific for myelin labelling, it could be used to observe other organs and 
hydrogen-dependent processes in the animal and therefore represent a significant 
contribution to the Three Rs (Replacement, Reduction and Refinement) in animal research, 
especially with the larger mammals. 
231 
 
CHAPTER VII: DISCUSSION 
 
7.1 Summary of results 
 
As discussed more extensively in ‘CHAPTER I. LITERATURE REVIEW’, the existing disease-
modifying treatments for MS are aimed towards modulating the immune response to 
suppress and prevent new inflammatory attacks and the formation of new lesions, therefore 
being most efficient in RRMS (Filippini et al., 2013; Mulero, Midaglia and Montalban, 2018), 
while not being able to target the non-inflammatory degenerative phase of the disease. The 
majority of current published high-throughput phenotypic drug screens to discover 
remyelination therapies have been focused on discovering pro-differentiation compounds by 
using antibody-based markers of endogenous MBP and the detection of increased numbers 
of MBP+ OLs as their primary output (Deshmukh et al., 2013; Eleuteri et al., 2017; Lariosa-
Willingham et al., 2016a, 2016c; Mei et al., 2014; Najm et al., 2015). However, recent data 
indicate that a more complex interplay between oligodendrocyte biology and the 
pathophysiology of MS exists beyond simple differentiation of oligodendrocyte precursor 
cells. For example, there is evidence towards MS lesions containing premyelinating OLs that 
have differentiated but have not produced complete myelin sheaths (Chang et al., 2002). In 
addition, single-cell transcriptomic analysis of OL lineage cells from an EAE model of MS 
showed a skewing of OLs towards immunomodulating roles (Falcão et al., 2018), and post-
mortem control versus MS brain tissue showed a shift of OL subclusters towards immature 
and intermediate populations of oligodendrocytes in MS (Jäkel et al., 2019), rather than the 
simple absence of differentiated oligodendrocytes that could myelinate. Based on these 
studies it could be argued that a broader variety of more physiologically-relevant high-
throughput phenotypic drug screening assays are required to support a more clinically 
relevant platform for remyelination drug discovery in MS. 
For my PhD project, I therefore identified a clinical need in the lack of remyelination therapies 
in treating MS, and the biological problem in current drug screens not targeting the key 
myelination phase in OL development and only being able to recapitulate the differentiation 
phase in vitro. In order to address these issues, I came up with a bioengineering solution to 
be able to construct a high throughput-compatible phenotypic drug screening platform in 
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which we would be able to identify compounds that influenced myelin sheath formation. 
First, in order to validate the difference between 2D differentiation and 3D myelination 
assays, I tested whether (1) pro-myelination compounds increased differentiation in 2D 
assays, and (2) pro-differentiation compounds increased myelination in 3D assays. As 
discussed in Chapter 3, Benztropine (Deshmukh et al., 2013) and Clemastine (Mei et al., 2014) 
were detected to statistically significantly increase differentiation at certain concentrations 
when tested on our 2D flat culture system. However, based on early results due to 
myelination media issues resulting in a low number of usable biological replicates, the pro-
myelination compound, small molecule PKCε activator FR236924 (Swire et al., 2019), did not 
seem to increase differentiation in the 2D assay. In addition, when the pro-differentiation 
compounds were tested on the 3D microfibre culture system, none of these compounds 
increased either myelin sheath length or number. Collectively, these data provide preliminary 
evidence, which increasing the number of biological replicates in the correct batch of B21 for 
the myelination media could further support, towards the idea that (1) pro-differentiation 
screens may not necessarily identify pro-myelination compounds, and (2) pro-differentiation 
compounds may not also be pro-myelination, and therefore validate the development of 
more complex and better in vitro cell models for MS in high-throughput drug discovery. 
The first stage in the development of a high throughput-compatible drug screening platform 
to allow for a more disease-relevant cell model was the bioengineering of a 96-well plate 
with suspended microfibres to miniaturise the 3D myelination microfibre system as 
previously described by Bechler, Byrne and ffrench-Constant (2015) and Lee et al. (2012, 
2013) (‘CHAPTER IV. CONSTRUCTION OF A HIGH-THROUGHPUT-COMPATIBLE 96-WELL 
MICROFIBRE PLATE’; Figure 7.1 Challenge and Solution #1). I was able to achieve this by 
optimising the electrospinning process using 10% poly-L-lactic acid (PLA) dissolved in 
hexafluoroisopropanol (HFIP) to control the fibre diameter, and by using a moving needle 
and a rotating collector covered with release paper for equal distribution and easy transfer 
of fibres. The sheet of electrospun fibres was then inserted into the base of a 96-well plate, 
and sealed and suspended with layers of adhesives above the optically-compatible cyclic 
olefin copolymer (COC) film as the base. As described in ‘CHAPTER V. VERIFICATION OF THE 
HIGH-THROUGHPUT 96-WELL MICROFIBRE PLATE PLATFORM’, OPCs purified by 
immunopanning, rather than mechanical isolation from mixed glia cultures, resulted in the 
lower appearance of contaminating cells, with plating at the density of 6-8,000 cells per well 
being optimal to detect individual oligodendrocytes and their respective myelin sheaths. 
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Although ongoing media issues restricted the extent to which the platform could be used to 
screen compounds during the scope of my PhD, I was also able to show that the plate appears 
to be compatible with high-throughput liquid-handling robots such as the Thermo Fisher 
MultidropTM and BioTek LS405 multiplate washer, and more suitable for high content imaging, 
such as on the Opera Phenix, than any similar products that are commercially available 
(Figure 7.1 Challenge and Solution #2). Preliminary results also suggest the potential of being 
able to adapt the assay to increase the sensitivity with fibrin coating. 
Lastly, I explored a label-free imaging technique that could be used to validate the pro-
myelination compounds that are identified from the 3D myelination 96-well microfibre assay 
in more complex in vivo and ex vivo models of myelination (‘CHAPTER VI. LABEL-FREE 
RAMAN-BASED IMAGING OF MYELIN’; Figure 7.1 Challenge and Solution #4). By targeting the 
CH2 bonds that are abundant in lipids, Coherent anti-Stokes Raman Spectroscopy (CARS) 
microscopy could be used to detect myelin in fixed and live ex vivo slices, and quantify their 
lengths in fixed slices. Although live in vivo imaging is restricted by the depth of penetration 
of light required for CARS microscopy, early results using Stimulated Raman Scattering (SRS) 
microscopy and deuterium in drinking water suggests that the 2H in deuterium may be 
incorporated into the myelin sheaths in the brains of these mice. Although extremely early 
in the validation process with increased numbers of biological replicates required to confirm 
initial observations, this preliminary result is promising as it suggests that it may be possible 
for an animal to undergo demyelination, and be simultaneously given the potential pro-
myelination compound and deuterium water to label the newly formed myelin sheaths that 
are formed during treatment and remyelination, and subsequently allow us to assess the pro-






Figure 7.1 Project overview of the high-throughput screening for remyelination treatment in 
MS 
The main high-throughput drug screening challenges of my thesis as introduced in the ‘CHAPTER I. 
LITERATURE REVIEW‘, and the corresponding solutions explored throughout my project. 
1. ‘CHAPTER IV. CONSTRUCTION OF A HIGH-THROUGHPUT-COMPATIBLE 96-WELL MICROFIBRE 
PLATE’: The bioengineering of high-throughput-compatible 96-well plates with suspended 
electrospun microfibres. 
2. ‘CHAPTER V. VERIFICATION OF THE HIGH-THROUGHPUT 96-WELL MICROFIBRE PLATE 
PLATFORM’: The imaging of the 3D myelin sheaths on the microfibres with the resolution to 
determine complete ensheathment. 
3. The quantification of complete myelin sheath formation, with the high-throughput 
automated pipeline using CellProfiler image analysis software being in development by Dr. 
Marie E. Bechler in collaboration with Dr. Beth A. Cimini and Professor Anne E. Carpenter of 
the Broad Institute. 
4. ‘CHAPTER VI. LABEL-FREE RAMAN-BASED IMAGING OF MYELIN’: The verification of CARS and 
SRS as label-free techniques of ex vivo myelin sheath imaging and quantification, with in 
progress exploration of deuterium to label newly formed myelin. 
(Figure adapted from ScideLight and Potma and Xie, 2004) 
 
7.2 Future prospects 
 
Due to the severe myelination media issues incurred during the PhD, there were limitations 
to the compound screens that could be performed and the optimisation of assay 
reproducibility. In the next stages of this research, once the myelination media issues have 
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been resolved, with several potential methods of resolution currently being explored and 
acted upon as discussed at the end of Chapter 5, there are various methods that could be 
explored to increase the reproducibility and throughput of the assay: 1) the incorporation of 
more liquid-handling robots into the high-throughput pipeline, 2) improved high content 
imaging platform, 3) the use of an automated image analysis pipeline, 4) the application of 
more physiological substrates to the electrospun fibres, 5) the optimisation of myelinating 
human cells on the microfibres, and 6) the development of the Raman-based imaging 
strategies as discussed in Chapter 6. 
As discussed in the chapter, the ThermoScientific MultidropTM and BioTek LS 405 microplate 
washer is compatible with the 96-well microfibre plate for plating, fixing, and staining. The 
Integra VIAFLO 96 is a power-assisted handheld microplate pipetting robot that enables the 
pipetting and transfer of liquids from 96 wells simultaneously. The use of this robot would 
increase the speed and accuracy of pipetting during media changes and drug additions, with 
4 to 5 changes required for the 14 days of culturing. This would increase the accuracy of 
compounds/DMSO added and the throughput of the assay, and decrease the amount of time 
the plates are out of the incubator (set at 37°C and 7.5% CO2) and in an uncontrolled 
environment. 
The PerkinElmer Opera Phenix imaging platform is also promising to increase the imaging 
capabilities and throughput beyond the limitations of the Leica SP8 MatrixScreener. This 
imaging system uses an advanced spinning-disk technology, called SynchronyTM Optics, which 
reduces the spectral cross talk between different lasers to allow up to 4 channels to be 
imaged simultaneously, and has an increased pinhole-to-pinhole distance which reduces 
spatial cross talk, an essential aspect for 3D imaging (Li et al., 2016). The Opera Phenix has 
been reported to have been used for complex 3D cellular models, such as the quantification 
of nuclei in hiPSC-derived 3D cardiac spheroids (Christoffersson et al., 2018), and is therefore 
extremely promising in increasing the speed and throughput of the imaging in the 96-well 
microfibre myelination assay. 
Lastly, in addition to the imaging, a major hurdle in increasing the throughput of the 3D 
myelination assay is image analysis, which currently requires manual quantification on Fiji. 
Dr. Marie Bechler in our lab has been working in collaboration with Dr. Beth A. Cimini and 
Professor Anne E. Carpenter, from the Broad Institute of MIT and Harvard, to develop a 
CellProfiler pipeline with machine learning targeted towards the automated quantification 
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of complete myelin sheath formation on the microfibre culture system (Figure 7.1 Challenge 
and Solution #3). As summarised in Figure 7.2 A, the pipeline takes the maximum projection 
of the original image, segments it, and then classifies what it has been taught with machine 
learning as complete myelin sheaths. The pipeline is currently able to perform this with 85% 
accuracy (Figure 7.2 B), and is able to detect the difference in the area of complete myelin 
sheaths produced by cortical- and spinal cord-derived oligodendrocytes on the microfibre 
culture system as previously reported by Bechler, Byrne and ffrench-Constant (2015) (Figure 
7.2 C). As the pipeline was developed and the machine learning performed on 
oligodendrocytes cultured on the 12-well microfibre scaffolds, mounted in Fluoromount G, 
and imaged with the 40x objective on the Leica SP8 imaging system, there will likely be 
differences in the segmentation and classification of myelin sheaths in 96-well plates filled 
with PBS, with images taken on the PerkinElmer Opera Phenix system. However, with 
adjustments and re-training of the CellProfiler pipeline with images taken on the Opera 
Phenix system, we should be able to significantly increase the throughput of the image 





Figure 7.2 CellProfiler pipeline with supervised machine learning for automated image 
analysis shows 85% classification accuracy for myelin sheaths and the ability to detect 
increased myelin sheath formation 
A. The stages of image processing by the CellProfiler pipeline: (1) Maximum projection of the 
original z-stack image, (2) segmentation, (3) classification into myelin sheaths, cell bodies and 
processes, multiple objects, and incomplete myelin sheaths. 
B. The comparison of classification between a human expert (Dr. Marie Bechler) and the 
CellProfiler pipeline with supervised machine learning, showing 77% overall accuracy and 
85% accuracy in detecting complete myelin sheaths. 
C. The quantification of the average myelin sheath area per oligodendrocyte between cortical- 
and spinal cord-derived oligodendrocytes, showing the ability to detect the increased myelin 
sheath produced by spinal cord OLs as previously reported by Bechler, Byrne and ffrench-
Constant (2015). 
This CellProfiler pipeline and the supervised machine learning was performed by Dr. Marie 
Bechler (ffrench-Constant Lab), and Dr. Beth A. Cimini and Professor Anne E. Carpenter 
(Broad Institute of MIT and Harvard) 
 
The 96-well microfibre plates produced in this thesis provides a basis for the ability to 
perform high-throughput screens in a more phenotypically-relevant 3D model than the 
current standard 2D flat culture screens. However, our drug screening platform still faces one 
of the key limitations of current disease models, which often lack the disease-relevant 
substrates and bioengineering tools to better recapitulate the mechanical and physiological 
environment that the cells are exposed to in vivo (Horvath et al., 2016). Using a technique 
called atomic force microscopy, which uses a cantilever across a surface to measure its 
deflection, the mechanical property of a PLA fibre was measured to be approximately 10GPa 
(Iqbal et al., 2015), whereas it is in the range of less than 7.5kPa in the neurite of fixed rat 
tissue and between approximately 50 to 300Pa in live rat hippocampal slices (Spedden and 
Staii, 2013), making the stiffness of the electrospun PLA fibre in the orders of magnitudes 
higher than in vivo. One method of tackling this would be to use another polymer, such as 
poly-glycerol-dodecanoate (PDG), which has distinct temperature-related properties, with its 
mechanical properties being approximately 1 MPa at 37°C (Migneco et al., 2009), the 
temperature at which the cells are cultured, with PDG also being shown to be biocompatible 
and compatible with electrospinning (Dai and Huang, 2014). Although these values are still 
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higher than neurons, the stiffness of PDG is approximately 10,000x lower than that of PLA, 
making it 10,000x stiffer than live brain tissue (calculated at 100Pa for this comparison) 
versus 100,000,000x. By additionally coating the fibres with matrigel (Dai and Huang, 2014), 
it may be possible to bring the mechanical stiffness of the electrospun fibres down even 
further. In targeting the physiological environment, it has recently been shown that it is 
possible to combine the decellularisation of human liver tissue with electrospun polymers to 
create a more physiologically relevant niche for hepatocytes (Grant et al., 2019). It may 
therefore be feasible to combine this technique with brain tissue and our electrospun fibres 
to create a more physiologically-relevant environment, either by using control brain tissue or 
even brain tissue from models or patients of MS in increasing the predictive validity by 
creating a more physiologically-relevant model, and therefore increasing the positive 
predictive value in drug discovery. 
Another aspect for consideration in enhancing the disease modelling is through the use of 
human cell models (Horvath et al., 2016). It has already been shown that it is possible to 
obtain human oligodendrocytes from pluripotent stem cells that show maturation-specific 
physiological and transcriptomic properties (Livesey et al., 2016; García-León et al., 2018), 
that this can be performed using patient-derived samples including MS (Livesey et al., 2016; 
García-León et al., 2018), and can be adapted to be high-throughput-compatible (García-León 
et al., 2018). The current fibre culture system has been optimised for rodent-derived cells, 
and the human pluripotent stem cell-derived oligodendrocytes for single cell 2D flat-culture 
or in neuronal co-cultures. However, with the optimisation of the appropriate myelination 
media and culture conditions and further development of its robustness for 3D in vitro 
myelination, it has already shown a degree of flexibility in working with control and patient-
derived cells and scalability by García-León et al. (2018) to be feasible to use in high-
throughput drug screens with improved cellular models of physiological and clinical 
relevancy than the current model developed in this thesis for future development. The ability 
to use patient-derived cells may offer the potential for personalised medicine in screening 
for the compound that is most likely to show pro-remyelinating effects on a patient-specific 
level from a selection of approved treatments in the future. 
The next major step in the CARS/SRS imaging with deuterium labelling would be to verify its 
presence in specifically newly formed myelin sheaths. This could be performed using two 
main methods: (1) by creating a focal lesion using LPC and detecting whether there is a higher 
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degree of deuterium labelling at this site of demyelination and remyelination, or (2) by co-
administering tamoxifen and deuterium water to the Pdgfrα-creERT2 x Rosa-mGFP double-
transgenic mouse line (Kang et al., 2010) during developmental myelination or remyelination 
to detect newly formed myelin sheaths as confirmed by the GFP labelling and correlating to 
the SRS deuterium signal as validation. These techniques, in particular the latter, would 
justify the use of the less invasive and cheaper deuterium labelling technique to the myelin 
research community in its acceptance as a viable method. In addition, as shown in Chapter 
6, although deuterium seems to be detectable in individual myelin sheaths, the signal 
intensity, due to the lower presence of CD2 bonds versus CH2 bonds, is low. Ando et al. (2003) 
used 30% D2O for 4 to 6 weeks in their mass spectrometry quantification of newly formed 
myelin, and Shi et al. (2018) administered 25% for SRS microscopy. It is difficult to justify 
increasing the dosage of deuterium due to its reported toxic effects at high concentrations, 
as reported by Thomson (1960). However, by combining CH2 and CD2 imaging, and 
verification with the proposed techniques, it may be possible to label newly formed myelin 
sheath using deuterium, and quantify their lengths using the corresponding CH2 imaging. 
These would allow for the in vivo testing of positive hits from the 96-well microfibre plates in 
improving remyelination while more accurately being able to take into consideration the 
degree of myelination left and the extent of demyelination caused by the demyelination 
model of MS used. 
Overall, the two main components of my PhD project were aimed at and have the potential 
to: (1) increase the identification of pro-myelinating compounds by increasing the complexity 
to a more physiologically-relevant model in a novel high-throughput drug screening platform 
for multiple sclerosis, and (2) expand our ability to test these compounds in vivo in terms of 
detecting the degree of remyelination more accurately, and in the number of animal models 
of MS available. Although the degree to which the 96-well drug screening platform could be 
biologically and pharmacologically  verified was severely restricted during the scope of my 
PhD by the ongoing media issues from an as of yet undetermined change to the B27/B21 
media supplement, the resolution of this issue would provide a highly valuable asset towards 
the screening and identification of novel compounds and therapeutic targets and thus 
provide and important piece in the puzzle towards developing effective treatments which 
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Supplementary Data 2.1: Columbus 96-well Flat Culture Analysis Pipeline Example 
 
 
Supplementary Data 2.2: Leica SP8 MatrixScreener Imaging Stitching Script 








//Source and target folders 
dir1=getDirectory("Select Screen Folder");  //Folder containing all the wells 
data i.e. well--U00--V00, well--U00--V01 
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dir2=getDirectory("Select Save Folder");  //Folder for saving the stacks 
listAll = getFileList(dir1); //list all wells subfolder in dir1 
// 
 
//Mapping the well subfolders into an array wellList 
print("Listing wells subfolders"); 
wellList = newArray(); 
for (n=0; n<listAll.length; n++){ 
 if (startsWith(listAll[n], "well--")){ 






//Processing well folder and the fields  
for (m=0; m<wellList.length; m++){ 
 wellName=substring(wellList[m], 0,lengthOf(wellList[m])-1); 
 print("**********************************"); 
 print("Processing well= "+wellName); 
 fieldList=getFileList(dir1+wellList[m]); 







//Function for sorting folder and subfolder 
function processField(fieldList) { 
for (k=0; k<fieldList.length; k++) { 
 print("Processing Field= "+dir1+wellList[m]+fieldList[k]); 
 fieldPath=dir1+wellList[m]+fieldList[k]; 
 indexOfX=indexOf(fieldPath, "X"); 
 indexOfY=indexOf(fieldPath, "Y"); 
 fieldX=substring(fieldPath, indexOfX,indexOfX+3); 









for(i=0; i<listRename.length; i++){ 
 pathImage=dir1+wellList[m]+fieldList[k]+listRename[i]; 
 if (startsWith(listRename[i], "image--")){ 






for(j=0; j<listImages.length; j++){ 
 pathToImage=dir1+wellList[m]+fieldList[k]+listImages[j]; 
 if (startsWith(listImages[j], "image--")){ 





 //print("Stitch directory= "+stitchDir); 
 } 
//run("Grid/Collection stitching", "type=[Grid: row-by-row] order=[Right & Up] grid_size_x=4 
grid_size_y=3 tile_overlap=10 first_file_index_i=1 directory="+[stitchDir]+" file_names={i}.tif 
output_textfile_name=TileConfiguration.txt fusion_method=[Max. Intensity] 
regression_threshold=0.30 max/avg_displacement_threshold=2.50 
absolute_displacement_threshold=3.50 compute_overlap computation_parameters=[Save 
computation time (but use more RAM)] image_output=[Fuse and display]"); 
 
















//Create final hyperstack 
function makeHyperstack(){ 
run("Images to Stack", "name=Stack title=[] use"); 
// Change channels & number of z-slice 










































print("****** DONE ******"); 
} 
 






for (i=0; i<list.length; i++){ 
 currentDir=list[i]; 
 print(currentDir); 
 if (endsWith(currentDir, "/")){ 
  indexSlash=indexOf(currentDir,"/"); 
  name=substring(currentDir, 0,indexSlash); 
  name=name+".tiff"; 
  print("final name ="+name); 
  dir=dir1+currentDir; 
  run("Grid/Collection stitching", "type=[Grid: row-by-row] order=[Right & Up] 
grid_size_x=4 grid_size_y=3 tile_overlap=10 first_file_index_i=1 directory="+dir+" 
file_names=tile_{i}.tif output_textfile_name=TileConfiguration.txt fusion_method=[Max. 
Intensity] regression_threshold=0.30 max/avg_displacement_threshold=2.50 
absolute_displacement_threshold=3.50 compute_overlap computation_parameters=[Save 
computation time (but use more RAM)] image_output=[Fuse and display]"); 
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  print("Saving file ="+dir1+currentDir+name); 
  saveAs("tiff", dir1+currentDir+name); 
  while (nImages>0) {  
   selectImage(nImages);  
   close();  
  } 
 } 
} 




Supplementary Data 2.3: CARS Flat-Field Correction Script for Tile Scan Images 
print("\\Clear"); 
setBatchMode(false); 
tileX=getNumber("tiles in X", 13); 
tileY=getNumber("tiles in Y", 13); 
 
dir2=getDirectory("Saving raw tiles"); 
//dir3=getDirectory("Saving corrected tiles"); 
openImage=getImageID(); 
//run("Z Project...", "projection=[Average Intensity]"); 
averageID=getImageID(); 
for (i=0; i<tileY; i++){    //tiles in Y axis 
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 for(j=0; j<tileX; j++){  //tiles in X axis 
  selectImage(averageID); 
  x=j*511;  //pixels - can make more fancy by adding line to divide pixels by 
number of tiles inputed at start 
  y=i*511; 
  makeRectangle(x, y+1, 511, 511); 
  run("Duplicate...", " "); 
  saveAs("tiff", dir2+"tile"+"_X_"+i+"_Y_"+j+".tiff"); 






run("Image Sequence...", "open=path sort"); 
rawStackID=getImageID(); 
rawStacktitle=getTitle(); 
run("Z Project...", "projection=[Average Intensity]"); 
avgID=getImageID(); 
avgTitle=getTitle(); 
run("Gaussian Blur...", "sigma=20"); 
getStatistics(area, mean); 
run("Calculator Plus", "i1="+rawStacktitle+" i2="+avgTitle+" operation=[Divide: i2 = (i1/i2) x 













Supplementary Figure 3.1 Time-point MBP+ cells percentage and preliminary live caspase 
flat culture drug screen results 
A+ B + C. (A) D1, (B) D3, and (C) D6 dose-response results of percentage of MBP+ cells over 
Hoechst+ cells. This experiment was performed using the same protocol for the flat culture 
drug screen experiments, but the cells were fixed 24 hours, 3 days, and 6 days after drug 
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addition, followed by staining, imaging on the Operetta, and analysis on Columbus. The D6 
plates had half media changes (to prevent cells from drying out) with fresh drugs added at 
the same final concentration on day 3. The average percentage of MBP+ cells from total nuclei 
for the DMSO control are depicted with solid (D1), dashed (D3), and dotted (D6) lines. n = 1 
D. Preliminary results from a live caspase cell viability experiment. The cells were plated and 
drugs added using the same protocol. On day 3, the cells were labelled for 30 minutes with 
Nucview® 488 Caspase-3/7 in DMSO (Biotium 10402) at 2.5μM, followed by 0.5x CellMask 
Deep Red plasma membrane stain (Thermo Fisher Scientific C10046) and Hoechst for 5 
minutes, all in the same myelination media that they were plated in. They were then imaged 
on the Operetta with 7.5% CO2 at 37°C using the 10x objective. Hoechst was quantified using 
Columbus, CellMask was excluded from quantification due to indistinct staining, and the 
NucView® counted by hand. The data was recorded in Excel and plotted on GraphPad Prism. 
n = 1 
Point of note 1: Clemastine at log[-5] had approximately 1000 Hoechst+ cells and Miconazole 
had approximately 2000 Hoechst+ cells at log[-5] and 4000 Hoechst+ cells at log[-5.48] 
compared to the DMSO control standard of between 5-6000 Hoechst+ cells. The lower ratio 
of Caspase+ cells at these concentrations are therefore due to the low presence of cells 
overall, rather than the low percentage of Caspase+ cells. 
Point of note 2: The number of caspase+ cells was extremely low, ranging from 0.25% to 9% 
of the total Hoechst+ cells. It is therefore difficult to draw any meaningful conclusions from 
this preliminary data. 
